PAC1 antibodies and uses thereof

By designing antibodies and antigen-binding fragments that specifically bind to PAC1 receptors, inhibiting PACAP-induced PAC1 activation has solved the problem of poor tolerance or ineffectiveness of existing treatment methods, achieving effective treatment for migraines, and significantly reducing vasodilation and headache symptoms.

CN111566126BActive Publication Date: 2024-11-12AMGEN INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980007841.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-01-12
Filing Date
2019-01-11
Publication Date
2024-11-12
Estimated Expiration
2039-01-11

AI Technical Summary

Technical Problem

Most existing migraine treatment methods are poorly tolerated or ineffective, and fail to effectively inhibit migraine attacks caused by trigeminal vasculature activation, especially the activation of the PACAP/PAC1 signaling pathway.

Method used

Design and produce antibodies that specifically bind to human pituitary adenylate cyclase-activated polypeptide type I receptor (PAC1) and effectively inhibit their biological activity, including isolated antibodies and antigen-binding fragments, by specifically binding to PAC1 receptor Epitopes to inhibit PACAP-induced activation, reduce vasodilation and improve migraine symptoms.

Benefits of technology

Achieving efficient inhibition of PACAP-induced PAC1 receptors significantly reduces migraine and other vascular headache symptoms, providing a potential new avenue for the treatment of migraines with higher inhibitory potency and lower IC50 values.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN111566126B_ABST
    Figure CN111566126B_ABST
Patent Text Reader

Abstract

The present invention relates to neutralizing antibodies to human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1), and pharmaceutical compositions comprising such antibodies. Methods of using these neutralizing antibodies to treat or prevent headache conditions such as migraine and cluster headache are also described.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 617,157, filed January 12, 2018, which is incorporated herein by reference in its entirety.

[0003] Instructions for electronic submission of text documents

[0004] This application contains a sequence listing that has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. A computer-readable copy of the sequence listing created on December 20, 2018, is named A-2189-WO-PCT_SeqList_ST25 and is 490 kilobytes in size. Technical Field

[0005] The present invention relates to the field of biopharmaceuticals. In particular, the present invention relates to antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and effectively inhibit its biological activity. The present invention also relates to pharmaceutical compositions containing these antibodies, as well as methods for producing and using these antibodies. Background Art

[0006] Migraine is an episodic headache that can involve significant pain, often accompanied by nausea, vomiting, and extreme sensitivity to light (photophobia) and sound (phonophobia), and sometimes with prior sensory warning symptoms or signs (aura). Migraine is a very common disease worldwide, with about 12% of the European population, and 18% of women and 6% of men in the United States suffering from migraine attacks (Lipton et al., Neurology, Vol. 68: 343-349, 2007; Lipton et al., Headache, Vol. 41: 646-657, 2001). A study evaluating the prevalence of migraine in the United States reported that nearly half of the migraine patient population had three or more migraines per month (Lipton et al., Neurology, Vol. 68: 343-349, 2007). In addition, migraine is associated with many psychiatric and medical comorbidities, such as depression and vascular disease (Buse et al., J. Neurol. Neurosurg. Psychiatry, Vol. 81: 428-432, 2010; Bigal et al., Neurology, Vol. 72: 1864-1871, 2009). Most current migraine treatments are either poorly tolerated or ineffective (Loder et al., Headache, Vol. 52: 930-945, 2012; Lipton et al., 2001); thus, migraine still represents an unmet medical need.

[0007] A major component of migraine pathogenesis involves activation of the trigeminovascular system. Trigeminal and parasympathetic neurotransmitters released from perivascular nerve fibers (Sánchez-del-Rio and Reuter, Curr. Opin. Neurol., Vol. 17(3):289-93, 2004) lead to vasodilation of cranial vessels and have been implicated in the onset of migraine (Edvinsson, Cephalagia, Vol. 33(13):1070-1072, 2013; Goadsby et al., New Engl J Med., Vol. 346(4):257-270, 2002).

[0008] Pituitary adenylate cyclase activating polypeptide (PACAP), named for its ability to stimulate cyclic AMP (cyclic adenosine monophosphate, cAMP) formation in anterior pituitary cells, is a 38-amino acid (PACAP38) or 27-amino acid (PACAP27) peptide first isolated from sheep hypothalamic extracts (Miyata et al., Biochem Biophys Res Commun., Vol. 164: 567-574, 1989; Miyata et al., Biochem Biophys Res Commun., Vol. 170: 643-648, 1990). PACAP belongs to the VIP / secretin / glucagon superfamily. The sequence of PACAP27 corresponds to the 27 N-terminal amino acids of PACAP38 and shares 68% identity with vasoactive intestinal polypeptide (VIP) (Pantaloni et al., J. Biol. Chem., Vol. 271: 22146-22151, 1996; Pisegna and Wank, Proc. Natl. Acad. Sci. USA, Vol. 90: 6345-49, 1993; Campbell and Scanes, Growth Regul., Vol. 2: 175-191, 1992). The major form of the PACAP peptide in humans is PACAP38, and the pharmacology of PACAP38 has not been shown to differ from that of PACAP27. Three PACAP receptors have been reported: one receptor that binds PACAP with high affinity and has a much lower affinity for VIP (PAC1 receptor), and two receptors that recognize PACAP and VIP equally well (VPAC1 and VPAC2 receptors) (Vaudry et al., Pharmacol Rev., Vol. 61:283-357, 2009).

[0009] Human experimental migraine models that use PACAP as a challenge agent to induce migraine-like headaches support a therapeutic approach for antagonizing the PACAP / PAC1 signaling pathway as migraine prevention. PACAP38 is elevated in plasma during spontaneous migraine attacks in migraine patients, and these elevated PACAP38 levels can be normalized with sumatriptan, an acute migraine therapy (Tuka et al., Cephalalgia [Headache Journal], Vol. 33: 1085-1095, 2013; Zagami et al., Ann. Clin. Transl. Neurol. [Clinical and Translational Neurology Annals], Vol. 1: 1036-1040, 2014). Infusion of PACAP38 causes headaches in healthy subjects and migraine-like headaches in migraine patients (Schytz et al., Brain, Vol. 132: 16-25, 2009; Amin et al., Brain, Vol. 137: 779-794, 2014; Guo et al., Cephalalgia, Vol. 37: 125-135, 2017). However, in the same model, VIP does not cause migraine-like headaches in migraine patients (Rahmann et al., Cephalalgia, Vol. 28: 226-236, 2008). The fact that VIP infusion does not induce migraine-like headaches suggests that the effects of the PACAP38 peptide are mediated through the PAC1 receptor rather than the VPAC1 or VPAC2 receptors, as VIP has a much higher affinity at the latter two receptors. This concept is further supported by animal studies in which PAC1 receptor antagonists inhibited nociceptive neuronal activity in the trigeminocervical complex in an in vivo model of migraine (Akerman et al., Sci. Transl. Med., Vol. 7:308ra157, 2015; Hoffmann et al., Cephalalgia, Vol. 37(1S):3, Abstract OC-BA-004, 2017). Taken together, these data suggest that pharmacological agents that inhibit PACAP activation of PAC1 receptors have the potential to treat migraine. Summary of the invention

[0010] The present invention is based in part on the design and generation of high affinity antibodies that specifically bind to human PAC1 and effectively inhibit human PAC1. Compared with previously described anti-PAC1 antibodies, these antibodies of the present invention have enhanced inhibitory potency against human PAC1, with IC50 values ​​in the picomolar range. The isolated antibodies and antigen-binding fragments thereof can be used to inhibit, interfere with or modulate the biological activity of human PAC1, including inhibiting or reducing PACAP-induced PAC1 activation, inhibiting or reducing vasodilation, and improving or treating the symptoms of migraine and other vascular headaches.

[0011] In some embodiments, the isolated antibodies and antigen-binding fragments thereof specifically bind to human PAC1 at an epitope comprising one or more amino acids selected from Asp59, Asn60, Ile61, Arg116, Asn117, Thr119, Glu120, Asp121, Gly122, Trp123, Ser124, Glu125, Pro126, Phe127, Pro128, His129, Tyr130, Phe131, Asp132, and Gly135 of SEQ ID NO: 1. In certain embodiments, the epitope comprises at least the amino acids Asn60, Ile61, Glu120, and Asp121 of human PAC1. In these and other embodiments, the antibodies and antigen-binding fragments of the invention comprise specific amino acids located at specific positions within the light and heavy chain variable regions that interact with the epitope residues. For example, in one embodiment, the antibodies or antigen-binding fragments comprise a light chain variable region, wherein the amino acid at position 29 according to AHo numbering is a basic amino acid (e.g., arginine or lysine) that interacts with amino acid Glu120 or Asp121 of human PAC1. In another embodiment, the antibodies or antigen-binding fragments comprise a heavy chain variable region, wherein the amino acid at position 61 according to AHo numbering is a hydrophobic, basic, or neutral hydrophilic amino acid (e.g., isoleucine, valine, leucine, glutamine, asparagine, arginine, or lysine) that interacts with amino acid Asn60 or Ile61 of human PAC1. In yet another embodiment, the antibodies or antigen-binding fragments comprise a heavy chain variable region, wherein the amino acid at position 66 according to AHo numbering is a basic or neutral hydrophilic amino acid (e.g., glutamine, asparagine, arginine, or lysine) that interacts with amino acid Asn60 or Ile61 of human PAC1.

[0012] The anti-PAC1 antibodies and antigen-binding fragments of the present invention can inhibit ligand-induced activation of the PAC1 receptor. For example, in some embodiments, the anti-PAC1 antibodies and antigen-binding fragments inhibit PACAP-induced activation of human PAC1, wherein the IC50 as measured by a cell-based cAMP assay is less than 500 pM. In other embodiments, the anti-PAC1 antibodies and antigen-binding fragments inhibit PACAP-induced activation of human PAC1, wherein the IC50 as measured by a cell-based cAMP assay is less than 300 pM. In certain embodiments, the anti-PAC1 antibodies and antigen-binding fragments inhibit PACAP-induced activation of the human PAC1 receptor, wherein the IC50 as measured by a cell-based cAMP assay is between about 50 pM and about 500 pM.

[0013] In some embodiments, the anti-PAC1 antibodies and antigen-binding fragments of the present invention cross-react with PAC1 receptors from other species. In one embodiment, the anti-PAC1 antibodies or antigen-binding fragments specifically bind to and inhibit PACAP-induced activation of the cynomolgus monkey PAC1 receptor. In such embodiments, the anti-PAC1 antibodies or antigen-binding fragments can inhibit PACAP-induced activation of the cynomolgus monkey PAC1 receptor, wherein the IC50 as measured by a cell-based cAMP assay is between about 0.1 nM and about 1 nM or between about 50 pM and about 500 pM. In another embodiment, the anti-PAC1 antibodies or antigen-binding fragments specifically bind to and inhibit PACAP-induced activation of the rat PAC1 receptor. The anti-PAC1 antibodies or antigen-binding fragments can inhibit PACAP-induced activation of the rat PAC1 receptor, wherein the IC50 as measured by a cell-based cAMP assay is less than 10 nM, for example, wherein the IC50 is between about 0.1 nM and about 10 nM or between about 100 pM and about 2 nM.

[0014] In certain embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising complementary determining regions CDRL1, CDRL2 and CDRL3 and a heavy chain variable region comprising complementary determining regions CDRH1, CDRH2 and CDRH3. The light chain variable regions and heavy chain variable regions or CDRs can be from any anti-PAC1 antibody described herein. For example, in some embodiments, the anti-PAC1 antibodies or antigen-binding fragments comprise: CDRL1 comprising a sequence selected from SEQ ID NO: 5-16; CDRL2 comprising a sequence selected from SEQ ID NO: 26; CDRL3 comprising a sequence selected from SEQ ID NO: 36-38; CDRH1 comprising a sequence selected from SEQ ID NO: 88-96; CDRH2 comprising a sequence selected from SEQ ID NO: 106-166; and CDRH3 comprising a sequence selected from SEQ ID NO: 171-177. In other embodiments, the anti-PAC1 antibodies or antigen-binding fragments comprise: CDRL1 comprising a sequence selected from SEQ ID NOs: 17-25; CDRL2 comprising a sequence selected from SEQ ID NOs: 27-35; CDRL3 comprising a sequence selected from SEQ ID NOs: 39-51; CDRH1 comprising a sequence selected from SEQ ID NOs: 97-105; CDRH2 comprising a sequence selected from SEQ ID NOs: 167-170; and CDRH3 comprising a sequence selected from SEQ ID NOs: 178-190.

[0015] In some embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising a sequence at least 90% identical or at least 95% identical to a sequence selected from SEQ ID NOs: 54-66 and SEQ ID NOs: 68-87. In these and other embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a heavy chain variable region comprising a sequence at least 90% identical or at least 95% identical to a sequence selected from SEQ ID NOs: 191-312. In one embodiment, the anti-PAC1 antibodies or antigen-binding fragments comprise a light chain variable region comprising a sequence selected from SEQ ID NOs: 54-66 and a heavy chain variable region comprising a sequence selected from SEQ ID NOs: 191-295. In another embodiment, the anti-PAC1 antibodies or antigen-binding fragments comprise a light chain variable region comprising a sequence selected from SEQ ID NOs: 68-87 and a heavy chain variable region comprising a sequence selected from SEQ ID NOs: 296-312.

[0016] In any of the embodiments described herein (including the embodiments described above), the anti-PAC1 antibody or antigen-binding fragment of the present invention is a monoclonal antibody or antigen-binding fragment thereof. In some embodiments, the monoclonal antibody or antigen-binding fragment thereof is a chimeric antibody or antigen-binding fragment thereof. In other embodiments, the monoclonal antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof. In yet other embodiments, the monoclonal antibody or antigen-binding fragment thereof is a fully human antibody or antigen-binding fragment thereof. The monoclonal antibody may be of any isotype, such as human IgG1, IgG2, IgG3, or IgG4. In a specific embodiment, the monoclonal antibody is a human IgG1 antibody. In another specific embodiment, the monoclonal antibody is a human IgG2 antibody. The monoclonal antibody may include a light chain containing a human kappa constant region. In some embodiments, the human kappa constant region comprises the sequence of SEQ ID NO: 318 or SEQ ID NO: 319. Thus, the anti-PAC1 antibodies or antigen-binding fragments of the invention may comprise a light chain comprising any of the light chain variable region sequences listed in Table 1A fused to a human kappa constant region comprising the sequence of SEQ ID NO: 318 or SEQ ID NO: 319. In other embodiments, the monoclonal antibody may comprise a light chain comprising a human lambda constant region. In certain embodiments, the human lambda constant region comprises the sequence of SEQ ID NO: 315. Thus, in some embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention may comprise a light chain comprising any of the light chain variable region sequences listed in Table 1A fused to a human lambda constant region comprising the sequence of SEQ ID NO: 315.

[0017] In certain embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the present invention may comprise one or more modifications that affect glycosylation of the antibody or antigen-binding fragment. In some embodiments, the antibody or antigen-binding fragment comprises one or more mutations to reduce or eliminate glycosylation. In such embodiments, the non-glycosylated antibody may comprise a mutation at amino acid position N297 (according to the EU numbering scheme) in its heavy chain, such as an N297G mutation. The non-glycosylated antibody may comprise additional mutations to stabilize the antibody structure. Such mutations may include cysteine ​​substitution pairs, such as A287C and L306C, V259C and L306C, R292C and V302C, and V323C and I332C (amino acid positions according to the EU numbering scheme). In one embodiment, the non-glycosylated antibody comprises R292C and V302C mutations on its heavy chain (according to the EU numbering scheme). In certain embodiments, the aglycosylated anti-PAC1 antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:324 or SEQ ID NO:325.

[0018] The present invention also includes isolated polynucleotides, and expression vectors encoding the anti-PAC1 antibodies and antigen-binding fragments described herein, and host cells (e.g., CHO cells) comprising the encoding polynucleotides and expression vectors. In certain embodiments, the present invention includes methods for producing the anti-PAC1 antibodies and antigen-binding fragments described herein. In one embodiment, the method includes culturing a host cell under conditions that allow expression of the antibody or antigen-binding fragment, the host cell comprising an expression vector encoding the anti-PAC1 antibody or antigen-binding fragment; and recovering the antibody or antigen-binding fragment from the culture medium or the host cell.

[0019] The anti-PAC1 antibodies or antigen-binding fragments described herein can be used in the production of pharmaceutical compositions or drugs for treating or preventing conditions associated with the biological activity of PAC1 (e.g., headache, migraine, cluster headache, and vasodilation symptoms). Therefore, the present invention also provides a pharmaceutical composition comprising the anti-PAC1 antibodies or antigen-binding fragments described herein and a pharmaceutically acceptable excipient. The pharmaceutical composition can be used in any of the methods described herein.

[0020] In certain embodiments, the present invention provides methods for treating or preventing headache conditions in a patient in need thereof, the methods comprising administering to the patient an effective amount of an anti-PAC1 antibody or antigen-binding fragment described herein. In some embodiments, the headache condition to be treated or prevented by the methods of the present invention is migraine. The migraine can be episodic migraine or chronic migraine. In other embodiments, the headache condition to be treated or prevented by the methods of the present invention is cluster headache. In certain embodiments, the methods provide prophylactic treatment for these conditions.

[0021] In some embodiments of the methods of the invention, the methods comprise administering to the patient a second headache therapeutic agent in combination with the anti-PAC1 antibody or antigen-binding fragment of the invention. The second headache therapeutic agent can be an acute headache therapeutic agent, such as a serotonin receptor agonist (e.g., 5HT 1B , 5HT 1D and / or 5HT 1F agonists of serotonin receptors). In some embodiments, the acute headache therapeutic is a triptan, ergotamine, nonsteroidal anti-inflammatory drug, or opioid. In other embodiments, the second headache therapeutic administered in combination with the anti-PAC1 antibody or antigen-binding fragment of the invention is a prophylactic headache therapeutic (e.g., an anti-epileptic drug, a beta-blocker, an antidepressant, or onabotulinum toxin A). The second headache therapeutic can be administered to the patient before, after, or simultaneously with the anti-PAC1 antibody or antigen-binding fragment of the invention.

[0022] In certain embodiments of the methods of the present invention, these methods include administering a CGRP pathway antagonist to a patient in combination with an anti-PAC1 antibody or antigen-binding fragment of the present invention. The CGRP pathway antagonist can be a human CGRP receptor antagonist, such as an antibody that specifically binds to a human CGRP receptor. In one embodiment, the CGRP pathway antagonist administered in combination with an anti-PAC1 antibody or antigen-binding fragment of the present invention is erenumab. In other embodiments, the CGRP pathway antagonist can be an antagonist of a CGRP ligand, such as an antibody that specifically binds to human α-CGRP and / or β-CGRP. In one such embodiment, the CGRP pathway antagonist administered in combination with an anti-PAC1 antibody or antigen-binding fragment of the present invention is fremanezumab. In another such embodiment, the CGRP pathway antagonist administered in combination with an anti-PAC1 antibody or antigen-binding fragment of the present invention is galcanezumab. In yet another such embodiment, the CGRP pathway antagonist administered in combination with an anti-PAC1 antibody or antigen-binding fragment of the invention is eptinezumab.

[0023] The present invention also includes methods of inhibiting vasodilation in a patient in need thereof. In one embodiment, the method comprises administering to the patient an effective amount of any of the anti-PAC1 antibodies or antigen-binding fragments described herein. In some embodiments, the patient in need of treatment suffers from a headache condition (e.g., migraine or cluster headache). In other embodiments, the patient in need of treatment suffers from vasodilation symptoms such as those associated with menopause (e.g., hot flashes, facial flushing, sweating, and night sweats).

[0024] The use of these anti-PAC1 antibodies or antigen-binding fragments in any method disclosed herein or for the preparation of a medicament according to any method disclosed herein is specifically contemplated. For example, the present invention includes an anti-PAC1 antibody or antigen-binding fragment for use in a method of treating or preventing a headache condition in a patient in need thereof. The headache condition includes migraine (e.g., episodic and chronic migraine) and cluster headache. In some embodiments, the present invention provides an anti-PAC1 antibody or antigen-binding fragment for use in a method of inhibiting vasodilation in a patient in need thereof. In such embodiments, the patient can be diagnosed as having or suffering from a headache condition. In other embodiments, the present invention provides an anti-PAC1 antibody or antigen-binding fragment for use in a method of inhibiting activation of a human PAC1 receptor in a patient suffering from a headache condition. The headache condition can be migraine (e.g., episodic or chronic migraine) or cluster headache.

[0025] The present invention also includes the use of an anti-PAC1 antibody or antigen-binding fragment in the preparation of a medicament for treating or preventing a headache condition in a patient in need thereof. The headache condition includes migraine (e.g., episodic and chronic migraine) and cluster headache. In certain embodiments, the present invention encompasses the use of an anti-PAC1 antibody or antigen-binding fragment in the preparation of a medicament for inhibiting vasodilation in a patient in need thereof. In such embodiments, the patient can be diagnosed as having or suffering from a headache condition. In other embodiments, the present invention includes the use of an anti-PAC1 antibody or antigen-binding fragment in the preparation of a medicament for inhibiting activation of a human PAC1 receptor in a patient suffering from a headache condition. The headache condition can be migraine (e.g., episodic or chronic migraine) or cluster headache. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1A It is a front view of the crystal structure of the complex between the human PAC1 extracellular domain (ECD) and the Fab fragment of the 29G4v9 antibody. VL = light chain variable region; CL = light chain constant region; VH = heavy chain variable region; and CH1 = heavy chain CH1 constant region.

[0027] Figure 1B is a side view of the crystal structure of the complex between human PAC1 ECD and the Fab fragment of the 29G4v9 antibody. The figure depicts Figure 1A The structure shown is rotated 90° to the left. In this figure, the light chain variable region (VL) is located behind the heavy chain variable region (VH), and the light chain constant region (CL) is located behind the heavy chain CH1 constant region.

[0028] Figure 2A is an expanded view of the interface between human PAC1 ECD and the light chain CDR1 of 29G4v9 Fab (amino acids 24 to 34 of SEQ ID NO: 3). Region 1 comprises the Glu120 and Aspl21 residues of human PAC1 ECD (SEQ ID NO: 1), while region 3 comprises the Phe127 residue of human PAC1 ECD.

[0029] Figure 2B is an expanded view of the interface between the human PAC1 ECD and the Arg93 residue in the light chain CDR3 of the 29G4v9 Fab.

[0030] Figure 3A is an expanded view of the interface between the human PAC1 ECD and the heavy chain CDR1 amino acids Arg31 and Phe32 of the 29G4v9 Fab. These two heavy chain CDR1 amino acids are located on either side of the Phe131 residue of the human PAC1 ECD.

[0031] Figure 3Bis an expanded view of the interface between the region of the human PAC1 ECD comprising amino acid residues Asn60 and Ile61 (relative to SEQ ID NO: 1) and the heavy chain CDR2 amino acids Tyr53, Asp54 and Gly56 of the 29G4v9 Fab.

[0032] Figure 3C Developed view of the interface between human PAC1 ECD and heavy chain CDR3 amino acids Val102, Leu103, and Thr104 of 29G4v9 Fab.

[0033] Figure 4 Schematic diagram of the selection method for improved binding mutants from a yeast-displayed antibody Fab mutant library.

[0034] Figure 5 Schematic diagram of the binding-dissociation rate-driven selection process for high-affinity binding mutants from a yeast display library.

[0035] Figure 6 The inhibitory effect of anti-PAC1 antibodies on maxadilan-induced increase in skin blood flow in rats is shown. Twenty-four hours before challenge with 10 ng maxadilan (intradermal injection), one of the seven antibodies (420653, 420845, 420943, 421873, 420889 (PL-50347), 421091 (PL-50350) and 421051 (PL-50351)) was administered intravenously to rats at a dose of 0.1 mg / kg or 0.3 mg / kg. Skin blood flow was assessed 30 minutes after maxadilan challenge using laser Doppler imaging. *p<0.05, **p<0.01 compared to the vehicle group using One-Way ANOVA followed by Dunnett's MCT.

[0036] Fig. 7A The dose-dependent effect of the anti-PAC1 antibody 420653 on maxadilan-induced skin blood flow in rats is shown. Twenty-four hours prior to challenge with 10 ng maxadilan (intradermal injection), the antibody was administered intravenously to rats at one of seven doses ranging from 0.01 mg / kg to 3 mg / kg. Skin blood flow was assessed 30 minutes after maxadilan challenge using laser Doppler imaging. *p<0.05, ****p<0.0001 compared to the vehicle group using one-way ANOVA followed by Dunnett's multiple comparison test.

[0037] Figure 7BThe dose-dependent effect of the anti-PAC1 antibody 420845 on maxadilan-induced skin blood flow in rats is shown. Twenty-four hours prior to challenge with 10 ng maxadilan (intradermal injection), the antibody was administered intravenously to rats at one of five doses ranging from 0.01 mg / kg to 3 mg / kg. Skin blood flow was assessed 30 minutes after maxadilan challenge using laser Doppler imaging. ****p<0.0001 compared to the vehicle group using one-way ANOVA followed by Dunnett's multiple comparison test.

[0038] Figure 7C The dose-dependent effect of 420943, an anti-PAC1 antibody, on maxadilan-induced increases in skin blood flow in rats was shown. Twenty-four hours prior to challenge with 10 ng maxadilan (intradermal injection), the antibody was administered intravenously to rats at one of six doses ranging from 0.1 mg / kg to 30 mg / kg. Skin blood flow was assessed 30 minutes after maxadilan challenge using laser Doppler imaging. ****p<0.0001 compared to the vehicle group using one-way ANOVA followed by Dunnett's multiple comparison test.

[0039] Fig.7D The dose-dependent effect of 421873 of the anti-PAC1 antibody on maxadilan-induced increases in skin blood flow in rats is shown. Twenty-four hours prior to challenge with 10 ng maxadilan (intradermal injection), the antibody was administered intravenously to rats at one of five doses ranging from 0.3 mg / kg to 30 mg / kg. Skin blood flow was assessed 30 minutes after maxadilan challenge using laser Doppler imaging. *p<0.05, ****p<0.0001 compared to the vehicle group using one-way ANOVA followed by Dunnett's multiple comparison test.

[0040] Fig. 8A is the serum concentration-time curve of anti-PAC1 antibodies 420653, 420845, 420943 and 421873 after a single intravenous dose of 1 mg / kg in rats.

[0041] Figure 8B is the serum concentration-time curve of anti-PAC1 antibodies 420653, 420845, 420943 and 421873 after a single intravenous dose of 5 mg / kg in rats.

[0042] Figure 8C is the serum concentration-time curve of anti-PAC1 antibodies 420653, 420845, 420943 and 421873 after a single intravenous dose of 25 mg / kg in rats.

[0043] Fig. 9 is the serum concentration-time curve of anti-PAC1 antibodies 420653, 420845, 420943, 421873 and 29G4v22 after a single intravenous dose of 10 mg / kg in cynomolgus monkeys.

[0044] Fig. 10A and 10B The time course of the inhibitory effect of anti-PAC1 antibodies 420653 and 29G4v22 on maxadilan-induced increases in skin blood flow in cynomolgus monkeys is shown. On day 0, 24 cynomolgus monkeys were given a single intravenous bolus injection of 0.1 mg / kg or 3 mg / kg of antibody 420653 or 10 mg / kg of antibody 29G4v22. The response after administration of maxadilan was measured on days 2, 4, 7, 10, 14, 21, 28, and 36 after antibody administration. In each case, skin blood flow was measured by laser Doppler imaging 30 minutes after 1 ng maxadilan intradermal injection. All data are expressed as mean ± standard error of the mean. Fig. 10A Shown are the % changes from baseline in skin blood flow induced by intradermal injection of maxadilan at the indicated days after antibody treatment. *p<0.05, **p<0.01, ***p<0.001 compared to day 0 in the same treatment by one-way ANOVA followed by Dunnett's multiple comparison test. There were 8 animals per group except day 36, where 4 animals were tested with 3 mg / kg of antibody 420653 as indicated by the ^ symbol. Fig. 10B Shown is the inhibitory effect of antibody treatment on the maxadilan-induced increase in skin blood flow (expressed as % inhibition). #p<0.05, ##p<0.01, ###p<0.001 comparisons between 3 mg / kg of antibody 420653 and 10 mg / kg of antibody 29G4v22 were performed at each time point by two-tailed unpaired t-test. DETAILED DESCRIPTION

[0045] The present invention relates to isolated antibodies and antigen-binding fragments thereof that specifically bind to pituitary adenylate cyclase activating polypeptide type I receptor (PAC1), in particular human PAC1. These antibodies of the present invention have enhanced inhibitory potency against human PAC1 compared to previously described anti-PAC1 antagonist antibodies. The antibodies of the present invention also cross-react with rat PAC1 receptor and cynomolgus monkey PAC1 receptor, thereby allowing preclinical in vivo evaluation of the antibodies in these species.

[0046] Human PAC1 is a 468 amino acid protein encoded by the ADCYAP1R1 gene on chromosome 7 (NCBI reference sequence NP_001109.2). The human PAC1 receptor is a G protein-coupled receptor that is positively coupled to adenylate cyclase. Activation of the human PAC1 receptor by its endogenous ligand (e.g., PACAP38 or PACAP27) leads to an increase in intracellular cyclic AMP (cyclic adenosine monophosphate, cAMP). The amino acid sequence of human PAC1 is provided as SEQ ID NO: 1 below.

[0047]

[0048] Amino acids 1 to 23 of the human PAC1 protein (SEQ ID NO: 1) constitute a signal peptide that is typically removed from the mature protein. The mature human PAC1 protein has the basic structure of a G protein-coupled receptor consisting of seven transmembrane domains, an extracellular domain consisting of an N-terminal region and three extracellular loops, three intracellular loops, and a C-terminal cytoplasmic domain. The N-terminal extracellular domain is approximately at amino acids 24-153 of SEQ ID NO: 1, and the first of the seven transmembrane domains begins at amino acids 154 of SEQ ID NO: 1. The C-terminal cytoplasmic domain is located approximately at amino acids 397-468 of SEQ ID NO: 1. See Blechman and Levkowitz, Front. Endocrinol., Vol. 4(55): 1-19, 2013 for the location of the domains within the amino acid sequence. The terms "human PAC1," "human PAC1 receptor," "hPAC1," and "hPAC1 receptor" are used interchangeably and may refer to a polypeptide of SEQ ID NO: 1, a polypeptide of SEQ ID NO: 1 minus the signal peptide (amino acids 1 to 23), an allelic variant of human PAC1, or a splice variant of human PAC1.

[0049] The present invention provides antibodies that specifically bind to human PAC1. An "antibody" is a protein comprising an antigen-binding fragment that specifically binds to an antigen, and a scaffold or framework portion that allows the antigen-binding fragment to adopt a conformation that promotes antibody binding to the antigen. As used herein, the term "antibody" generally refers to a tetrameric immunoglobulin protein comprising two light chain polypeptides (each about 25 kDa) and two heavy chain polypeptides (each about 50-70 kDa). The term "light chain" or "immunoglobulin light chain" refers to a polypeptide comprising a single immunoglobulin light chain variable region (VL) and a single immunoglobulin light chain constant region (CL) from the amino terminus to the carboxyl terminus. The immunoglobulin light chain constant region (CL) can be a human kappa (κ) or human lambda (λ) constant region. The term "heavy chain" or "immunoglobulin heavy chain" refers to a polypeptide comprising, from amino terminus to carboxyl terminus, a single immunoglobulin heavy chain variable region (VH), an immunoglobulin heavy chain constant region 1 (CH1), an immunoglobulin hinge region, an immunoglobulin heavy chain constant region 2 (CH2), an immunoglobulin heavy chain constant region 3 (CH3), and optionally an immunoglobulin heavy chain constant region 4 (CH4). Heavy chains are classified into mu (μ), delta (Δ), gamma (γ), alpha (α), and epsilon (ε), and the isotype of the antibody is defined as IgM, IgD, IgG, IgA, and IgE, respectively. These IgG and IgA class antibodies are further divided into subclasses, i.e., IgG1, IgG2, IgG3, and IgG4, as well as IgA1 and IgA2, respectively. The heavy chains in IgG, IgA and IgD antibodies have three constant domains (CH1, CH2 and CH3), whereas the heavy chains in IgM and IgE antibodies have four constant domains (CH1, CH2, CH3 and CH4). The immunoglobulin heavy chain constant regions can be from any immunoglobulin isotype (including subtypes). The antibody chains are linked together by inter-polypeptide disulfide bonds between the CL domain and the CH1 domain (i.e., between the light chain and the heavy chain) and between the hinge regions of the two antibody heavy chains.

[0050] The present invention also includes antigen-binding fragments of the anti-PAC1 antibodies described herein. An "antigen-binding fragment," used interchangeably herein with "binding fragment" or "fragment," is a portion of an antibody that lacks at least some of the amino acids present in the full-length heavy and / or light chains, but is still able to specifically bind to an antigen. Antigen-binding fragments include, but are not limited to, single-chain variable region fragments (scFv), nanobodies (e.g., the VH domain of a camelid heavy chain antibody; VHH fragments, see Cortez-Retamozo et al., Cancer Research, Vol. 64: 2853-57, 2004), Fab fragments, Fab' fragments, F(ab')2 fragments, Fv fragments, Fd fragments, and complementary determining region (CDR) fragments, and may be derived from any mammalian (e.g., human, mouse, rat, rabbit, or camelid) source. Antigen-binding fragments may compete for binding of a target antigen to an intact antibody, and fragments may be produced by modifying an intact antibody (e.g., enzymatic or chemical cleavage) or by de novo synthesis using recombinant DNA technology or peptide synthesis. In some embodiments, the antigen binding fragment comprises at least one CDR from an antibody that binds to an antigen, such as a heavy chain CDR3 from an antibody that binds to an antigen. In other embodiments, the antigen binding fragment comprises all three CDRs from the heavy chain of an antibody that binds to an antigen, or all three CDRs from the light chain of an antibody that binds to an antigen. The antigen binding fragment comprises all six CDRs from an antibody that binds to an antigen (three from the heavy chain and three from the light chain).

[0051] The term "isolated molecule" (wherein the molecule is, for example, a polypeptide, polynucleotide, antibody, or antigen-binding fragment) is a molecule that, by virtue of its origin or derivation, is (1) free from naturally associated components with which it is naturally associated, (2) substantially free of other molecules from the same species, (3) expressed by cells from a different species, or (4) not found in nature. Thus, a molecule that is chemically synthesized or expressed in a cell system different from the cell from which it naturally originates will be "isolated" from its naturally associated components. A molecule can also be rendered substantially free of naturally associated components by separation using purification techniques well known in the art. Molecular purity or homogeneity can be determined by a number of methods well known in the art. For example, the purity of a polypeptide sample can be determined using techniques well known in the art using polyacrylamide gel electrophoresis and staining of the gel to visualize the polypeptide. For some purposes, purification can be performed using HPLC or other methods well known in the art to provide higher resolution.

[0052] In certain embodiments of the invention, the antibodies or antigen-binding fragments thereof specifically bind to human PAC1. An antibody or antigen-binding fragment thereof "specifically binds" a target antigen when it has a significantly higher binding affinity than that of other unrelated proteins under similar binding assay conditions and is therefore able to discriminate the antigen. An antibody or antigen-binding fragment that specifically binds to an antigen may have an equilibrium dissociation constant (K D )≤1x10 -6 M. When K D ≤1x10 -8 When K is 0.04, the antibody or binding fragment specifically binds to the antigen with "high affinity". In one embodiment, these antibodies or binding fragments of the present invention bind to human PAC1, wherein K is D ≤5x10 -9 In another embodiment, the antibodies or binding fragments of the invention bind to human PAC1, wherein K D ≤1x10 -9 In yet another embodiment, the antibodies or binding fragments of the invention bind to human PAC1, wherein K D ≤5x10 -10 In another embodiment, the antibodies or binding fragments of the invention bind to human PAC1, wherein K D ≤1x10 -10 M. In certain embodiments, the antibodies or binding fragments of the invention bind to human PAC1, wherein K D ≤5x10 -11 M. In other embodiments, the antibodies or binding fragments of the invention bind to human PAC1, wherein K D ≤1x10 -11 In a specific embodiment, the antibodies or binding fragments of the invention bind to human PAC1, wherein K D ≤5x10 -12 In another specific embodiment, the antibodies or binding fragments of the present invention bind to human PAC1, wherein K D ≤1x10 -12 M.

[0053] Affinity is determined using various techniques, one example of which is an affinity ELISA assay. In various embodiments, affinity is determined by surface plasmon resonance (e.g., based on Using this methodology, the binding rate constant (in M) can be measured. -1 s -1 Indicates k a ) and the dissociation rate constant (in s -1 Indicates k d). The kinetic rate constant (k d / k a ) to calculate the equilibrium dissociation constant (K in M D In some embodiments, affinity is determined by kinetic methods, such as the kinetic exclusion assay (KinExA) described in Rathanaswami et al. Analytical Biochemistry, Vol. 373: 52-60, 2008. Using the KinExA assay, the equilibrium dissociation constant (K expressed in M) can be measured. D ) and the binding rate constant (in M -1 s -1 k a ). These values ​​(K D xk a ) to calculate the dissociation rate constant (in s -1 Indicates k d In other embodiments, affinity is determined by biolayer interferometry, such as described in Kumaraswamy et al., Methods Mol. Biol., Vol. 1278: 165-82, 2015, and used System (PallForteBio). Biolayer interferometry can be used to calculate the kinetics (k a and k d ) and affinity (K D ) constant. In some embodiments, the antibodies or binding fragments described herein exhibit desirable characteristics, such as the k of human PAC1. d The binding affinity measured by the dissociation rate constant is about 10 -2 , 10 -3 , 10 -4 , 10 -5 , 10 -6 , 10 -7 , 10 -8 , 10 -9 , 10 -10 s -1 or lower (lower values ​​indicate higher binding affinity), and / or as determined by the K of human PAC1 D The binding affinity measured by the equilibrium dissociation constant is about 10 -8 , 10 -9 , 10 -10 , 10 -11 , 10 -12 M or lower (lower values ​​indicate higher binding affinity).

[0054] Preferably, the antibodies or binding fragments of the invention do not significantly bind to or cross-react with other members of the secretin / glucagon receptor family, such as the human VPAC1 receptor (NCBI reference sequence NP_004615.2) and the human VPAC2 receptor (NCBI reference sequence NP_003373.2). As used herein, an antibody or binding fragment "does not significantly bind" to a target antigen when it has a binding affinity for the antigen that is comparable to its affinity for other unrelated proteins under similar binding assay conditions. Antibodies or binding fragments that do not significantly bind to a target antigen may also include those proteins that do not generate a statistically different signal compared to a negative control in an affinity assay, such as those antibodies or binding fragments described herein for a target antigen. For example, an antibody may be detected in an ELISA-based or ELISA-based assay. An antibody or binding fragment that does not significantly bind to an antigen may have an equilibrium dissociation constant (K) for the antigen. D ) is higher than 1x10 -6 M, higher than 1x10 -5 M, higher than 1x10 -4 M, or higher than 1x10 -3 M. Thus, in certain embodiments, the antibodies and binding fragments of the invention selectively bind to human PAC1 relative to human VPAC1 and human VPAC2. In other words, the antibodies and binding fragments of the invention do not significantly bind to human VPAC1 or human VPAC2.

[0055] The antibodies and antigen-binding fragments of the present invention can inhibit, interfere with or modulate one or more biological activities of the human PAC1 receptor. The biological activities of the human PAC1 receptor include, but are not limited to, inducing PACAP-mediated receptor signal transduction pathways, inducing vasodilation, and inhibiting vasoconstriction. In some embodiments, the antibodies or binding fragments of the present invention inhibit the binding of PACAP (e.g., PACAP38 or PACAP27) to the human PAC1 receptor. For example, by measuring the binding in an in vitro competitive binding assay, "binding inhibition" occurs when an excess of the antibody or binding fragment reduces the amount of human PAC1 receptor bound to PACAP, and vice versa, for example, by reducing at least about 40%, about 50%, about 60%, about 70%, about 80%, about 85%, about 90%, about 95%, about 97%, about 99% or more. The inhibition constant (Ki) indicates the effectiveness of the antibodies or antigen-binding fragments of the present invention in preventing PACAP from binding to the human PAC1 receptor and can be calculated from such a competitive binding assay. For example, a radioactive isotope (e.g., 125I) is attached to a receptor ligand (e.g., PACAP38), and the assay measures the binding of the radiolabeled ligand to the human PAC1 receptor in the presence of increasing concentrations of anti-PAC1 antibodies or binding fragments thereof. The Ki value can be calculated using the equation Ki = IC50 / (1+([L] / Kd)), where [L] is the concentration of the radioligand used (e.g., 125 I labeled PACAP38), and Kd is the dissociation constant of the radioligand. See, e.g., Keen M, MacDermot J (1993) Analysis of receptors by radioligand binding. In: Wharton J, Polak JM (eds.) Receptor autoradiography, principles and practice. Oxford University Press, Oxford. The lower the Ki value of the antagonist, the more potent the antagonist. In some embodiments, the antibodies or antigen-binding fragments thereof of the invention compete for binding to human PAC1 receptors with radiolabeled PACAP ligands, wherein Ki≤1 nM. In other embodiments, the antibodies or antigen-binding fragments thereof of the invention compete for binding to human PAC1 receptors with radiolabeled PACAP ligands, wherein Ki≤500 pM. In yet other embodiments, the antibodies or antigen-binding fragments thereof of the invention compete for binding to human PAC1 receptors with radiolabeled PACAP ligands, wherein Ki≤200 pM. In certain other embodiments, the antibodies or antigen-binding fragments thereof of the invention compete for binding to human PAC1 receptor with radiolabeled PACAP ligand, wherein Ki≤100 pM.

[0056] In certain embodiments, the antibodies and antigen-binding fragments of the invention inhibit ligand-induced activation of the human PAC1 receptor. The ligand can be an endogenous ligand of the receptor, such as PACAP38 or PACAP27, or the ligand can be another known agonist of the receptor, such as maxadilan. Maxadilan is a 65 amino acid peptide originally isolated from sand flies that has excellent selectivity for PAC1 compared to VPAC1 or VPAC2 and is therefore useful as a PAC1 selective agonist (Lerner et al., J Biol Chem., Vol. 266(17):11234-11236, 1991; Lerner et al., Peptides, Vol. 28(9):1651-1654, 2007). Various assays for assessing PAC1 receptor activation are known in the art, including cell-based assays that measure ligand-induced calcium mobilization and cAMP production. An exemplary cell-based cAMP assay is described in Example 3. Other suitable PAC1 receptor activation assays are described in Dickson et al., Ann. NY Acad. Sci., Vol. 1070: 239-42, 2006; Bourgault et al., J. Med. Chem., Vol. 52: 3308-3316, 2009; and U.S. Patent Application No. 2011 / 0229423, all of which are incorporated herein by reference in their entirety.

[0057] The inhibitory activity of these antibodies or antigen binding fragments on PAC1 receptor activation can be quantified by calculating the IC50 in any functional assay of the receptor, such as those described above. "IC50" is the dose / concentration required to achieve 50% inhibition of biological or biochemical function. For radioligands, IC50 is the concentration of the competing ligand that displaces 50% of the specific binding of the radioligand. The IC50 of any particular substance or antagonist can be determined by constructing a dose-response curve and examining the effect of different concentrations of the drug or antagonist on the reversal of agonist activity in a specific functional assay. The IC50 value of a given antagonist or drug can be calculated by determining the concentration required to inhibit half of the maximal biological response of the agonist. Therefore, in any functional assay (such as the cAMP assay described in the Examples) to activate the human PAC1 receptor, the IC50 value of any anti-PAC1 antibody or binding fragment thereof of the present invention can be determined by determining the concentration of the antibody or binding fragment required to inhibit half of the maximal biological response of the ligand (e.g., PACAP27, PACAP38 or maxadilan). An anti-PAC1 antibody or binding fragment thereof that inhibits ligand-induced (eg, PACAP-induced) activation of the PAC1 receptor is understood to be a neutralizing or antagonist antibody or binding fragment of the PAC1 receptor.

[0058] In certain embodiments, the antibodies or antigen-binding fragments of the invention inhibit PACAP-induced (PACAP38-induced or PACAP27-induced) activation of the human PAC1 receptor. For example, the antibodies or antigen-binding fragments can inhibit PACAP-induced activation of the human PAC1 receptor, wherein the IC50 as measured by a cell-based calcium mobilization assay or a cAMP assay is less than about 10 nM, less than about 8 nM, less than about 5 nM, less than about 3 nM, less than about 1 nM, less than about 800 pM, less than about 500 pM, less than about 400 pM, less than about 300 pM, less than about 200 pM, or less than about 100 pM. In a specific embodiment, the antibodies or antigen-binding fragments of the invention inhibit PACAP-induced activation of the human PAC1 receptor, wherein the IC50 as measured by a cell-based cAMP assay is less than about 5 nM. In another specific embodiment, the antibodies or antigen-binding fragments of the invention inhibit PACAP-induced activation of the human PAC1 receptor, wherein the IC50 as measured by a cell-based cAMP assay is less than about 1 nM. In still another specific embodiment, the antibodies or antigen-binding fragments of the invention inhibit PACAP-induced activation of the human PAC1 receptor, wherein the IC50 as measured by a cell-based cAMP assay is less than about 500 pM. In another embodiment, the antibodies or antigen-binding fragments of the invention inhibit PACAP-induced activation of the human PAC1 receptor, wherein the IC50 as measured by a cell-based cAMP assay is less than about 300 pM. In some embodiments, the antibodies or antigen-binding fragments of the invention inhibit PACAP-induced activation of the human PAC1 receptor, wherein the IC50 as measured by a cell-based cAMP assay is between about 0.1 nM and about 1 nM. In other embodiments, the antibodies or antigen-binding fragments of the invention inhibit PACAP-induced activation of the human PAC1 receptor, wherein the IC50 as measured by a cell-based cAMP assay is between about 50 pM and about 500 pM.

[0059] In some embodiments, the antibodies or antigen-binding fragments of the invention bind to and inhibit PAC1 receptors from other species. For example, the antibodies or antigen-binding fragments bind to and inhibit the cynomolgus monkey PAC1 receptor (NCBI reference sequence XP_015303041.1). In such embodiments, the antibodies or antigen-binding fragments inhibit PACAP-induced activation of the cynomolgus monkey PAC1 receptor, wherein the IC50 as measured by a cell-based calcium mobilization assay or a cAMP assay is less than about 10 nM, less than about 8 nM, less than about 5 nM, less than about 3 nM, less than about 1 nM, less than about 800 pM, less than about 500 pM, less than about 400 pM, less than about 300 pM, less than about 200 pM, or less than about 100 pM. In one embodiment, the antibodies or antigen-binding fragments of the invention inhibit PACAP-induced activation of the cynomolgus monkey PAC1 receptor, wherein the IC50 as measured by a cell-based cAMP assay is less than about 1 nM. In another embodiment, the antibodies or antigen-binding fragments of the invention inhibit PACAP-induced activation of the cynomolgus monkey PAC1 receptor, wherein the IC50 as measured by a cell-based cAMP assay is less than about 500 pM. In yet another embodiment, the antibodies or antigen-binding fragments of the invention inhibit PACAP-induced activation of the cynomolgus monkey PAC1 receptor, wherein the IC50 as measured by a cell-based cAMP assay is between about 0.1 nM and about 1 nM. In yet another embodiment, the antibodies or antigen-binding fragments of the invention inhibit PACAP-induced activation of the cynomolgus monkey PAC1 receptor, wherein the IC50 as measured by a cell-based cAMP assay is between about 50 pM and about 500 pM.

[0060] In certain embodiments, the antibodies or antigen-binding fragments bind to and inhibit rat PAC1 receptor (NCBI reference sequence NP_598195.1). In these embodiments, the antibodies or antigen-binding fragments can inhibit PACAP-induced activation of rat PAC1 receptor, wherein the IC50 as measured by a cell-based calcium mobilization assay or cAMP assay is less than about 10 nM, less than about 8 nM, less than about 5 nM, less than about 3 nM, less than about 1 nM, less than about 800 pM, less than about 500 pM, less than about 400 pM, less than about 300 pM, less than about 200 pM, or less than about 100 pM. In one embodiment, the antibodies or antigen-binding fragments of the invention inhibit PACAP-induced activation of rat PAC1 receptor, wherein the IC50 as measured by a cell-based cAMP assay is less than about 10 nM. In another embodiment, the antibodies or antigen-binding fragments of the invention inhibit PACAP-induced activation of rat PAC1 receptor, wherein the IC50 as measured by a cell-based cAMP assay is less than about 5 nM. In yet another embodiment, the antibodies or antigen-binding fragments of the invention inhibit PACAP-induced activation of rat PAC1 receptors, wherein the IC50 as measured by a cell-based cAMP assay is less than about 500 pM. In still another embodiment, the antibodies or antigen-binding fragments of the invention inhibit PACAP-induced activation of rat PAC1 receptors, wherein the IC50 as measured by a cell-based cAMP assay is less than about 300 pM. In some embodiments, the antibodies or antigen-binding fragments of the invention inhibit PACAP-induced activation of rat PAC1 receptors, wherein the IC50 as measured by a cell-based cAMP assay is between about 0.1 nM and about 10 nM. In still another embodiment, the antibodies or antigen-binding fragments of the invention inhibit PACAP-induced activation of rat PAC1 receptors, wherein the IC50 as measured by a cell-based cAMP assay is between about 100 pM and about 2 nM. In some embodiments, where the antibodies or binding fragments of the invention cross-react with PAC1 receptors from other species, the antibodies or binding fragments can inhibit PACAP-induced activation of PAC1 receptors with appropriate potency. For example, the antibodies or binding fragments of the invention can inhibit PACAP-induced activation of the human PAC1 receptor with an IC50 similar to the IC50 of the antibodies or binding fragments inhibiting PACAP-induced activation of the cynomolgus monkey or rat PAC1 receptor. Cross-reactivity with other species of PAC1 receptors of the antibodies or binding fragments of the invention can be advantageous because the therapeutic efficacy of these antibodies or binding fragments can be evaluated in additional preclinical animal models.

[0061] Typically, these antibodies or antigen-binding fragments of the present invention do not significantly inhibit ligand-induced activation of the human VPAC1 receptor or VPAC2 receptor (e.g., PACAP38, PACAP27 or VIP-induced). As used herein, an antibody or antigen-binding fragment will "not significantly inhibit" receptor activation or ligand binding to its receptor if there is no statistical difference between ligand-induced receptor activation or ligand binding to the receptor in the presence or absence of the antibody or antigen-binding fragment. For example, if the amount of cAMP produced by PACAP or VIP-induced cAMP in cells expressing the human VPAC1 receptor in the presence of the antibody or binding fragment is significantly different from the amount produced in the absence of the antibody or binding fragment, then the antibody or binding fragment will be considered to not significantly inhibit PACAP / VIP-induced activation of the human VPAC1 receptor. Similarly, if the amount of PACAP or VIP bound to the human VPAC1 receptor in the presence of an excess of the antibody or binding fragment is significantly different from the amount of PACAP or VIP bound to the receptor in the absence of the antibody or binding fragment, then the antibody or binding fragment will be considered to not significantly inhibit the binding of PACAP or VIP to the human VPAC1 receptor. In certain embodiments, the antibodies or binding fragments of the present invention inhibit PACAP-induced activation of the human PAC1 receptor, but do not significantly inhibit PACAP-induced activation of the human VPAC1 receptor or the human VPAC2 receptor. Therefore, relative to the human VPAC1 receptor and the human VPAC2 receptor, the antibodies and binding fragments of the present invention selectively inhibit the human PAC1 receptor.

[0062] In some embodiments, these antibodies and binding fragments of the present invention can bind to a specific region or epitope of human PAC1. As used herein, "epitope" refers to any determinant that can be specifically bound by an antibody or its fragment. An epitope is a region of an antigen that binds or interacts with an antibody or binding fragment that targets the antigen, and when the antigen is a protein, includes specific amino acids that directly contact or interact with the antibody or binding fragment. An epitope can be formed by continuous amino acids, or by non-continuous amino acids juxtaposed by the tertiary folding of a protein. A "linear epitope" is an epitope in which the primary sequence of amino acids contains a recognition epitope. A linear epitope typically includes at least 3 or 4 amino acids in a single sequence, and more usually at least 5, at least 6, or at least 7 amino acids, for example, about 8 to about 10 amino acids. In contrast to a linear epitope, a "conformational epitope" is a group of discontinuous amino acids (e.g., in a polypeptide, it is an amino acid residue that is discontinuous in the primary sequence of a polypeptide, but in the context of the tertiary and quaternary structures of the polypeptide, close enough to each other to be bound by an antibody or its binding fragment). Epitope determinants may include chemically active surface molecular groups, such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and may have specific three-dimensional structural characteristics and / or specific charge characteristics. Typically, an antibody or binding fragment specific for a particular target molecule will preferentially recognize an epitope on the target molecule in a complex mixture of proteins and / or macromolecules.

[0063] In certain embodiments, the antibodies or antigen-binding fragments of the invention bind to human PAC1 at an epitope within the N-terminal extracellular domain (ECD) of human PAC1 (SEQ ID NO:4). In related embodiments, the antibodies or antigen-binding fragments bind to human PAC1 at an epitope within amino acids 24-153 of SEQ ID NO:1. In other related embodiments, the antibodies or antigen-binding fragments bind to human PAC1 at an epitope within amino acids 50-140 of SEQ ID NO:1. As described in Example 1, the crystal structure of a complex of the human PAC1 N-terminal ECD and the Fab region of an anti-PAC1 neutralizing antibody revealed key amino acids within the human PAC1 ECD that comprise the binding interface with the anti-PAC1 Fab. These core interface amino acids, all of which are located in the Fab at positions 1 to 50 from non-hydrogen atoms. or less, and contains at least one non-hydrogen atom at a distance of Asp59, Asn60, Ile61, Arg116, Asn117, Thr119, Asp121, Gly122, Trp123, Ser124, Glu125, Pro126, Phe127, Pro128, His129, Tyr130, Phe131, Asp132 and Gly135 (relative to the amino acid position number of SEQ ID NO: 1). Thus, in some embodiments, the antibodies or binding fragments of the invention bind to human PAC1 at an epitope comprising one or more amino acids selected from Asp59, Asn60, Ile61, Arg116, Asn117, Thr119, Glu120, Asp121, Gly122, Trp123, Ser124, Glu125, Pro126, Phe127, Pro128, His129, Tyr130, Phe131, Asp132, and Gly135 of SEQ ID NO: 1. In other embodiments, the antibodies or binding fragments bind to human PAC1 at an epitope comprising at least amino acids Asn60, Ile61, Glu120, and Asp121 of SEQ ID NO: 1. In yet other embodiments, the antibodies or binding fragments bind to human PAC1 at an epitope comprising at least Asn60, Ile61, Glu120, Asp121, Phe127, and Phe131 of amino acids SEQ ID NO: 1. In certain other embodiments, the antibodies or binding fragments bind to human PAC1 at an epitope comprising all amino acids selected from the group consisting of Asp59, Asn60, Ile61, Arg116, Asn117, Thr119, Glu120, Asp121, Gly122, Trp123, Ser124, Glu125, Pro126, Phe127, Pro128, His129, Tyr130, Phe131, Asp132, and Gly135 of SEQ ID NO: 1.

[0064] The crystal structure of the human PAC1 ECD-Fab complex described in Example 1 also revealed important residues in the CDRs of the heavy and light chains of the Fab that interact with amino acids in the human PAC1 ECD, thereby identifying key amino acids in the paratope of the antibody. A "paratope" is the region of an antibody that recognizes and binds to a target antigen. Paratope residues include Gln27, Gly30, Arg31, and Ser32 in the light chain variable region (SEQ ID NO: 3) and Arg31, Phe32, Tyr53, Asp54, Gly56 in the heavy chain variable region (SEQ ID NO: 2). Specific mutations of several of these residues in the paratope are designed to improve interactions with core interface residues (i.e., residues in the epitope) in the human PAC1 ECD, resulting in enhanced binding affinity and inhibitory potency compared to the parent antibody (see Examples 1-3). Gln27, Gly30, Arg31 and Ser32 in the light chain variable region of SEQ ID NO:3 or SEQ ID NO:52 correspond to amino acid positions 29, 32, 39 and 40, respectively, in AHo numbering, and Arg31, Phe32, Tyr53, Asp54, Gly56 in the heavy chain variable region of SEQ ID NO:2 or SEQ ID NO:191 correspond to amino acid positions 33, 39, 60, 61 and 66, respectively, in AHo numbering. The AHo numbering scheme is a structure-based numbering scheme that introduces gaps in the CDR regions to minimize deviations from the average structure of the aligned domains (Honegger and Pluckthun, J. Mol. Biol. 309(3):657-670; 2001). In the AHo numbering scheme, structurally equivalent positions in different antibodies will have the same residue number.

[0065] In some embodiments, the present invention provides an antibody or antigen-binding fragment thereof that specifically binds to human PAC1 (SEQ ID NO: 1), wherein the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region, wherein the amino acid at position 29 according to AHo numbering is a basic amino acid that interacts with amino acid Glu120 or Asp121 of human PAC1, and (ii) a heavy chain variable region, wherein the amino acid at position 61 according to AHo numbering is a hydrophobic, basic or neutral hydrophilic amino acid that interacts with amino acid Asn60 or Ile61 of human PAC1. As used herein, an amino acid is said to interact with another amino acid when one or more atoms in the amino acid form a non-covalent bond with one or more atoms in the other amino acid through, for example, van der Waals forces, hydrophobic or electrostatic forces. Basic amino acids include arginine, lysine and histidine, while neutral hydrophilic amino acids include asparagine, glutamine, serine and threonine. Hydrophobic amino acids include phenylalanine, tryptophan, tyrosine, alanine, isoleucine, leucine and valine. In certain embodiments, the amino acid at position 29 in the light chain variable region according to AHo numbering is lysine or arginine. In a specific embodiment, the amino acid at position 29 in the light chain variable region according to AHo numbering is lysine. In a related embodiment, the amino acid at position 61 in the heavy chain variable region according to AHo numbering is isoleucine, leucine, valine, glutamine, asparagine, arginine or lysine. In one embodiment, the amino acid at position 61 in the heavy chain variable region according to AHo numbering is isoleucine. In another embodiment, the amino acid at position 61 in the heavy chain variable region according to AHo numbering is glutamine or asparagine. In yet another embodiment, the amino acid at position 61 in the heavy chain variable region according to AHo numbering is arginine.

[0066] In some embodiments, the amino acid at position 66 according to AHo numbering in the heavy chain variable region of the antibody or antigen-binding fragment thereof is a basic or neutral hydrophilic amino acid that interacts with amino acid Asn60 or Ile61 of human PAC1 (SEQ ID NO: 1). The amino acid at position 66 according to AHo numbering in the heavy chain variable region can be glutamine, asparagine, arginine or lysine. In one embodiment, the amino acid at position 66 according to AHo numbering in the heavy chain variable region is arginine. In another embodiment, the amino acid at position 66 according to AHo numbering in the heavy chain variable region is asparagine.

[0067] The paratope-epitope interactions described above were found to be associated with improvements in inhibitory potency, with IC50 values ​​in the picomolar range. See Example 3. Thus, antibodies or antigen-binding fragments thereof having the above-specified amino acids at position 29 in the light chain variable region and at positions 61 and / or 66 in the heavy chain variable region according to AHo numbering and interacting with specific residues in the human PAC1 receptor (Glu120, Aspl21, Asn60, and / or Ile61 of SEQ ID NO: 1) would be expected to have improved inhibitory potency, e.g., inhibiting PACAP-induced activation of human PAC1, with an IC50 of less than 500 pM as measured by a cell-based cAMP assay. In some embodiments, such antibodies or antigen-binding fragments can inhibit PACAP-induced activation of human PAC1, with an IC50 of less than 300 pM as measured by a cell-based cAMP assay. In these and other embodiments, the antibodies or antigen-binding fragments thereof can have a light chain variable region comprising a sequence at least 90% identical to that of SEQ ID NO:52 and a heavy chain variable region comprising a sequence at least 90% identical to that of SEQ ID NO:191.

[0068] These antibodies or antigen-binding fragments of the present invention may comprise one or more complementary determining regions (CDRs) from the light chain and heavy chain variable regions of an antibody that specifically binds to human PAC1 as described herein. The term "CDR" refers to the complementary determining region (also referred to as the "minimum recognition unit" or "hypervariable region") within the antibody variable sequence. There are three heavy chain variable region CDRs (CDRH1, CDRH2, and CDRH3) and three light chain variable region CDRs (CDRL1, CDRL2, and CDRL3). As used herein, the term "CDR region" refers to a group of three CDRs that appear in a single variable region (i.e., three light chain CDRs or three heavy chain CDRs). The CDRs in each chain of the two chains are typically aligned by a framework region (FR) to form a structure that specifically binds to a specific epitope or domain on a target protein (e.g., human PAC1). From the N-terminus to the C-terminus, both naturally occurring light and heavy chain variable regions are typically consistent with the order of the following elements: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. A numbering system has been devised for assigning numbers to the amino acids that occupy positions in each of these domains. This numbering system is defined in the Kabat sequences of proteins of immunological interest (1987 and 1991, NIH, Bethesda, MD) or in Chothia and Lesk, 1987, J. Mol. Biol. 196:901-917; Chothia et al., 1989, Nature 342:878-883. Using this system, the complementarity determining regions (CDRs) and framework regions (FRs) of a given antibody can be identified. Other numbering systems for amino acids in immunoglobulin chains include (international ImMunoGeneTicsinformation system; Lefranc et al., Dev. Comp. Immunol. 29:185-203; 2005) and AHo (Honegger and Pluckthun, J. Mol. Biol. 309(3):657-670; 2001).

[0069] In certain embodiments, the anti-PAC1 antibodies or antigen-binding fragments thereof of the invention comprise: at least one light chain variable region comprising CDRL1, CDRL2, and CDRL3 and at least one heavy chain variable region comprising CDRH1, CDRH2, and CDRH3 from any of the anti-PAC1 antibodies described herein. The light and heavy chain variable regions and associated CDRs of exemplary human anti-PAC1 antibodies are listed below in Tables 1A and 1B, respectively.

[0070] Table 1A. Exemplary anti-human PAC1 antibody light chain variable region amino acid sequences

[0071]

[0072]

[0073]

[0074]

[0075]

[0076]

[0077]

[0078]

[0079]

[0080]

[0081]

[0082]

[0083]

[0084]

[0085]

[0086]

[0087]

[0088]

[0089]

[0090]

[0091] Table 1B. Exemplary anti-human PAC1 antibody heavy chain variable region amino acid sequences

[0092]

[0093]

[0094]

[0095]

[0096]

[0097]

[0098]

[0099]

[0100]

[0101]

[0102]

[0103]

[0104]

[0105]

[0106]

[0107]

[0108]

[0109]

[0110]

[0111]

[0112]

[0113]

[0114]

[0115]

[0116] The anti-PAC1 antibodies or antigen-binding fragments of the invention may comprise one or more light chain CDRs (i.e., CDRLs) and / or heavy chain CDRs (i.e., CDRHs) shown in Tables 1A and 1B, respectively. In some embodiments, the anti-PAC1 antibodies or binding fragments thereof are derived from antibodies 29G4v9, 29G4v10, or 29G4v22 (i.e., have one or more substitutions in one or more CDRLs and / or CDRHs of 29G4v9, 29G4v10, or 29G4v22 antibodies). For example, in certain embodiments, the anti-PAC1 antibodies or antigen-binding fragments comprise one or more light chain CDRs selected from the group consisting of: (i) a CDRL1 selected from SEQ ID NOs: 5 to 16, (ii) a CDRL2 selected from SEQ ID NO: 26, and (iii) a CDRL3 selected from SEQ ID NOs: 36 to 38, and (iv) a CDRL of (i), (ii) and (iii) comprising one or more, e.g., one, two, three, four or more amino acid substitutions (e.g., conservative amino acid substitutions), no more than five, four, three, two, or one amino acid deletion or insertion. In these and other embodiments, the anti-PAC1 antibodies or antigen-binding fragments comprise one or more heavy chain CDRs selected from: (i) a CDRH1 selected from SEQ ID NOs: 88 to 96, (ii) a CDRH2 selected from SEQ ID NOs: 106 to 166, and (iii) a CDRH3 selected from SEQ ID NOs: 171 to 177, and (iv) a CDRH of (i), (ii) and (iii) comprising one or more, e.g., one, two, three, four or more amino acid substitutions (e.g., conservative amino acid substitutions), no more than five, four, three, two, or one amino acid deletion or insertion.

[0117] In other embodiments, the anti-PAC1 antibody or its binding fragment is derived from antibody 19H8 (i.e., has one or more substitutions in one or more CDRLs and / or CDRHs of the 19H8 antibody). In such embodiments, the anti-PAC1 antibodies or antigen-binding fragments comprise one or more light chain CDRs selected from (i) CDRL1 selected from SEQ ID NOs: 17 to 25, (ii) CDRL2 selected from SEQ ID NOs: 27 to 35, and (iii) CDRL3 selected from SEQ ID NOs: 39 to 51, and (iv) CDRLs of (i), (ii), and (iii) comprising one or more, e.g., one, two, three, four or more amino acid substitutions (e.g., conservative amino acid substitutions), no more than five, four, three, two, or one amino acid deletion or insertion. In these and other embodiments, the anti-PAC1 antibodies or antigen-binding fragments comprise one or more heavy chain CDRs selected from: (i) a CDRH1 selected from SEQ ID NOs: 97 to 105, (ii) a CDRH2 selected from SEQ ID NOs: 167 to 170, and (iii) a CDRH3 selected from SEQ ID NOs: 178 to 190, and (iv) a CDRH of (i), (ii) and (iii) comprising one or more, e.g., one, two, three, four or more amino acid substitutions (e.g., conservative amino acid substitutions), no more than five, four, three, two, or one amino acid deletion or insertion.

[0118] In certain embodiments, the anti-PAC1 antibodies or antigen-binding fragments may comprise 1, 2, 3, 4, 5, or 6 variant forms of the CDRs listed in Tables 1A and 1B, each having at least 80%, 85%, 90%, or 95% sequence identity with the CDR sequences listed in Tables 1A and 1B. In some embodiments, the anti-PAC1 antibodies or antigen-binding fragments comprise 1, 2, 3, 4, 5, or 6 of the CDRs listed in Tables 1A and 1B, each differing by no more than 1, 2, 3, 4, or 5 amino acids from the CDRs listed in these tables. In some embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise: a CDRL1 comprising a sequence selected from SEQ ID NOs: 5 to 16, or a variant thereof having one, two, three or four amino acid substitutions; a CDRL2 comprising a sequence selected from SEQ ID NO: 26, or a variant thereof having one, two, three or four amino acid substitutions; a CDRL3 comprising a sequence selected from SEQ ID NOs: 36 to 38, or a variant thereof having one, two, three or four amino acid substitutions; a CDRH1 comprising a sequence selected from SEQ ID NOs: 88 to 96, or a variant thereof having one, two, three or four amino acid substitutions; a CDRH2 comprising a sequence selected from SEQ ID NOs: 106 to 166, or a variant thereof having one, two, three or four amino acid substitutions; and a CDRH3 comprising a sequence selected from SEQ ID NOs: 171 to 177, or a variant thereof having one, two, three or four amino acid substitutions. In other embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise: CDRL1 comprising a sequence selected from SEQ ID NOs: 5 to 16; CDRL2 comprising a sequence selected from SEQ ID NO: 26; CDRL3 comprising a sequence selected from SEQ ID NOs: 36 to 38; CDRH1 comprising a sequence selected from SEQ ID NOs: 88 to 96; CDRH2 comprising a sequence selected from SEQ ID NOs: 106 to 166; and CDRH3 comprising a sequence selected from SEQ ID NOs: 171 to 177.

[0119] In other embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise: a CDRL1 comprising a sequence selected from SEQ ID NOs: 17 to 25, or a variant thereof having one, two, three or four amino acid substitutions; a CDRL2 comprising a sequence selected from SEQ ID NOs: 27 to 35, or a variant thereof having one, two, three or four amino acid substitutions; a CDRL3 comprising a sequence selected from SEQ ID NOs: 39 to 51, or a variant thereof having one, two, three or four amino acid substitutions; a CDRH1 comprising a sequence selected from SEQ ID NOs: 97 to 105, or a variant thereof having one, two, three or four amino acid substitutions; a CDRH2 comprising a sequence selected from SEQ ID NOs: 167 to 170, or a variant thereof having one, two, three or four amino acid substitutions; and a CDRH3 comprising a sequence selected from SEQ ID NOs: 178 to 190, or a variant thereof having one, two, three or four amino acid substitutions. In other embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise: CDRL1 comprising a sequence selected from SEQ ID NOs: 17 to 25; CDRL2 comprising a sequence selected from SEQ ID NOs: 27 to 35; CDRL3 comprising a sequence selected from SEQ ID NOs: 39 to 51; CDRH1 comprising a sequence selected from SEQ ID NOs: 97 to 105; CDRH2 comprising a sequence selected from SEQ ID NOs: 167 to 170; and CDRH3 comprising a sequence selected from SEQ ID NOs: 178 to 190.

[0120] In specific embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the present invention comprise a light chain variable region comprising CDRL1, CDRL2 and CDRL3, wherein: (a) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 7, 26 and 36, respectively; (b) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 5, 26 and 36, respectively; (c) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 12, 26 and 36, respectively; or (d) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 13, 26 and 36, respectively.

[0121] In other specific embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the present invention comprise a heavy chain variable region comprising CDRH1, CDRH2 and CDRH3, wherein: (a) CDRH1, CDRH2 and CDRH3 have sequences of SEQ ID NOs: 88, 108 and 171, respectively; (b) CDRH1, CDRH2 and CDRH3 have sequences of SEQ ID NOs: 88, 116 and 171, respectively; (c) CDRH1, CDRH2 and CDRH3 have sequences of SEQ ID NOs: 88, 134 and 171, respectively; (d) CDRH1, CDRH2 and CDRH3 have sequences of SEQ ID NOs: 92, 145 and 174, respectively; (e) CDRH1, CDRH2 and CDRH3 have sequences of SEQ ID NOs: 88, 108 and 172, respectively; (f) CDRH1, CDRH2 and CDRH3 have sequences of SEQ ID NOs: 88, 116 and 171, respectively. (g) CDRH1, CDRH2 and CDRH3 have sequences of SEQ ID NOs:88, 153 and 171, respectively; (i) CDRH1, CDRH2 and CDRH3 have sequences of SEQ ID NOs:88, 154 and 171, respectively; or (j) CDRH1, CDRH2 and CDRH3 have sequences of SEQ ID NOs:88, 155 and 171, respectively.

[0122] In certain embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise: a light chain variable region comprising CDRL1, CDRL2, and CDRL3 and a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein:

[0123] (a) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 7, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 88, 108 and 171, respectively;

[0124] (b) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 7, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 88, 116 and 171, respectively;

[0125] (c) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 5, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 88, 134 and 171, respectively;

[0126] (d) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 5, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 92, 145 and 174, respectively;

[0127] (e) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 7, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 88, 108 and 172, respectively;

[0128] (f) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 5, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 88, 128 and 172, respectively;

[0129] (g) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 7, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 88, 134 and 171, respectively;

[0130] (h) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 12, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 88, 153 and 171, respectively;

[0131] (i) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 12, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 88, 154 and 171, respectively; or

[0132] (j) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 13, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 88, 155 and 171, respectively.

[0133] In one embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises: a light chain variable region comprising CDRL1, CDRL2 and CDRL3 and a heavy chain variable region comprising CDRH1, CDRH2 and CDRH3, wherein CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 7, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 88, 108 and 171, respectively. In another embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises: a light chain variable region comprising CDRL1, CDRL2 and CDRL3 and a heavy chain variable region comprising CDRH1, CDRH2 and CDRH3, wherein CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 7, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 88, 116 and 171, respectively. In yet another embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises: a light chain variable region comprising CDRL1, CDRL2 and CDRL3 and a heavy chain variable region comprising CDRH1, CDRH2 and CDRH3, wherein CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 5, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 88, 134 and 171, respectively. In yet another embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises: a light chain variable region comprising CDRL1, CDRL2 and CDRL3 and a heavy chain variable region comprising CDRH1, CDRH2 and CDRH3, wherein CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 5, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 92, 145 and 174, respectively. In a specific embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises: a light chain variable region comprising CDRL1, CDRL2 and CDRL3 and a heavy chain variable region comprising CDRH1, CDRH2 and CDRH3, wherein CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 7, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 88, 108 and 172, respectively.In another specific embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises: a light chain variable region comprising CDRL1, CDRL2 and CDRL3 and a heavy chain variable region comprising CDRH1, CDRH2 and CDRH3, wherein CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 12, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 88, 153 and 171, respectively.

[0134] In certain embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the present invention comprise a light chain variable region comprising CDRL1, CDRL2 and CDRL3, wherein: (a) CDRL1, CDRL2 and CDRL3 have sequences of SEQ ID NOs: 25, 31 and 42, respectively; (b) CDRL1, CDRL2 and CDRL3 have sequences of SEQ ID NOs: 20, 30 and 44, respectively; (c) CDRL1, CDRL2 and CDRL3 have sequences of SEQ ID NOs: 17, 33 and 42, respectively; (d) CDRL1, CDRL2 and CDRL3 have sequences of SEQ ID NOs: 23, 31 and 50, respectively; (e) CDRL1, CDRL2 and CDRL3 have sequences of SEQ ID NOs: 17, 31 and 44, respectively; (f) CDRL1, CDRL2 and CDRL3 have sequences of SEQ ID NOs: 17, 27 and 39, respectively; (g) CDRL1, CDRL2 and CDRL3 have sequences of SEQ ID NOs: 17, 27 and 39, respectively. NO:18, 31 and 46; (h) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NO:17, 28 and 40, respectively; (i) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NO:18, 30 and 43, respectively; or (j) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NO:22, 28 and 49, respectively.

[0135] In certain other embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the present invention comprise a heavy chain variable region comprising CDRH1, CDRH2 and CDRH3, wherein: (a) CDRH1, CDRH2 and CDRH3 have sequences of SEQ ID NOs: 98, 168 and 190, respectively; (b) CDRH1, CDRH2 and CDRH3 have sequences of SEQ ID NOs: 100, 168 and 182, respectively; (c) CDRH1, CDRH2 and CDRH3 have sequences of SEQ ID NOs: 99, 168 and 187, respectively; (d) CDRH1, CDRH2 and CDRH3 have sequences of SEQ ID NOs: 97, 167 and 178, respectively; (e) CDRH1, CDRH2 and CDRH3 have sequences of SEQ ID NOs: 98, 168 and 189, respectively; (f) CDRH1, CDRH2 and CDRH3 have sequences of SEQ ID NOs: or (g) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 102, 169 and 182, respectively.

[0136] In some embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise: a light chain variable region comprising CDRL1, CDRL2, and CDRL3 and a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein:

[0137] (a) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 25, 31 and 42, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 98, 168 and 190, respectively;

[0138] (b) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 20, 30 and 44, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 100, 168 and 182, respectively;

[0139] (c) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 17, 33 and 42, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 99, 168 and 187, respectively;

[0140] (d) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 23, 31 and 50, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 97, 167 and 178, respectively;

[0141] (e) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 17, 31 and 44, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 98, 168 and 189, respectively;

[0142] (f) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 17, 27 and 39, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 100, 168 and 182, respectively;

[0143] (g) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 18, 31 and 46, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 98, 168 and 179, respectively;

[0144] (h) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 17, 28 and 40, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 98, 168 and 179, respectively;

[0145] (i) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 18, 30 and 43, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 100, 168 and 182, respectively; or

[0146] (j) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 22, 28 and 49, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 102, 169 and 182, respectively.

[0147] In one embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises: a light chain variable region comprising CDRL1, CDRL2 and CDRL3 and a heavy chain variable region comprising CDRH1, CDRH2 and CDRH3, wherein CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 25, 31 and 42, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 98, 168 and 190, respectively. In another embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises: a light chain variable region comprising CDRL1, CDRL2 and CDRL3 and a heavy chain variable region comprising CDRH1, CDRH2 and CDRH3, wherein CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 20, 30 and 44, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 100, 168 and 182, respectively. In yet another embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises: a light chain variable region comprising CDRL1, CDRL2 and CDRL3 and a heavy chain variable region comprising CDRH1, CDRH2 and CDRH3, wherein CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 17, 33 and 42, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 99, 168 and 187, respectively. In yet another embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises: a light chain variable region comprising CDRL1, CDRL2 and CDRL3 and a heavy chain variable region comprising CDRH1, CDRH2 and CDRH3, wherein CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 23, 31 and 50, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 97, 167 and 178, respectively. In a specific embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises: a light chain variable region comprising CDRL1, CDRL2 and CDRL3 and a heavy chain variable region comprising CDRH1, CDRH2 and CDRH3, wherein CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 17, 31 and 44, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 98, 168 and 189, respectively.In another specific embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises: a light chain variable region comprising CDRL1, CDRL2 and CDRL3 and a heavy chain variable region comprising CDRH1, CDRH2 and CDRH3, wherein CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 17, 27 and 39, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 100, 168 and 182, respectively.

[0148] In certain embodiments, the antibodies and antigen-binding fragments of the invention comprise an immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain variable region (VL) from an antibody that specifically binds to human PAC1, such as those described herein. "Variable region" is used interchangeably herein with "variable domain" (variable region of light chain (VL), variable region of heavy chain (VH)) to refer to the region in each light and heavy immunoglobulin chain that is directly involved in the binding of the antibody to the antigen. As described above, the variable light and heavy chain regions have the same general structure, and each region comprises four framework regions (FRs), the sequences of which are widely conserved and connected by three CDRs. The framework regions adopt a β-sheet conformation, and the CDRs can form loops connecting the β-sheet structure. The CDRs in each chain maintain their three-dimensional structure through the framework regions and form an antigen binding site together with the CDRs from the other chain.

[0149] Therefore, in some embodiments, the anti-PAC1 antibodies and antigen-binding fragments of the present invention may comprise a light chain variable region selected from LV-01 to LV-15 as shown in Table 1A, and / or a heavy chain variable region selected from HV-01 to HV-105 as shown in Table 1B, and binding fragments, derivatives and variants of these light and heavy chain variable regions. In other embodiments, the anti-PAC1 antibodies and antigen-binding fragments of the present invention may comprise a light chain variable region selected from LV-16 to LV-36 as shown in Table 1A, and / or a heavy chain variable region selected from HV-106 to HV-122 as shown in Table 1B, and binding fragments, derivatives and variants of these light and heavy chain variable regions.

[0150] Each light chain variable region listed in Table 1A can be combined with any heavy chain variable region listed in Table 1B to form an anti-PAC1 antibody or antigen-binding fragment thereof of the present invention. Examples of such combinations include, but are not limited to: (i) LV-03 with any one of HV-03 to HV-26, HV-32 to HV-47, and HV-57 to HV-62; (ii) LV-04 with any one of HV-11 to HV-91; (iii) LV-05 with any one of HV-01, HV-03, HV-07, HV-09, and HV-10; (iv) LV-06 with any one of HV-01, HV-03, HV-07, HV-09, and HV-10; (v) LV-07 with any one of HV-01, HV-03, HV-07, HV-09, and HV-10. (vi) LV-08 and HV-01; (vii) LV-09 and HV-01; (viii) LV-10 and HV-01; (ix) LV-11 and any one of HV-92, HV-93, HV-95 to HV-97, and HV-99 to HV-101; (x) LV-12 and HV-94; (xi) LV-13 and HV-98; (xii) LV-14 and any one of HV-102 to HV-104; (xiii) LV-1 5 and HV-105; (xiv) LV-17 and HV-107; (xv) LV-18 and HV-108; (xvi) LV-19 and HV-109; (xvii) LV-20 and HV-110; (xviii) LV-21 and HV-110; (xix) LV-22 and HV-111; (xx) LV-23 and HV-107; (xxi) LV-24 and HV-112; (xxii) LV-25 and HV-113; (xxiii) LV-26 and HV-114; (xxiv) LV -27 with HV-106 or HV-110; (xxv) LV-28 with HV-115 or HV-118; (xxvi) LV-29 with HV-116; (xxvii) LV-30 with HV-117; (xxviii) LV-31 with HV-119; (xxix) LV-32 with HV-120; (xxx) LV-33 with HV-121; (xxxi) LV-34 with HV-122; (xxxii) LV-35 with HV-110; and (xxxiii) LV-36 with HV-110.

[0151] In certain embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising the sequence of LV-03 (SEQ ID NO:54) and a heavy chain variable region comprising the sequence of HV-04 (SEQ ID NO:194). In some embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising the sequence of LV-03 (SEQ ID NO:54) and a heavy chain variable region comprising the sequence of HV-13 (SEQ ID NO:203). In other embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising the sequence of LV-04 (SEQ ID NO:55) and a heavy chain variable region comprising the sequence of HV-38 (SEQ ID NO:228). In still other embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising the sequence of LV-04 (SEQ ID NO:55) and a heavy chain variable region comprising the sequence of HV-84 (SEQ ID NO:274). In some embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising the sequence of LV-03 (SEQ ID NO:54) and a heavy chain variable region comprising the sequence of HV-24 (SEQ ID NO:214). In certain embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising the sequence of LV-04 (SEQ ID NO:55) and a heavy chain variable region comprising the sequence of HV-50 (SEQ ID NO:240). In one embodiment, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising the sequence of LV-03 (SEQ ID NO:54) and a heavy chain variable region comprising the sequence of HV-38 (SEQ ID NO:228). In another embodiment, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising the sequence of LV-11 (SEQ ID NO:62) and a heavy chain variable region comprising the sequence of HV-92 (SEQ ID NO:282). In yet another embodiment, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising the sequence of LV-11 (SEQ ID NO: 62) and a heavy chain variable region comprising the sequence of HV-93 (SEQ ID NO: 283). In yet another embodiment, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising the sequence of LV-12 (SEQ ID NO: 63) and a heavy chain variable region comprising the sequence of HV-94 (SEQ ID NO: 284).

[0152] In certain other embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising the sequence of LV-34 (SEQ ID NO:85) and a heavy chain variable region comprising the sequence of HV-122 (SEQ ID NO:312). In some embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising the sequence of LV-21 (SEQ ID NO:72) and a heavy chain variable region comprising the sequence of HV-110 (SEQ ID NO:300). In other embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising the sequence of LV-30 (SEQ ID NO:81) and a heavy chain variable region comprising the sequence of HV-117 (SEQ ID NO:307). In still other embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising the sequence of LV-27 (SEQ ID NO:78) and a heavy chain variable region comprising the sequence of HV-106 (SEQ ID NO:296). In some embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising the sequence of LV-32 (SEQ ID NO:83) and a heavy chain variable region comprising the sequence of HV-120 (SEQ ID NO:310). In certain embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising the sequence of LV-36 (SEQ ID NO:87) and a heavy chain variable region comprising the sequence of HV-110 (SEQ ID NO:300). In one embodiment, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising the sequence of LV-23 (SEQ ID NO:74) and a heavy chain variable region comprising the sequence of HV-107 (SEQ ID NO:297). In another embodiment, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising the sequence of LV-17 (SEQ ID NO: 68) and a heavy chain variable region comprising the sequence of HV-107 (SEQ ID NO: 297). In yet another embodiment, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising the sequence of LV-20 (SEQ ID NO: 71) and a heavy chain variable region comprising the sequence of HV-110 (SEQ ID NO: 300). In yet another embodiment, the anti-PAC1 antibodies or antigen-binding fragments of the invention comprise a light chain variable region comprising the sequence of LV-26 (SEQ ID NO: 77) and a heavy chain variable region comprising the sequence of HV-114 (SEQ ID NO: 304).

[0153] In some embodiments, these anti-PAC1 antibodies or antigen-binding fragments thereof comprise a light chain variable region comprising a contiguous amino acid sequence that differs from the sequence of a light chain variable region in Table 1A (i.e., VL selected from LV-01 to LV-36) by only 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid residues, wherein each such sequence difference is independently a deletion, insertion, or substitution of one amino acid, wherein such deletions, insertions, and / or substitutions result in no more than 15 amino acid changes relative to the aforementioned variable domain sequence. The light chain variable region in some anti-PAC1 antibodies and binding fragments comprises an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NOs: 52 to 87 (i.e., the light chain variable region in Table 1A).

[0154] In one embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising a sequence having at least 90% identity to a sequence selected from SEQ ID NOs: 54-66. In another embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising a sequence having at least 95% identity to a sequence selected from SEQ ID NOs: 54-66. In yet another embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising a sequence selected from SEQ ID NOs: 54-66. In some embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising a sequence selected from SEQ ID NOs: 54-66. In other embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising a sequence of SEQ ID NO: 54. In other embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising a sequence of SEQ ID NO: 55. In yet other embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising a sequence of SEQ ID NO: 62. In still other embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the sequence of SEQ ID NO:63.

[0155] In another embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising a sequence having at least 90% identity to a sequence selected from SEQ ID NOs: 68-87. In yet another embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising a sequence having at least 95% identity to a sequence selected from SEQ ID NOs: 68-87. In yet another embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising a sequence selected from SEQ ID NOs: 68-87. In certain embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising a sequence of SEQ ID NO: 68. In some embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising a sequence of SEQ ID NO: 71. In other embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising a sequence of SEQ ID NO: 72. In yet other embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the sequence of SEQ ID NO: 74. In still other embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the sequence of SEQ ID NO: 77. In certain embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the sequence of SEQ ID NO: 78. In other embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the sequence of SEQ ID NO: 81. In one embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the sequence of SEQ ID NO: 83. In another embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the sequence of SEQ ID NO: 85. In yet another embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the sequence of SEQ ID NO:87.

[0156] In these and other embodiments, the anti-PAC1 antibodies and antigen-binding fragments thereof comprise a heavy chain variable region comprising a contiguous amino acid sequence that differs from the sequence of a heavy chain variable region in Table 1B (i.e., a VH selected from HV-01 to HV-122) by only 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acid residues, wherein each such sequence difference is independently a deletion, insertion or substitution of one amino acid, wherein the deletions, insertions and / or substitutions result in no more than 15 amino acid changes relative to the aforementioned variable domain sequence. The heavy chain variable region in some anti-PAC1 antibodies and antigen-binding fragments comprises an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% sequence identity with the amino acid sequence of SEQ ID NOs: 191 to 312 (i.e., a heavy chain variable region in Table 1B).

[0157] In one embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a sequence having at least 90% identity to a sequence selected from SEQ ID NOs: 191-295. In another embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a sequence having at least 95% identity to a sequence selected from SEQ ID NOs: 191-295. In yet another embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a sequence selected from SEQ ID NOs: 191-295. In some embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a sequence selected from SEQ ID NOs: 191-295. In other embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a sequence of SEQ ID NO: 194. In other embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a sequence of SEQ ID NO: 203. In yet other embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 214. In still other embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 228. In certain embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 240. In other embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 274. In one embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 282. In another embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 283. In yet another embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the sequence of SEQ ID NO:284.

[0158] In another embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a sequence having at least 90% identity to a sequence selected from SEQ ID NOs: 296-312. In yet another embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a sequence having at least 95% identity to a sequence selected from SEQ ID NOs: 296-312. In yet another embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a sequence selected from SEQ ID NOs: 296-312. In some embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a sequence of SEQ ID NO: 296. In other embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a sequence of SEQ ID NO: 297. In yet other embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 300. In still other embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 304. In certain embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 307. In other embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 310. In one embodiment, the anti-PAC1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 312.

[0159] As used herein, the term "identity" refers to the relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by alignment and comparison of sequences. As used herein, "percent identity" refers to the percentage of identical residues between amino acids or nucleotides in the molecules being compared, and is calculated based on the size of the smallest molecule being compared. For these calculations, gaps in the alignment, if any, must be resolved by a specific mathematical model or computer program (i.e., an "algorithm"). Methods that can be used to calculate the identity of aligned nucleic acids or polypeptides include those described in Computational Molecular Biology (Lesk, AM, ed.), 1988, New York: Oxford University Press; Biocomputing Informatics and Genome Projects (Smith, DW, ed.), 1993, New York: Academic Press; Computer Analysis of Sequence Data, Part I (Griffin, AM, and Griffin, HG, eds.), 1994, New Jersey: Humana Press; von Heinje, G., 1987, Sequence Analysis in Molecular Biology, New York: Academic Press; Sequence Analysis Primer [Sequence Analysis Primer], (Gribskov, M. and Devereux, J., eds.), 1991, New York: Stockton Press; and Carillo et al., 1988, SIAM J. Applied Math. [Journal of the Society for Industrial and Applied Mathematics] 48:1073. For example, sequence identity can be determined by standard methods that are commonly used to compare the similarity of amino acid positions of two polypeptides. Using computer programs such as BLAST or FASTA, two polypeptide or two polynucleotide sequences are aligned for the best match of their respective residues (along the entire length of one or both sequences, or along a predetermined portion of one or both sequences).These programs provide default open penalty and default gap penalty, and for example PAM 250 (Dayhoff et al., Atlas of Protein Sequence and Structure [protein sequence and structure atlas], Vol. 5, Supplement No. 3, 1978) or BLOSUM62 (Henikoff et al., 1992, Proc. Natl. Acad. Sci. USA [National Academy of Sciences] 89: 10915-10919) scoring matrices can be used with computer programs. For example, then the percentage identity can be calculated as: the total number of identical matches multiplied by 100, then divided by the length of the longer sequence in the matching range and the sum of the spaces introduced into the longer sequence, so as to compare the two sequences. When calculating the percentage identity, the sequences to be compared are compared in a manner that gives the maximum match between the sequences.

[0160] The GCG program package is a computer program that can be used to determine percent identity, which includes GAP (Devereux et al., 1984, Nucl. Acid Res. [Nucleic Acids Research] 12: 387; Genetics Computer Group, University of Wisconsin, Madison, WI [Genetics Computer Group, University of Wisconsin, Madison, Wisconsin]). The computer algorithm GAP is used to compare two polypeptides or two polynucleotides whose percent sequence identity is to be determined. The sequences are aligned so that their respective amino acids or nucleotides achieve the best match (such as the "match range" determined by the algorithm). The gap open penalty (calculated as 3x average diagonal, where the "average diagonal" is the average of the diagonals of the comparison matrix used; the "diagonal" is the score or number assigned to each complete amino acid match by a specific comparison matrix) and the gap extension penalty (usually 1 / 10 times the gap open penalty) and the comparison matrix (e.g., PAM250 or BLOSUM62) are used in conjunction with the algorithm. In certain embodiments, standard comparison matrices are also used by the algorithm (see, Dayhoff et al., 1978, Atlas of Protein Sequence and Structure 5:345-352, for the PAM250 comparison matrix; Henikoff et al., 1992, Proc. Natl. Acad. Sci. USA 89:10915-10919, for the BLOSUM 62 comparison matrix).

[0161] Recommended parameters for determining percent identity of polypeptide or nucleotide sequences using the GAP program include:

[0162] Algorithm: Needleman et al. 1970, J. Mol. Biol. 48:443-453;

[0163] Comparison matrix: BLOSUM 62 from Henikoff et al., 1992, supra;

[0164] Gap Penalty: 12 (but no penalty for end gaps)

[0165] Gap length penalty: 4

[0166] Threshold similarity: 0

[0167] Certain alignment schemes for aligning two amino acid sequences can result in the matching of only a short region of the two sequences, and even if there is no significant relationship between the two full-length sequences, this small alignment region can also have a very high sequence identity. Therefore, if necessary, the selected alignment method (GAP program) can be adjusted to produce an alignment of at least 50 consecutive amino acids across the target polypeptide.

[0168] These anti-PAC1 antibodies of the present invention may comprise any immunoglobulin constant region. The terms "constant region" and "constant domain" are used interchangeably herein to refer to all domains of an antibody except the variable region. The constant region is not directly involved in the binding of an antigen, but exhibits various effector functions. As described above, antibodies are divided into specific isotypes (IgA, IgD, IgE, IgG, and IgM) and subtypes (IgG1, IgG2, IgG3, IgG4, IgA1, IgA2) depending on the amino acid sequence of the heavy chain constant region of the antibody. The light chain constant region may be, for example, a κ or λ type light chain constant region, such as a human κ or λ type light chain constant region, which is in all five antibody isotypes. Examples of human immunoglobulin light chain constant region sequences are shown in the following table.

[0169] Table 2. Exemplary human immunoglobulin light chain constant regions

[0170]

[0171] The heavy chain constant region of the anti-PAC1 antibodies of the present invention can be, for example, an α, δ, ε, γ or μ type heavy chain constant region, such as a human α, δ, ε, γ or μ type heavy chain constant region. In some embodiments, the anti-PAC1 antibodies comprise a heavy chain constant region from an IgG1, IgG2, IgG3 or IgG4 immunoglobulin, such as a human IgG1, IgG2, IgG3 or IgG4 immunoglobulin. In one embodiment, the anti-PAC1 antibody comprises a heavy chain constant region from a human IgG1 immunoglobulin. In such embodiments, as described in more detail herein, the human IgG1 immunoglobulin constant region may comprise one or more mutations to prevent glycosylation of the antibody. In another embodiment, the anti-PAC1 antibody comprises a heavy chain constant region from a human IgG2 immunoglobulin. In yet another embodiment, the anti-PAC1 antibody comprises a heavy chain constant region from a human IgG4 immunoglobulin. Examples of human IgG1, IgG2 and IgG4 heavy chain constant region sequences are shown in Table 3 below.

[0172] Table 3. Exemplary human immunoglobulin heavy chain constant regions

[0173]

[0174]

[0175] Each light chain variable region disclosed in Table 1A and each heavy chain variable region disclosed in Table 1B can be attached to the above light chain constant region (Table 2) and heavy chain constant region (Table 3) to form complete antibody light chains and heavy chains, respectively. In addition, each of the heavy and light chain sequences thus produced can be combined to form a complete antibody structure. It should be understood that the heavy and light chain variable regions provided herein can also be attached to other constant structure regions having sequences different from the exemplary sequences listed above.

[0176] The anti-PAC1 antibodies or antigen-binding fragments of the present invention can be any of the anti-PAC1 antibodies or antigen-binding fragments disclosed herein. For example, in certain embodiments, the anti-PAC1 antibody is an anti-PAC1 antibody selected from any one of the antibodies listed in Tables 9, 10, 12, 13, 14, 19 and 20. In some embodiments, the anti-PAC1 antibodies comprise a light chain variable region and / or a heavy chain variable region having one or more amino acid substitutions listed in Tables 9, 10, 12, 13, 19 or 20. For example, in one embodiment, the anti-PAC1 antibody comprises a light chain variable region comprising the sequence of SEQ ID NO: 52 having a mutation at one or more amino acid positions 27, 28, 30, 31, 32 and / or 93. In certain embodiments, the mutation is selected from Q27K, Q27R, Q27H, S28A, G30M, G30W, R31Q, R31L, R31H, R31W, R31Y, S32A, S32N, S32L, R93F, R93M, R93Y, or a combination thereof. In these and other embodiments, the anti-PAC1 antibody comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 191 having a mutation at one or more amino acid positions 31, 32, 49, 52, 53, 54, 56, 57, 62, 70, 102, 103, and / or 104. In some embodiments, the mutation is selected from R31F, R31H, R31Y, R31M, R31K, F32Y, A49G, S52N, S52T, Y53F, Y53H, Y53S, D54I, D54L, D54N, D54R, D54Q, D54Y, D54F, D54M, D54S, D54T, G56Q, G56N , G56R, G56H, G56A, G56S, G56T, G56D, N57A, N57F, N57G, N57S, N57Q, N57L, N57T, E62R, I70V, I70L, I70M, V102P, V102L, V102I, V102F, V102M, L103M, T104S, or a combination thereof.

[0177] In another embodiment, the anti-PAC1 antibody comprises a light chain variable region comprising the sequence of SEQ ID NO: 67 having a mutation at one or more amino acid positions 28, 30, 31, 34, 49, 50, 51, 52, 53, 91, 92, 93, 94 and / or 96. The mutation may be selected from S28Y, S28T, S28K, S28P, S28Q, S28R, S28M, S30A, S30V, R31Q, N34V, N34S, Y49F, A50V, A50G, A51G, A51S, S52Q, S52H, S52N, S52Y, S52R, S52L, S53I, S53Y, S53N, S53M, S53H, S53R, S91A, Y92I, S93G, S93Q, S93I, S93N, S93M, P94E, P94M, P94N, P94Q, P94A, P94T, P94I, F96Y, or a combination thereof. In these and other embodiments, the anti-PAC1 antibody comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 296 having a mutation at one or more amino acid positions 31, 32, 33, 57, 58, 60, 103, 105, 106, 107, and / or 110. In some embodiments, the mutation is selected from S31N, N32R, N32K, N32H, S33L, S33Q, S33Y, S33V, S33D, S57G, K58Q, S60K, T103M, T103Q, T103R, T103V, K105N, K105E, K105D, K105I, K105A, K105S, K105Q, Q106G, Q106E, L107D, L107N, L110M, L110F, or a combination thereof.

[0178] In certain embodiments, the anti-PAC1 antibody or antigen-binding fragment of the invention is selected from antibodies 420653, 420845, 420943, 421873, 420889, 421091, 421051, 480711, 480706, 480713, 448730, 448195, 448788, 448901, 448689, 448202, 452128, 448924, 3574 and 3575, or an antigen-binding fragment thereof, the variable region and CDR sequences of which are listed in Tables 1A and 1B. In some embodiments, the anti-PAC1 antibody is an antibody selected from antibodies 420653, 420845, 420943, 421873, 420889, 421091, 421051, 480711, 480706, and 480713. In other embodiments, the anti-PAC1 antibody is an antibody selected from antibodies 448730, 448195, 448788, 448901, 448689, 448202, 452128, 448924, 3574, and 3575. The full-length light chain sequences and full-length heavy chain sequences of three exemplary human anti-PAC1 antibodies are listed in Tables 4A and 4B below, respectively.

[0179] Table 4A. Exemplary anti-PAC1 antibody light chain sequences

[0180]

[0181]

[0182]

[0183]

[0184]

[0185]

[0186]

[0187]

[0188]

[0189] Table 4B. Exemplary anti-PAC1 antibody heavy chain sequences

[0190]

[0191]

[0192]

[0193]

[0194]

[0195]

[0196]

[0197]

[0198]

[0199]

[0200]

[0201]

[0202]

[0203]

[0204]

[0205]

[0206] In certain embodiments, the anti-PAC1 antibodies of the invention may comprise a light chain selected from LC-01 to LC-05 as shown in Table 4A, and / or a heavy chain selected from HC-01 to HC-11 as shown in Table 4B, and binding fragments, derivatives and variants of these light and heavy chains. In other embodiments, the anti-PAC1 antibodies of the invention may comprise an anti-PAC1 antibody selected from LC-06 to LC-15 as shown in Table 4A, and / or a heavy chain selected from HC-12 to HC-18 as shown in Table 4B, and binding fragments, derivatives and variants of these light and heavy chains.

[0207] Each of the light chains listed in Table 4A can be combined with any of the heavy chains listed in Table 4B to form an anti-PAC1 antibody or antigen-binding fragment thereof of the invention. For example, in certain embodiments, the anti-PAC1 antibodies of the invention comprise: a light chain comprising the sequence of LC-03 (SEQ ID NO: 506) and a heavy chain comprising the sequence of HC-03 (SEQ ID NO: 521). In some embodiments, the anti-PAC1 antibodies of the invention comprise: a light chain comprising the sequence of LC-03 (SEQ ID NO: 506) and a heavy chain comprising the sequence of HC-04 (SEQ ID NO: 522). In other embodiments, the anti-PAC1 antibodies of the invention comprise: a light chain comprising the sequence of LC-01 (SEQ ID NO: 504) and a heavy chain comprising the sequence of HC-05 (SEQ ID NO: 523). In still other embodiments, the anti-PAC1 antibodies of the invention comprise: a light chain comprising the sequence of LC-01 (SEQ ID NO: 504) and a heavy chain comprising the sequence of HC-06 (SEQ ID NO: 524). In some embodiments, the anti-PAC1 antibodies of the invention comprise: a light chain comprising the sequence of LC-03 (SEQ ID NO: 506) and a heavy chain comprising the sequence of HC-07 (SEQ ID NO: 525). In certain embodiments, the anti-PAC1 antibodies of the invention comprise: a light chain comprising the sequence of LC-01 (SEQ ID NO: 504) and a heavy chain comprising the sequence of HC-08 (SEQ ID NO: 526). In one embodiment, the anti-PAC1 antibodies of the invention comprise: a light chain comprising the sequence of LC-03 (SEQ ID NO: 506) and a heavy chain comprising the sequence of HC-05 (SEQ ID NO: 523). In another embodiment, the anti-PAC1 antibodies of the invention comprise: a light chain comprising the sequence of LC-04 (SEQ ID NO: 507) and a heavy chain comprising the sequence of HC-09 (SEQ ID NO: 527). In yet another embodiment, the anti-PAC1 antibodies of the invention comprise: a light chain comprising the sequence of LC-04 (SEQ ID NO: 507) and a heavy chain comprising the sequence of HC-10 (SEQ ID NO: 528). In yet another embodiment, the anti-PAC1 antibodies of the invention comprise: a light chain comprising the sequence of LC-05 (SEQ ID NO: 508) and a heavy chain comprising the sequence of HC-11 (SEQ ID NO: 529).

[0208] In certain other embodiments, the anti-PAC1 antibodies of the invention comprise: a light chain comprising the sequence of LC-07 (SEQ ID NO:510) and a heavy chain comprising the sequence of HC-13 (SEQ ID NO:531). In some embodiments, the anti-PAC1 antibodies of the invention comprise: a light chain comprising the sequence of LC-08 (SEQ ID NO:511) and a heavy chain comprising the sequence of HC-14 (SEQ ID NO:532). In other embodiments, the anti-PAC1 antibodies of the invention comprise: a light chain comprising the sequence of LC-09 (SEQ ID NO:512) and a heavy chain comprising the sequence of HC-15 (SEQ ID NO:533). In still other embodiments, the anti-PAC1 antibodies of the invention comprise: a light chain comprising the sequence of LC-10 (SEQ ID NO:513) and a heavy chain comprising the sequence of HC-16 (SEQ ID NO:534). In some embodiments, the anti-PAC1 antibodies of the invention comprise: a light chain comprising the sequence of LC-11 (SEQ ID NO:514) and a heavy chain comprising the sequence of HC-17 (SEQ ID NO:535). In certain embodiments, the anti-PAC1 antibodies of the invention comprise: a light chain comprising the sequence of LC-12 (SEQ ID NO:515) and a heavy chain comprising the sequence of HC-17 (SEQ ID NO:535). In one embodiment, the anti-PAC1 antibodies of the invention comprise: a light chain comprising the sequence of LC-13 (SEQ ID NO:516) and a heavy chain comprising the sequence of HC-14 (SEQ ID NO:532). In another embodiment, the anti-PAC1 antibodies of the invention comprise: a light chain comprising the sequence of LC-14 (SEQ ID NO:517) and a heavy chain comprising the sequence of HC-18 (SEQ ID NO:536). In yet another embodiment, the anti-PAC1 antibodies of the invention comprise: a light chain comprising the sequence of LC-06 (SEQ ID NO: 509) and a heavy chain comprising the sequence of HC-14 (SEQ ID NO: 532). In yet another embodiment, the anti-PAC1 antibodies of the invention comprise: a light chain comprising the sequence of LC-15 (SEQ ID NO: 518) and a heavy chain comprising the sequence of HC-12 (SEQ ID NO: 530).

[0209] In some embodiments, the anti-PAC1 antibodies comprise a light chain comprising a contiguous amino acid sequence that differs from the sequence of a light chain in Table 4A (i.e., a light chain selected from LC-01 to LC-15) by only 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid residues, wherein each such sequence difference is independently a deletion, insertion, or substitution of one amino acid, wherein the deletions, insertions, and / or substitutions result in no more than 15 amino acid changes relative to the aforementioned light chain sequence. The light chain in some anti-PAC1 antibodies comprises an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% sequence identity to an amino acid sequence of SEQ ID NOs: 504 to 518 (i.e., a light chain in Table 4A).

[0210] In these and other embodiments, the anti-PAC1 antibodies comprise a heavy chain comprising a contiguous amino acid sequence that differs from the sequence of a heavy chain in Table 4B (i.e., a heavy chain selected from HC-01 to HC-18) by only 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acid residues, wherein each such sequence difference is independently a deletion, insertion or substitution of one amino acid, wherein the deletions, insertions and / or substitutions result in no more than 15 amino acid changes relative to the aforementioned heavy chain sequence. The heavy chain in some anti-PAC1 antibodies comprises an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% sequence identity to an amino acid sequence of SEQ ID NOs: 519 to 536 (i.e., a heavy chain in Table 4B).

[0211] The anti-PAC1 antibodies or antigen-binding fragments of the present invention may be monoclonal antibodies, polyclonal antibodies, recombinant antibodies, human antibodies, humanized antibodies, chimeric antibodies, or multispecific antibodies or antigen-binding fragments thereof. In certain embodiments, the anti-PAC1 antibody is a monoclonal antibody. In such embodiments, the anti-PAC1 antibody may be a chimeric antibody, a humanized antibody, or a fully human antibody having a human immunoglobulin constant structural region. In these and other embodiments, the anti-PAC1 antibody is a human IgG1, IgG2, IgG3, or IgG4 antibody. Thus, the anti-PAC1 antibody may have a human IgG1, IgG2, IgG3, or IgG4 constant structural region in some embodiments. In one embodiment, the anti-PAC1 antibody is a monoclonal human IgG1 antibody. In another embodiment, the anti-PAC1 antibody is a monoclonal human IgG2 antibody. In yet another embodiment, the anti-PAC1 antibody is a monoclonal human IgG4 antibody.

[0212] As used herein, the term "monoclonal antibody" (or "mAb") refers to an antibody obtained from a substantially homogeneous antibody population, i.e., the individual antibodies constituting the population are identical, except for possible naturally occurring mutations that may be present in small amounts. Monoclonal antibodies are highly specific, directed against a single antigenic site or epitope, in contrast to polyclonal antibody preparations that typically include different antibodies directed against different epitopes. Monoclonal antibodies can be produced using any technique known in the art, for example, by immortalizing spleen cells harvested from an animal after an immunization program is complete. These spleen cells can be immortalized using any technique known in the art, such as by fusing spleen cells with myeloma cells to produce hybridomas. See, for example, Antibodies; Harlow and Lane, Cold Spring Harbor Laboratory Press, 1st edition (e.g., 1988), or 2nd edition (e.g., 2014). Myeloma cells used in fusion procedures for producing hybridomas are preferably non-antibody-producing, have high fusion efficiency and enzyme defects, so that they cannot grow in certain selective culture media that only support the growth of desired fusion cells (hybridomas). The example of suitable cell line used in fusion with mouse cell includes but is not limited to Sp-20, P3-X63 / Ag8, P3-X63-Ag8.653, NS1 / 1.Ag41, Sp210-Ag14, FO, NSO / U, MPC-11, MPC11-X45-GTG 1.7 and S194 / 5XXO Bul. The example of suitable cell line for fusion with rat cell includes but is not limited to R210.RCY3, Y3-Ag 1.2.3, IR983F and 4B210. Other cell lines for cell fusion are U-266, GM1500-GRG2, LICR-LON-HMy2 and UC729-6.

[0213] In some cases, hybridoma cell lines are generated by immunizing animals (e.g., rabbits, rats, mice, or transgenic animals with human immunoglobulin sequences) with a PAC1 immunogen (see, e.g., WO2014 / 144632); harvesting spleen cells from these immunized animals; fusing the harvested spleen cells with a myeloma cell line to generate hybridoma cells; establishing hybridoma cell lines from the hybridoma cells, and identifying hybridoma cell lines that produce antibodies that bind to PAC1. Another useful method for generating monoclonal antibodies is the SLAM method described in Babcook et al., Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States], Vol. 93: 7843-7848, 1996.

[0214] Monoclonal antibodies secreted by hybridoma cell lines can be purified using any technique known in the art (e.g., protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography). Hybridoma supernatants or mAbs can be further screened to identify mAbs with specific properties, such as the ability to bind to PAC1 (e.g., human PAC1, cynomolgus PAC1, or rat PAC1); cross-reactivity to other PAC1 family members (e.g., human VPAC1 or human VPAC2); the ability to block or interfere with the binding of PACAP ligand to PAC1, or the ability to functionally block PACAP-induced activation of the PAC1 receptor, such as the cAMP assay described herein.

[0215] In some embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the present invention are chimeric or humanized antibodies or antigen-binding fragments thereof, based on the CDR and variable region sequences of the antibodies described herein. Chimeric antibodies are antibodies composed of protein segments from different antibodies that are covalently linked to produce functional immunoglobulin light or heavy chains or binding fragments thereof. Typically, a portion of the heavy and / or light chain is identical or homologous to a corresponding sequence in an antibody derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical or homologous to a corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass. For methods involving chimeric antibodies, see, e.g., U.S. Pat. No. 4,816,567 and Morrison et al., 1985, Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States of America] 81:6851-6855, both of which are incorporated herein by reference in their entirety.

[0216] In general, the purpose of preparing chimeric antibodies is to produce chimeras, wherein the number of amino acids from the expected species is maximized. An example is the antibody of "CDR transplantation", wherein the antibody comprises one or more CDRs from a specific species or belonging to a specific antibody class or subclass, and the remainder of the (these) antibody chain is consistent or homologous with the corresponding sequence in the antibody derived from another species or belonging to another antibody class or subclass. For example, CDR transplantation is described in U.S. Patent Nos. 6,180,370, 5,693,762, 5,693,761, 5,585,089 and 5,530,101. In order to use in humans, the variable region or selected CDR from rodent or rabbit antibodies is usually transplanted into human antibodies, replacing the naturally occurring variable region or CDR of human antibodies.

[0217] A useful type of chimeric antibody is a "humanized" antibody. Typically, a humanized antibody is produced from a monoclonal antibody originally obtained in a non-human animal (e.g., a rodent or rabbit). Certain amino acid residues in the monoclonal antibody, typically from the non-antigen recognition portion of the antibody, are modified to be homologous to corresponding residues in a human antibody of the corresponding isotype. For example, humanization can be performed, for example, by replacing the corresponding region of a human antibody with at least a portion of the variable region of a rodent or rabbit using various methods (see, e.g., U.S. Patent Nos. 5,585,089 and 5,693,762; Jones et al., 1986, Nature [Nature] 321: 522-525; Riechmann et al., 1988, Nature [Nature] 332: 323-27; and Verhoeyen et al., 1988, Science [Science] 239: 1534-1536).

[0218] On the one hand, the light chain and the CDR of the variable region of heavy chain of these antibodies provided herein (referring to, table 1A and 1B) are transplanted to framework region (FR) from the antibody from the same or different phylogenetic species.For example, the CDR of the variable region of heavy chain and light chain listed in table 1A and 1B can be transplanted on the common people FR.For producing the common people FR, the FR from several kinds of people's heavy chain or light chain amino acid sequence can be compared to identify the common amino acid sequence.Alternately, the transplanted variable region from a heavy chain or light chain can be used together with constant region, and this constant region is different from the constant region of the specific heavy chain or light chain disclosed herein.In other embodiments, the variable region of these transplants is a part for single-chain Fv antibody.

[0219] In certain embodiments, the anti-PAC1 antibodies or antigen-binding fragments of the present invention are fully human antibodies or antigen-binding fragments thereof. The immunogens or fragments thereof described in WO 2014 / 144632 can produce fully human antibodies that specifically bind to human PAC1, such as polypeptides consisting of the sequence of SEQ ID NO: 1 or SEQ ID NO: 4. "Fully human antibodies" are antibodies that contain variable and constant regions that are derived from or indicative of human germline immunoglobulin sequences. One specific means provided for implementing fully human antibodies is "humanization" of the humoral immune system of mice. Introducing human immunoglobulin (Ig) loci into mice in which endogenous Ig genes have been inactivated is a method for producing fully human monoclonal antibodies (mAbs) in mice, which are animals that can be immunized with any desired antigen. The use of fully human antibodies can minimize immunogenicity and allergic reactions that can sometimes be caused by administering mouse mAbs or mouse-derived mAbs to humans as therapeutic agents.

[0220] Fully human antibodies can be produced by immunizing transgenic animals (usually mice) that are capable of producing a human antibody repertoire in the absence of endogenous immunoglobulin production. Antigens for this purpose typically have six or more consecutive amino acids and are optionally conjugated to a carrier, such as a hapten. See, for example, Jakobovits et al., 1993, Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States] 90: 2551-2555; Jakobovits et al., 1993, Nature [Nature] 362: 255-258; and Bruggermann et al., 1993, Year in Immunol. [Year of Immunology] 7: 33. In one example of this method, transgenic animals are produced by the following method: the endogenous mouse immunoglobulin loci encoding the mouse heavy and light immunoglobulin chains are disabled, and a large fragment of human genomic DNA containing the loci encoding human heavy and light chain proteins is inserted into the mouse genome. The partially modified animals with less than the full complement of human immunoglobulin loci are then crossed to obtain animals with all the desired immune system modifications. When an immunogen is administered, these transgenic animals produce antibodies (including variable regions) that are immunospecific for the immunogen but have human amino acid sequences rather than mouse amino acid sequences. For more details on such methods, see, e.g., WO 96 / 33735 and WO 94 / 02602. Additional methods for generating human antibodies involving transgenic mice are described in U.S. Pat. Nos. 5,545,807; 6,713,610; 6,673,986; 6,162,963; 5,939,598; 5,545,807; 6,300,129; 6,255,458; 5,877,397; 5,874,299; and 5,545,806; PCT Publication Nos. WO 91 / 10741, WO 90 / 04036, WO 94 / 02602, WO 96 / 30498, WO 98 / 24893, and EP 546073 Bl and EP 546073 Al.

[0221] The transgenic mice, referred to as "HuMab" mice, contain human immunoglobulin gene minilocus encoding unrearranged human heavy chain (μ and γ) and κ light chain immunoglobulin sequences, as well as targeted mutations that inactivate endogenous μ and κ chain loci (Lonberg et al., 1994, Nature 368: 856-859). As a result, the mice exhibit reduced expression of mouse IgM and κ proteins, and in response to immunization, the introduced human heavy and light chain transgenes undergo class switching and somatic mutation to produce high-affinity human IgGκ monoclonal antibodies (Lonberg and Huszar, 1995, Intern. Rev. Immunol. 13: 65-93; Harding and Lonberg, 1995, Ann. N. Y Acad. Sci. 764: 536-546). Details of HuMab mouse preparation are described as follows: Taylor et al., 1992, Nucleic Acids Research 20:6287-6295; Chen et al., 1993, International Immunology 5:647-656; Tuaillon et al., 1994, J. Immunol. 152:2912-2920; Lonberg et al., 1994, Nature 368:856-859; Lonberg, 1994, Handbook of Exp. Pharmacology 113:49-101; Taylor et al., 1994, International Immunology 5:647-656. Immunology 6:579-591; Lonberg and Huszar, 1995, Intern. Rev. Immunol. 13:65-93; Harding and Lonberg, 1995, Ann. N. Y Acad. Sci. 764:536-546; Fishwild et al., 1996, Nature Biotechnology 14:845-851; the foregoing references are incorporated herein by reference in their entirety.See, additionally, U.S. Patent No. 5,545,806; U.S. Patent No. 5,569,825; U.S. Patent No. 5,625,126; U.S. Patent No. 5,633,425; U.S. Patent No. 5,789,650; U.S. Patent No. 5,877,397; U.S. Patent No. 5,661,016; U.S. Patent No. 5,814,318; U.S. Patent No. 5,874,299; and U.S. Patent No. 5,770,429; and U.S. Patent No. 5,545,807; International Publication Nos. WO 93 / 1227; WO 92 / 22646; and WO 92 / 03918, the entire disclosures of which are incorporated herein by reference in their entirety. The techniques used in these transgenic mice for producing human antibodies are also disclosed in WO 98 / 24893, and Mendez et al., 1997, Nature Genetics 15:146-156, which are incorporated herein by reference. For example, HCo7 and HCo12 transgenic mouse strains can be used to produce fully human anti-PAC1 antibodies. One particular transgenic mouse line suitable for producing fully human anti-PAC1 antibodies is described below. Transgenic mouse lines: U.S. Patent Nos. 6,114,598; 6,162,963; 6,833,268; 7,049,426; 7,064,244; Green et al., 1994, Nature Genetics 7:13-21; Mendez et al., 1997, Nature Genetics 15:146-156; Green and Jakobovitis, 1998, J. Ex. Med, 188:483-495; Green, 1999, Journal of Immunological Methods 231:11-23; Kellerman and Green, 2002, Current Opinion in Biotechnology 13, 593-597, all of which are incorporated herein by reference in their entirety.

[0222] Phage display technology can also be used to produce human antibodies. Phage display is described in, for example, Dower et al., WO 91 / 17271, McCafferty et al., WO 92 / 01047, and Caton and Koprowski, 1990, Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States], 87: 6450-6454, each of which is incorporated herein by reference in its entirety. Antibodies produced by phage technology are generally produced as antigen-binding fragments, for example, Fv or Fab fragments in bacteria, and therefore lack effector functions. Effector functions can be introduced by one of the following two strategies: if necessary, the fragment can be engineered into a complete antibody for expression in mammalian cells, or engineered into a bispecific antibody fragment with a second binding site that can trigger effector functions. Typically, the Fd fragment (VH-CH1) and light chain (VL-CL) of the antibody are cloned by PCR and randomly recombined in a combinatorial phage display library, and then it can be selected to bind to a specific antigen. Antibody fragments are expressed on the phage surface, and the selection of Fv or Fab (thus containing phages encoding DNA of antibody fragments) is completed by several rounds of antigen binding and re-amplification by antigen binding, and the process is called panning. Antibody fragments with specificity for antigens are enriched and finally separated. Phage display technology can also be used in the humanization method for rodent monoclonal antibodies, which is called "guided selection" (see Jespers, LS et al., 1994, Bio / Technology [Biology / Technology] 12, 899-903). For this reason, the Fd fragment of mouse monoclonal antibodies can be displayed in combination with a human light chain library, and then the resulting hybrid Fab library can be selected with antigen. Therefore, the mouse Fd fragment provides a template for guiding selection. Subsequently, the selected human light chain is combined with the human Fd fragment library. The resulting library is selected to produce human Fab completely.

[0223] Once cells producing anti-PAC1 antibodies according to the invention have been obtained using any of the above-described immunization and other techniques, specific antibody genes can be cloned by isolating and amplifying DNA or mRNA therefrom according to standard procedures described herein. The antibodies produced thereby can be sequenced and the CDRs identified, and the DNA encoding the CDRs can be manipulated as described herein to produce other anti-PAC1 antibodies or antigen-binding fragments according to the invention.

[0224] In certain embodiments, the anti-PAC1 antibodies and antigen-binding fragments of the present invention may comprise one or more mutations or modifications to the constant region. For example, the heavy chain constant region or Fc region of the anti-PAC1 antibodies may comprise one or more amino acid substitutions that affect the glycosylation, effector function, and / or Fcγ receptor binding of the antibody. The term "Fc region" refers to the C-terminal region of the immunoglobulin heavy chain, which can be produced by papain digestion of an intact antibody. The Fc region of an immunoglobulin generally comprises two constant structural regions (CH2 domain and CH3 domain), and optionally comprises a CH4 domain. In certain embodiments, the Fc region is an Fc region from an IgG1, IgG2, IgG3 or IgG4 immunoglobulin. In some embodiments, the Fc region comprises CH2 and CH3 domains from human IgG1 or human IgG2 immunoglobulins. The Fc region may retain effector functions, such as C1q binding, complement dependent cytotoxicity (CDC), Fc receptor binding, antibody dependent cell-mediated cytotoxicity (ADCC) and phagocytosis. In other embodiments, as described in further detail below, the Fc region can be modified to reduce or eliminate effector function.

[0225] Unless otherwise indicated by reference to a particular sequence, throughout the specification and claims, the numbering of amino acid residues in an immunoglobulin heavy or light chain is according to AHo numbering as described in Honegger and Pluckthun, J. Mol. Biol. 309(3):657-670; 2001; or EU numbering as described in Edelman et al., Proc. Natl. Acad. USA, Vol. 63:78-85 (1969). As used herein, the AHo numbering scheme is typically used when referring to the position of amino acids within the variable region, whereas the EU numbering scheme is usually used when referring to the position of amino acids with an immunoglobulin constant region.

[0226] Amino acid substitutions in amino acid sequences are typically represented herein by single-letter abbreviations of the amino acid residue in the specific position, followed by the numerical amino acid position relative to the original target sequence, followed by the single-letter abbreviations of the amino acid residue substituted therein. For example, "T30D" represents a substitution of a threonine residue by an aspartic acid residue at amino acid position 30 relative to the original target sequence. Another example, "S218G" represents a substitution of a serine residue by a glycine residue at amino acid position 218 relative to the original target amino acid sequence.

[0227] One of the functions of an immunoglobulin Fc region is to communicate with the immune system when the immunoglobulin binds to its target. This is often referred to as "effector function". Communication results in antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and / or complement-dependent cytotoxicity (CDC). ADCC and ADCP are mediated by the binding of the Fc region to Fc receptors on the surface of immune system cells. CDC is mediated by the binding of the Fc region to proteins of the complement system (e.g., C1q). In some embodiments, these anti-PAC1 antibodies of the present invention comprise one or more amino acid substitutions in the Fc region to enhance effector functions, including ADCC activity, CDC activity, ADCP activity, and / or clearance or half-life of the antibody. Exemplary amino acid substitutions that can enhance effector function (according to the EU numbering scheme) include, but are not limited to, E233L, L234I, L234Y, L235S, G236A, S239D, F243L, F243V, P247I, D280H, K290S, K290E, K290N, K290Y, R292P, E294L, Y296W, S298A, S298D , S298V, S298G, S298T, T299A, Y300L, V305I, Q311M, K326A, K326E, K326W, A330S, A330L, A330M, A330F, I332E, D333A, E333S, E333A, K334A, K334V, A339D, A339Q, P396L, or any combination of the foregoing.

[0228] In other embodiments, the anti-PAC1 antibodies of the invention comprise one or more amino acid substitutions in the Fc region to reduce effector function. Exemplary amino acid substitutions that can reduce effector function (according to the EU numbering scheme) include, but are not limited to, C220S, C226S, C229S, E233P, L234A, L234V, V234A, L234F, L235A, L235E, G237A, P238S, S267E, H268Q, N297A, N297G, V309L, E318A, L328F, A330S, A331S, P331S, or any combination of the foregoing.

[0229] Glycosylation can contribute to the effector functions of antibodies, particularly IgG1 antibodies. Thus, in some embodiments, the anti-PAC1 antibodies of the present invention may comprise one or more amino acid substitutions that affect the level or type of glycosylation of the antibody. Glycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of a carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine (where X is any amino acid except proline) are recognition sequences for enzymatic attachment of a carbohydrate moiety to the asparagine side chain. Thus, the presence of any of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.

[0230] In certain embodiments, glycosylation of the anti-PAC1 antibodies described herein is accomplished by adding one or more glycosylation sites, for example, to the Fc region of the antibody. Addition of glycosylation sites to an antibody can be conveniently accomplished by altering the amino acid sequence to contain one or more of the tripeptide sequences described above (for N-linked glycosylation sites). The alteration can also be made by adding or replacing one or more serine or threonine residues to the starting sequence (for O-linked glycosylation sites). Conveniently, the antibody amino acid sequence can be altered by changes at the DNA level, particularly by mutating the DNA encoding the target polypeptide at preselected bases to generate codons that will convert to the desired amino acids.

[0231] The present invention also encompasses the production of antibody molecules with modified carbohydrate structures that result in changes in effector activity, including antibodies with missing or reduced fucosylation that exhibit improved ADCC activity. Various methods are known in the art to reduce or eliminate fucosylation. For example, ADCC effector activity is mediated by the binding of antibody molecules to FcγRIII receptors, and it has been shown that the activity depends on the glycosylated carbohydrate structure of the N-linked residue N297 of the CH2 domain. Non-fucosylated antibodies bind to the receptor with increased affinity and trigger FcγRIII-mediated effector function more effectively than natural fucosylated antibodies. For example, the recombinant production of non-fucosylated antibodies in CHO cells in which α-1,6-fucosyltransferase has been knocked out results in antibodies with a 100-fold increased ADCC activity (see Yamane-Ohnuki et al., Biotechnol Bioeng. [Biotechnology and Bioengineering] 87 (5): 614-22, 2004). Similar effects can be achieved by reducing the activity of α-1,6-fucosyltransferase or other enzymes in the fucosylation pathway, for example by siRNA or antisense RNA treatment, engineering cell lines to knock out one or more enzymes, or culturing with selective glycosylation inhibitors (see Rothman et al., Mol Immunol. 26(12): 1113-23, 1989). Some host cell lines (e.g., Lec13 or rat hybridoma YB2 / 0 cell lines) naturally produce antibodies with lower levels of fucosylation (see Shields et al., J Biol Chem. 277(30): 26733-40, 2002 and Shinkawa et al., J Biol Chem. 278(5): 3466-73, 2003). Increased levels of bispecific carbohydrate, for example by recombinant production of the antibody in cells overexpressing the GnTIII enzyme, has also been determined to increase ADCC activity (see Umana et al., Nat Biotechnol. 17(2): 176-80, 1999).

[0232] In other embodiments, glycosylation of the anti-PAC1 antibodies described herein is reduced or eliminated by removing one or more glycosylation sites (e.g., from the Fc region of the antibody). In some embodiments, the anti-PAC1 antibody is an unglycosylated human monoclonal antibody, such as an unglycosylated human IgG1 monoclonal antibody. Amino acid substitutions that eliminate or alter N-linked glycosylation sites can reduce or eliminate antibody N-linked glycosylation. In certain embodiments, the anti-PAC1 antibodies described herein comprise a heavy chain mutation at position N297 (according to the EU numbering scheme), such as N297Q, N297A, or N297G. In some embodiments, the anti-PAC1 antibodies of the invention comprise an Fc region from a human IgG1 antibody having a mutation at position N297. In a specific embodiment, the anti-PAC1 antibodies of the invention comprise an Fc region from a human IgG1 antibody having an N297G mutation. For example, in some embodiments, the anti-PAC1 antibodies of the invention comprise a heavy chain constant region comprising the sequence of SEQ ID NO: 324.

[0233] To improve the stability of molecules comprising the N297 mutation, the Fc region of the anti-PAC1 antibody can be further engineered. For example, in some embodiments, one or more amino acids in the Fc region are substituted with cysteine ​​to promote disulfide bond formation in the dimer state. Residues corresponding to V259, A287, R292, V302, L306, V323 or I332 (according to the EU numbering scheme) in the IgG1 Fc region can therefore be substituted with cysteine. Preferably, specific residue pairs are substituted with cysteine ​​so that they preferentially form disulfide bonds with each other, thereby limiting or preventing disulfide bond clutter. Preferred residue pairs include, but are not limited to, A287C and L306C, V259C and L306C, R292C and V302C, and V323C and I332C. In certain embodiments, the anti-PAC1 antibodies described herein comprise an Fc region from a human IgG1 antibody having mutations R292C and V302C. In such embodiments, the Fc region may further comprise an N297 mutation, such as an N297G mutation.In some embodiments, the anti-PAC1 antibodies of the invention comprise a heavy chain constant region comprising the sequence of SEQ ID NO:325.

[0234] It may also be desirable to modify the anti-PAC1 antibodies of the invention to increase serum half-life, for example, by incorporating or adding a salvage receptor binding epitope (e.g., by mutating the appropriate region or by incorporating the epitope into a peptide tag that is then fused to the antibody at either end or in the middle, for example, by DNA or peptide synthesis; see, e.g., WO96 / 32478) or adding a molecule such as PEG or other water-soluble polymers (including polysaccharide polymers). The salvage receptor binding epitope preferably constitutes a region in which any one or more amino acid residues from one or both loops of the Fc region are transferred to an analogous position in the antibody. Even more preferably, three or more residues from one or both loops of the Fc region are transferred. Still more preferably, the epitope is taken from the CH2 domain of the Fc region (e.g., an IgG Fc region) and transferred to the CH1, CH3 or VH region of the antibody, or more than one such region. Alternatively, the epitope is taken from the CH2 domain of the Fc region and transferred to the CL region or VL region or both of the antibody. See International Applications WO 97 / 34631 and WO 96 / 32478 for a description of Fc variants and their interaction with salvage receptors.

[0235] The present invention includes one or more isolated polynucleotides or isolated nucleic acids encoding the anti-PAC1 antibodies or antigen-binding fragments described herein. In addition, the present invention encompasses vectors comprising the nucleic acids, host cells or cell lines comprising the nucleic acids, and methods for preparing the anti-PAC1 antibodies and antigen-binding fragments of the present invention. The nucleic acids include, for example, polynucleotides encoding all or part of an antibody or antigen-binding fragment; for example, a single strand or double strand of an antibody of the present invention, or a fragment, derivative or variant thereof; polynucleotides sufficient for use as hybridization probes; PCR primers or sequencing primers for identifying, analyzing, mutating or amplifying polynucleotides encoding polypeptides; antisense oligonucleotides for inhibiting expression of polynucleotides, and the aforementioned complementary sequences. Nucleic acids can be of any length suitable for the desired use or function, and can include one or more additional sequences, such as regulatory sequences, and / or a portion of a larger nucleic acid (e.g., a vector). The nucleic acid molecules of the present invention include DNA and RNA in single-stranded and double-stranded forms, and corresponding complementary sequences. DNA includes, for example, cDNA, genomic DNA, chemically synthesized DNA, DNA amplified by PCR, and combinations thereof. The nucleic acid molecules of the present invention include combinations of full-length genes or cDNA molecules and fragments thereof. The nucleic acids of the invention may be derived from human sources as well as non-human species.

[0236] The relevant amino acid sequence from an immunoglobulin or its region (e.g., variable region, Fc region, etc.) or a polypeptide of interest can be determined by direct protein sequencing, and a suitable coding nucleotide sequence can be designed according to a universal codon table. Alternatively, conventional procedures (e.g., by using oligonucleotide probes that specifically bind to the heavy and light chains of the encoding monoclonal antibodies) can be used to separate and sequence the genome or cDNA encoding the monoclonal antibodies of the present invention or their binding fragments from cells producing these antibodies.

[0237] "Isolated nucleic acid" used interchangeably with "isolated polynucleotide" herein is a nucleic acid separated from adjacent genetic sequences present in the genome of an organism, in the case where the nucleic acid is separated from a naturally occurring source, and the nucleic acid of the organism is isolated. In the case of enzymatic synthesis of nucleic acids from a template or chemically, such as PCR products, cDNA molecules or oligonucleotides, it should be understood that the nucleic acids produced by these processes are isolated nucleic acids. Isolated nucleic acid molecules refer to nucleic acid molecules in the form of separate fragments or as components of larger nucleic acid constructs. In a preferred embodiment, these nucleic acids are substantially free of contaminated endogenous substances. Nucleic acid molecules are preferably derived from DNA or RNA separated at least once in a substantially pure form and by being able to be identified, manipulated and recovered in the quantity or concentration of its component nucleotide sequences by standard biochemical methods (such as those summarized in Sambrook et al., Molecular Cloning: A Laboratory Manual [Molecular Cloning: Laboratory Manual], 2nd Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) (1989)). Such sequences are preferably provided and / or constructed in the form of an open reading frame that is not interrupted by internal non-translated sequences or introns, which are typically present in eukaryotic genes. The sequence of non-translated DNA may be present at 5' or 3' of the open reading frame, wherein the open reading frame does not interfere with the manipulation or expression of the coding region. Unless otherwise indicated, the left-hand end of any single-stranded polynucleotide sequence discussed herein is 5'; the left-hand direction of a double-stranded polynucleotide sequence is referred to as the 5' direction. The 5' to 3' direction of production of a nascent RNA transcript is referred to as the transcription direction; a DNA strand having the same sequence as an RNA transcript, the sequence region from 5' to the 5' end of the RNA transcript is referred to as an "upstream sequence"; a DNA strand having the same sequence as an RNA transcript, the sequence region from 3' to the 3' end of the RNA transcript is referred to as a "downstream sequence".

[0238] The present invention also includes nucleic acids that hybridize to nucleic acids encoding polypeptides as described herein under moderate stringency conditions, and more preferably under high stringency conditions. Basic parameters that affect the selection of hybridization conditions and guidance for designing suitable conditions are set forth by Sambrook, Fritsch and Maniatis (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, Chapters 9 and 11; and Current Protocols in Molecular Biology, 1995, Ausubel et al., ed., John Wiley & Sons, Inc., Sections 2.10 and 6.3-6.4), and can be readily determined by one of ordinary skill in the art based on, for example, the length and / or base composition of the DNA. One way to achieve moderate stringency conditions involves using a pre-wash solution containing 5xSSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0), a hybridization buffer of about 50% formamide, 6xSSC, and a hybridization temperature of about 55°C (or other similar hybridization solutions, such as a hybridization solution containing about 50% formamide, wherein the hybridization temperature is about 42°C), and a wash condition of about 60°C in 0.5xSSC, 0.1% SDS. Generally, high stringency conditions are defined as hybridization conditions as above, but wherein washing is performed at about 68°C, 0.2xSSC, 0.1% SDS. SSPE (lx SSPE is 0.15M NaCl, 10mM NaH2PO4, and 1.25mM EDTA, pH 7.4) can replace SSC (lx SSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; after hybridization is complete, washing is performed for 15 minutes. It will be appreciated that the wash temperature and wash salt concentration can be adjusted as necessary to achieve the desired degree of stringency by applying the basic principles of controlling hybridization reactions and duplex stability, as known to those skilled in the art and further described below (see, e.g., Sambrook et al., 1989).

[0239] When a nucleic acid is hybridized to a target nucleic acid of unknown sequence, the hybridization length is assumed to be the length of the hybridized nucleic acid. When nucleic acids of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of these nucleic acids and identifying one or more regions of optimal sequence complementarity. The hybridization temperature of a hybrid expected to be less than 50 base pairs in length should be 5°C to 10°C lower than the melting temperature (Tm) of the hybrid, where Tm is determined according to the following equation. For hybrids less than 18 base pairs in length, Tm (°C) = 2 (#A+T bases) + 4 (#G+C bases). For hybrids greater than 18 base pairs in length, Tm (°C) = 81.5 + 16.6 (log10 [Na+]) + 0.41 (%G+C) - (600 / N), where N is the number of bases in the hybrid, and [Na+] is the concentration of sodium ions in the hybridization buffer ([Na+] for lxSSC = 0.165M). Preferably, each such hybridizing nucleic acid has a length of at least 15 nucleotides (or more preferably at least 18 nucleotides, or at least 20 nucleotides, or at least 25 nucleotides, or at least 30 nucleotides, or at least 40 nucleotides, or most preferably at least 50 nucleotides), or at least 25% (more preferably at least 50%, or at least 60%, or at least 70%, and most preferably at least 80%) of the length of the nucleic acid of the invention to which it hybridizes, and has at least 60% sequence identity (more preferably at least 70%, at least 70%, and most preferably at least 80%) to the nucleic acid of the invention to which it hybridizes. %, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, and most preferably at least 99.5%), wherein the sequence identity is determined by comparing the sequences of the hybridizing nucleic acids when aligned as described in more detail above so as to maximize overlap and identity while minimizing sequence gaps.

[0240] Variants of the anti-PAC1 antibodies and antigen-binding fragments described herein can be prepared as follows: using cassette or PCR mutagenesis or other techniques well known in the art, such as those described in Example 3, by site-directed mutagenesis of nucleotides in the DNA encoding the polypeptide to produce DNA encoding the variant, and thereafter expressing the recombinant DNA in cell culture as outlined herein. However, antibodies or antigen-binding fragments containing variant CDRs having up to about 100-150 residues can be prepared by in vitro synthesis using established techniques. These variants generally exhibit the same qualitative biological activity as the naturally occurring analogs, such as binding to the antigen. Such variants include, for example, deletions and / or insertions and / or substitutions of residues within the amino acid sequence of the antibody. Any combination of deletions, insertions and substitutions can be performed to arrive at the final construct, provided that the final construct has the desired characteristics. Amino acid changes can also alter the post-translational processes of the antibody, such as changing the number or position of glycosylation sites. In certain embodiments, antibody variants are prepared with the intent to modify those amino acid residues that are directly involved in epitope binding. In other embodiments, for the purposes discussed herein, modification of residues that are not directly involved in epitope binding or residues that are not involved in epitope binding in any way is desirable. Mutagenesis in any CDR region and / or framework region is contemplated. Those skilled in the art can design useful modifications in the amino acid sequence of an antibody using covariance analysis techniques. See, e.g., Choulier, et al., Proteins 41:475-484, 2000; Demarest et al., J. Mol. Biol. 335:41-48, 2004; Hugo et al., Protein Engineering 16(5):381-86, 2003; Aurora et al., U.S. Patent Publication No. 2008 / 0318207 A1; Glaser et al., U.S. Patent Publication No. 2009 / 0048122 A1; Urech et al., WO 2008 / 110348 A1; Borras et al., WO 2009 / 000099 A2. Such modifications, as determined by covariance analysis, can improve the potency, pharmacokinetic, pharmacodynamic and / or manufacturability characteristics of the antibody.

[0241] Tables 4A and 4B show exemplary nucleic acid sequences encoding full-length light and heavy chains, respectively, of the anti-PAC1 antibodies described herein. Tables 5A and 5B show exemplary nucleic acid sequences encoding light and heavy chain variable regions, respectively, of the anti-PAC1 antibodies described herein. Polynucleotides encoding anti-PAC1 variable regions, optionally with nucleic acids encoding light and heavy chain constant regions listed in Tables 2 and 3, respectively, can be used to construct these antibodies and antigen-binding fragments of the invention.

[0242] Table 5A. Exemplary anti-PAC1 antibody light chain variable region nucleic acid sequences

[0243]

[0244]

[0245]

[0246]

[0247]

[0248]

[0249]

[0250] Table 5B. Exemplary anti-PAC1 antibody heavy chain variable region nucleic acid sequences

[0251]

[0252]

[0253]

[0254]

[0255]

[0256]

[0257]

[0258]

[0259]

[0260]

[0261]

[0262]

[0263]

[0264]

[0265]

[0266]

[0267]

[0268]

[0269]

[0270] The isolated nucleic acids encoding the anti-PAC1 antibodies or antigen-binding fragments of the invention may comprise a nucleotide sequence having at least 80% identity, at least 90% identity, at least 95% identity, or at least 98% identity to any of the nucleotide sequences listed in Tables 4A, 4B, 5A, and 5B. In some embodiments, the isolated nucleic acid encoding the anti-PAC1 antibody light chain variable region comprises a sequence having at least 80% identity, at least 90% identity, at least 95% identity, or at least 98% identity to a sequence selected from SEQ ID NOs: 328 to 342. In other embodiments, the isolated nucleic acid encoding the anti-PAC1 antibody light chain variable region comprises a sequence having at least 80% identity, at least 90% identity, at least 95% identity, or at least 98% identity to a sequence selected from SEQ ID NOs: 343 to 363. In certain embodiments, the isolated nucleic acid encoding the anti-PAC1 antibody light chain variable region comprises a sequence selected from SEQ ID NOs: 328 to 342. In certain other embodiments, the isolated nucleic acid encoding the anti-PAC1 antibody light chain variable region comprises a sequence selected from SEQ ID NOs: 343 to 363. In related embodiments, the isolated nucleic acid encoding the anti-PAC1 antibody heavy chain variable region comprises a sequence having at least 80% identity, at least 90% identity, at least 95% identity, or at least 98% identity to a sequence selected from SEQ ID NOs: 364 to 468. In other related embodiments, the isolated nucleic acid encoding the anti-PAC1 antibody heavy chain variable region comprises a sequence having at least 80% identity, at least 90% identity, at least 95% identity, or at least 98% identity to a sequence selected from SEQ ID NOs: 469 to 485. In some embodiments, the isolated nucleic acid encoding the anti-PAC1 antibody heavy chain variable region comprises a sequence selected from SEQ ID NOs: 364 to 468. In other embodiments, the isolated nucleic acid encoding the anti-PAC1 antibody heavy chain variable region comprises a sequence selected from SEQ ID NOs: 469 to 485.

[0271] In some embodiments, the isolated nucleic acid encoding an anti-PAC1 antibody light chain comprises a sequence having at least 80% identity, at least 90% identity, at least 95% identity, or at least 98% identity to a sequence selected from SEQ ID NOs: 537 to 541. In other embodiments, the isolated nucleic acid encoding an anti-PAC1 antibody light chain comprises a sequence having at least 80% identity, at least 90% identity, at least 95% identity, or at least 98% identity to a sequence selected from SEQ ID NOs: 542 to 551. In certain embodiments, the isolated nucleic acid encoding an anti-PAC1 antibody light chain comprises a sequence selected from SEQ ID NOs: 537 to 541. In certain other embodiments, the isolated nucleic acid encoding an anti-PAC1 antibody light chain comprises a sequence selected from SEQ ID NOs: 542 to 551. In related embodiments, the isolated nucleic acid encoding an anti-PAC1 antibody heavy chain comprises a sequence having at least 80% identity, at least 90% identity, at least 95% identity, or at least 98% identity to a sequence selected from SEQ ID NOs: 552 to 562. In other related embodiments, the isolated nucleic acid encoding an anti-PAC1 antibody heavy chain comprises a sequence having at least 80% identity, at least 90% identity, at least 95% identity, or at least 98% identity to a sequence selected from SEQ ID NOs: 563 to 569. In some embodiments, the isolated nucleic acid encoding an anti-PAC1 antibody heavy chain comprises a sequence selected from SEQ ID NOs: 552 to 562. In other embodiments, the isolated nucleic acid encoding an anti-PAC1 antibody heavy chain comprises a sequence selected from SEQ ID NOs: 563 to 569.

[0272] The nucleic acid sequences provided in Tables 4A, 4B, 5A and 5B are exemplary only. As will be appreciated by those skilled in the art, due to the degeneracy of the genetic code, a very large number of nucleic acids can be prepared, all of which encode the CDRs, variable regions, and heavy and light chains or other components of the antibodies and antigen-binding fragments described herein. Therefore, after identifying a specific amino acid sequence, those skilled in the art can prepare any number of different nucleic acids by simply modifying the sequence of one or more codons in a manner that does not change the amino acid sequence of the encoded protein.

[0273] The present invention also includes vectors, which contain one or more nucleic acids encoding one or more components of these antibodies or antigen-binding fragments (e.g., variable regions, light chains, and heavy chains) of the present invention. The term "vector" refers to any molecule or entity (e.g., nucleic acid, plasmid, bacteriophage, or virus) used to transfer protein coding information to a host cell. Examples of vectors include, but are not limited to, plasmids, viral vectors, mammalian vectors of non-episomal genes, and expression vectors (e.g., recombinant expression vectors). As used herein, the term "expression vector" or "expression construct" refers to a recombinant DNA molecule containing a desired coding sequence and suitable nucleic acid control sequences necessary for expressing an operably connected coding sequence in a specific host cell. An expression vector may include, but is not limited to, sequences that affect or control transcription and translation, and if introns are present, RNA splicing of the coding region operably connected thereto is affected. Nucleic acid sequences necessary for expression in prokaryotes include promoters, optionally operating sequences, ribosome binding sites, and possible other sequences. It is known that eukaryotic cells utilize promoters, enhancers, and terminators as well as polyadenylation signals.

[0274] The secretory signal peptide sequence can also be optionally encoded by an expression vector, operably linked to the target coding sequence, so that the expressed polypeptide can be secreted by the recombinant host cell, if necessary, so as to more easily separate the target polypeptide from the cell. For example, in some embodiments, the signal peptide sequence can be attached / fused to the amino terminus of any variable region polypeptide sequence listed in Tables 1A and 1B or any full-chain polypeptide sequence listed in Tables 4A and 4B. In certain embodiments, the signal peptide with the amino acid sequence of MDMRVPAQLLGLLLLWLRGARC (SEQ ID NO: 486) is fused to the amino terminus of any variable region polypeptide sequence in Tables 1A and 1B or the full-chain polypeptide sequence in Tables 4A and 4B. In other embodiments, the signal peptide with the amino acid sequence of MAWALLLLTLLTQGTGSWA (SEQ ID NO: 487) is fused to the amino terminus of any variable region polypeptide sequence in Tables 1A and 1B or the full-chain polypeptide sequence in Tables 4A and 4B. In still other embodiments, a signal peptide having an amino acid sequence of MTCSPLLLTLLIHCTGSWA (SEQ ID NO: 488) is fused to the amino terminus of any variable region polypeptide sequence in Tables 1A and 1B or the full-chain polypeptide sequence in Tables 4A and 4B. Other suitable signal peptide sequences that can be fused to the amino terminus of the variable region polypeptide sequence or the full-chain polypeptide sequence described herein include: MEAPAQLLFLLLLWLPDTTG (SEQ ID NO: 489), MEWTWRVLFLVAAATGAHS (SEQ ID NO: 490), METPAQLLFLLLLWLPDTTG (SEQ ID NO: 491), METPAQLLFLLLLWLPDTTG (SEQ ID NO: 492), MKHLWFFLLLVAAPRWVLS (SEQ ID NO: 493), MEWSWVFLFFLSVTTGVHS (SEQ ID NO: 494), MDIRAPTQLLGLLLLWLPGAKC (SEQ ID NO: 495), MDIRAPTQLLGLLLLWLPGARC (SEQ ID NO: 496), MDTRAPTQLLGLLLLWLPGATF (SEQ ID NO: 497), MDTRAPTQLLGLLLLWLPGARC (SEQ ID NO: 498), MDTRAPTQLLGLLLLWLPGARC (SEQ ID NO: 499), MDTRAPTQLLGLLLLWLPGARC (SEQ ID NO: 500), MDTRAPTQLLGLLLLWLPGARC (SEQ ID NO: 501), MDTRAPTQLLGLLLLWLPGARC (SEQ ID NO: 502), MDTRAPTQLLGLLLLWLPGARC (SEQ ID NO: 503), MDTRAPTQLLGLLLLWLPGARC (SEQ ID NO: 504), MDTRAPTQLLGLLLLWLPGARC (SEQ ID NO: 505), MDTRAPTQLLGLLLLWLPGARC (SEQ ID NO: 506), MDTRAPTQLLGLLLLWLPGARC (SEQ ID NO: 507), MDTRAPTQLLGLLLLWLPGARC (SEQ ID NO: NO:498), METGLRWLLLVAVLKGVQC (SEQ ID NO:499), METGLRWLLLVAVLKGVQCQE (SEQ ID NO:500), and MDMRAPTQLLGLLLLWLPGARC (SEQ ID NO:501).Other signal or secretory peptides are known to those skilled in the art and can be fused to any of the variable region polypeptide chains listed in Tables 1A and 1B or the full-chain polypeptide sequences in Tables 4A and 4B, for example, to promote or optimize expression in a particular host cell.

[0275] Typically, expression vectors used to produce these anti-PAC1 antibodies and antigen-binding fragments of the invention in host cells will contain sequences for plasmid maintenance and for cloning and expression of exogenous nucleotide sequences encoding components of the antibodies and antigen-binding fragments. In certain embodiments, these sequences (collectively referred to as "flanking sequences") will typically include one or more of the following nucleotide sequences: a promoter, one or more enhancer sequences, an origin of replication, a transcription termination sequence, an intact intron sequence containing donor and acceptor splice sites, a sequence encoding a leader sequence for polypeptide secretion, a ribosome binding site, a polyadenylation sequence, a polylinker region for insertion of a nucleic acid encoding a polypeptide to be expressed, and a selectable marker element. Each of these sequences is discussed below.

[0276] Optionally, the vector may contain a "tag"-coding sequence, i.e., an oligonucleotide molecule located at the 5' or 3' end of the polypeptide coding sequence; the oligonucleotide tag sequence encodes polyHis (e.g., hexaHis), FLAG, HA (hemagglutinin influenza virus), myc, or another "tag" molecule of an existing commercially available antibody. The tag is usually fused to the polypeptide when the polypeptide is expressed and can be used as a means for affinity purification or detection of the polypeptide from the host cell. Affinity purification can be accomplished, for example, by column chromatography using antibodies to the tag as an affinity matrix. Optionally, the tag can then be removed from the purified polypeptide by various methods, such as cleavage using certain peptidases.

[0277] The flanking sequence may be homologous (i.e., from the same species and / or strain as the host cell); heterologous (i.e., from a species other than the host cell species or strain); hybrid (i.e., from a combination of more than one flanking sequence); synthetic or native. Thus, the source of the flanking sequence may be any prokaryotic or eukaryotic organism, any vertebrate or invertebrate, or any plant, provided that the flanking sequence functions in and can be activated by the host cell machinery.

[0278] Useful flanking sequences in vectors of the present invention can be obtained by any of several methods well known in the art. Typically, flanking sequences useful herein are previously identified by mapping and / or by restriction endonuclease digestion, and can therefore be isolated from a suitable tissue source using an appropriate restriction endonuclease. In some cases, the complete nucleotide sequence of the flanking sequence may be known. At this point, conventional methods for nucleic acid synthesis or cloning may be used to synthesize flanking sequences.

[0279] Whether all or only part of the flanking sequence is known, it can be obtained using the polymerase chain reaction (PCR) and / or by screening a genomic library with suitable probes (e.g., oligonucleotides and / or flanking sequence fragments from the same or another species). In the case where the flanking sequence is unknown, a DNA fragment containing the flanking sequence can be isolated from a larger DNA fragment, which may contain, for example, a coding sequence or even another gene or genes. The DNA fragment can be generated by restriction endonuclease digestion, followed by agarose gel purification, Separation can be accomplished by column chromatography (Chatsworth, CA) or other methods known to those skilled in the art. To achieve this goal, the selection of appropriate enzymes will be apparent to those of ordinary skill in the art.

[0280] The replication origin is normally a part of those commercially available prokaryotic expression vectors, and the starting point contributes to the amplification of the vector in the host cell. If the carrier selected does not contain the replication origin site, the replication origin site can be chemically synthesized based on known sequences, and connected to the vector. For example, the replication origin from plasmid pBR322 (New England Biolabs, Beverly, Massachusetts) is applicable to most gram-negative bacteria and various viral sources (such as SV40, polyomavirus, adenovirus, vesicular oral virus (VSV) or papillomavirus (such as HPV or BPV)) can be used for cloning vectors in mammalian cells. Usually, mammalian expression vectors do not need a replication origin component (for example, usually only using SV40 to originate because it also contains viral early promoter).

[0281] The transcription termination sequence is usually located at the 3' end of the polypeptide coding region and is used to terminate transcription. Typically, the transcription termination sequence in prokaryotes is a GC-rich fragment followed by a poly-T sequence. Although the sequence is easily cloned from a library or even commercially available as part of a vector, it can also be easily synthesized using known nucleic acid synthesis methods.

[0282] Selectable marker genes encode proteins necessary for the survival and growth of host cells grown in selective media. Typical proteins encoded by selectable marker genes (a) confer resistance to antibiotics or other toxins, such as ampicillin, tetracycline or kanamycin to prokaryotic host cells; (b) supplement the auxotrophic defects of cells; or (c) provide key nutrients that are not available in complex or specific media. Specific selectable markers are kanamycin resistance genes, ampicillin resistance genes and tetracycline resistance genes. Advantageously, the neomycin resistance gene can also be used for selection in prokaryotic and eukaryotic host cells simultaneously.

[0283] Other selectable genes can be used to increase the gene to be expressed. Amplification is such a process, wherein the gene required for the protein that is essential for growth or cell survival is repeated in tandem in the chromosome of the successive generations of recombinant cells. Examples of suitable selective markers for mammalian cells include dihydrofolate reductase (DHFR) and promoterless thymidine kinase genes. Mammalian cell transformants are placed under selection pressure, wherein the selectable genes present in the vector only make the transformants uniquely adapt to survival. Selective pressure is applied by culturing transformed cells under the conditions of continuous increase in the concentration of the selector in the culture medium, thereby resulting in the amplification of the DNA of the selectable gene and encoding another gene (such as one or more components of these antibodies or antigen-binding fragments described herein). Therefore, the polypeptide of the increased amount is synthesized from the amplified DNA.

[0284] A ribosome binding site is usually required for the initiation of mRNA translation and is characterized by a Shine-Dalgarno sequence (prokaryotes) or a Kozak sequence (eukaryotes). This element is typically located at the 3' end of the promoter and the 5' end of the coding sequence of the polypeptide to be expressed. In certain embodiments, one or more coding regions may be operably linked to an internal ribosome binding site (IRES), allowing translation of two open reading frames from a single RNA transcript.

[0285] In some cases, such as where glycosylation is desired in a eukaryotic host cell expression system, various pre-sequences or prosequences can be manipulated to improve glycosylation or yield. For example, the peptidase cleavage site of a specific signal peptide can be changed, or a prosequence can be added, which can also affect glycosylation. The final protein product can have one or more accidentally expressed additional amino acids at the -1 position (relative to the first amino acid of the mature protein), which may not have been completely removed. For example, the final protein product can be found to have one or two amino acid residues in the peptidase cleavage site, attached to the amino terminus. Alternatively, if the enzyme cuts in such a region within the mature polypeptide, using some enzyme cleavage sites can result in a slightly truncated form of the desired polypeptide.

[0286] The expression and cloning vectors of the present invention will generally contain a promoter that is recognized by the host organism and operably connected to the molecule encoding the polypeptide. As used herein, the term "operably connected" refers to the connection of two or more nucleic acid sequences in the following manner: such a manner that a nucleic acid molecule capable of directing the transcription of a given gene and / or synthesizing a desired protein molecule is produced. For example, a control sequence in a vector that is "operably connected" to a protein coding sequence is connected thereto so as to achieve expression of the protein coding sequence under conditions compatible with the transcriptional activity of the control sequence. More specifically, if a promoter and / or enhancer sequence (including any combination of cis-acting transcriptional control elements) stimulates or regulates the transcription of a coding sequence in a suitable host cell or other expression system, the promoter and / or enhancer sequence is operably connected to the coding sequence.

[0287] Promoter is a non-transcribed sequence (usually in about 100-1000bp) located upstream (i.e. 5') of the start codon of a structural gene, which controls the transcription of the structural gene. Routinely, promoters are divided into one of two categories (inducible promoters and constitutive promoters). In response to certain changes in culture conditions (such as the presence or absence of nutrients or changes in temperature), the transcription level from DNA is increased under the control of an inducible promoter. On the other hand, constitutive promoters uniformly transcribe the genes to which they are operably connected, wherein there is little or no control over gene expression control. A large number of promoters recognized by various potential host cells are well known. By removing the promoter from the source DNA by restriction enzyme digestion and inserting the desired promoter sequence into the vector, a suitable promoter is operably connected to the DNA encoding for example heavy chain, light chain or other components of these antibodies and antigen-binding fragments of the present invention.

[0288] Promoters suitable for use with yeast hosts are also well known in the art. Yeast enhancers are advantageously used with yeast promoters. Suitable promoters for mammalian host cells are well known and include, but are not limited to, those obtained from viral genomes, such as polyoma virus, fowl pox virus, adenovirus (e.g., adenovirus serotype 2, 8, or 9), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, retrovirus, hepatitis B virus, and simian virus 40 (SV40). Other suitable mammalian promoters include heterologous mammalian promoters, such as heat shock promoters and actin promoters.

[0289] Other specific promoters that may be promoters of interest include, but are not limited to, the SV40 early promoter (Benoist and Chambon, 1981, Nature 290:304-310); the CMV promoter (Thornsen et al., 1984, Proc. Natl. Acad. USA 81:659-663); the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., 1980, Cell 22:787-797); the herpes virus thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. USA 78:1444-1445); promoter and regulatory sequences from metallothionein genes (Prinster et al., 1982, Nature 296:39-42); and prokaryotic promoters, such as the β-lactamase promoter (Villa-Kamaroff et al., 1978, Proc. Natl. Acad. Sci. USA 75:3727-3731); or the tac promoter (DeBoer et al., 1983, Proc. Natl. Acad. Sci. USA 80:21-25).Also of interest are the following animal transcriptional control regions, which exhibit tissue specificity and have been used in transgenic animals: the elastase I gene control region, which is active in pancreatic acinar cells (Swift et al., 1984, Cell, 38:639-646; Ornitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol., 50:399-409; MacDonald, 1987, Hepatology, 7:425-515); the insulin gene control region, which is active in pancreatic β cells (Hanahan, 1985, Nature, 315:115-122); the immunoglobulin gene control region, which is active in lymphocytes (Grosschedl et al., 1984, Cell, 38:647-651); 58; Adames et al., 1985, Nature 318:533-538; Alexander et al., 1987, Mol. Cell. Biol. 7:1436-1444); a mouse mammary tumor virus control region active in testis, mammary gland, lymphoid, and mast cells (Leder et al., 1986, Cell 45:485-495); an albumin gene control region active in liver (Pinkert et al., 1987, Genes and Devel. [Genes and Development] 1: 268-276); the α-fetoprotein gene control region active in the liver (Krumlauf et al., 1985, Mol. Cell. Biol. [Molecular Cell Biology] 5: 1639-1648; Hammer et al., 1987, Science [Science] 253: 53-58); the α1-antitrypsin gene control region active in the liver (Kelsey et al., 1987, Gene ... Devel. [Genes and Development] 1: 161-171); the β-globin gene control region active in bone marrow cells (Mogram et al., 1985, Nature [Nature] 315: 338-340; Kollias et al., 1986, Cell [Cell] 46: 89-94); the myelin basic protein gene control region active in oligodendrocytes in the brain (Readhead et al., 1987, Cell [Cell] 48: 703-712); the myosin light chain-2 gene control region active in skeletal muscle (Sani, 1985, Nature [Nature] 314: 283-286); and the gonadotropin-releasing hormone gene control region active in the hypothalamus (Mason et al., 1986, Science [Science] 234: 1372-1378).

[0290] Enhancer sequences can be inserted into vectors to increase the transcription of DNA encoding components of these antibodies or antigen-binding fragments (e.g., light chain, heavy chain or variable region) by higher eukaryotic organisms. Enhancers are cis-acting elements of DNA, usually about 10-300bp in length, acting on promoters to increase transcription. Enhancers are independent of direction and position and have been found at 5' and 3' positions of transcription units. Several enhancer sequences available from mammalian genes are known (e.g., globulin, elastase, albumin, α-fetoprotein and insulin). However, enhancers from viruses are generally used. SV40 enhancers, cytomegalovirus early promoter enhancers, polyoma enhancers and adenovirus enhancers known in the art are exemplary enhancing elements for activating eukaryotic promoters. Although enhancers can be located in vectors 5' or 3' of the coding sequence, they are generally located at the 5' site of the promoter. Sequences encoding suitable natural or heterologous signal sequences (leader sequences or signal peptides) can be incorporated into expression vectors to promote extracellular secretion of antibodies or antigen-binding fragments as described above. The choice of signal peptide or leader sequence depends on the type of host cell in which the antibody or antigen-binding fragment is to be produced, and a heterologous signal sequence can replace the native signal sequence. Examples of signal peptides are described above. Other signal peptides that are functional in mammalian host cells include: the signal sequence of interleukin-7 (IL-7) described in U.S. Patent No. 4,965,195; the signal sequence of the interleukin-2 receptor described in Cosman et al., 1984, Nature [Nature] 312: 768; the interleukin-4 receptor signal peptide described in EP Patent No. 0367566; the type I interleukin-1 receptor signal peptide described in U.S. Patent No. 4,968,607; and the type II interleukin-1 receptor signal peptide described in EP Patent No. 0460846.

[0291] The provided expression vectors can be constructed from a starting vector, such as a commercially available vector. These vectors may or may not contain all desired flanking sequences. When one or more flanking sequences described herein are not already present in the vector, they can be obtained separately and connected to the vector. Methods for obtaining each flanking sequence are well known to those skilled in the art. The expression vector can be introduced into a host cell to produce proteins, including antibodies and antigen-binding fragments encoded by nucleic acids as described herein.

[0292] In certain embodiments, nucleic acids encoding different components of the anti-PAC1 antibodies or antigen-binding fragments of the present invention may be inserted into the same expression vector. For example, nucleic acids encoding anti-PAC1 antibody light chains or variable regions may be cloned into the same vector as nucleic acids encoding anti-PAC1 antibody heavy chains or variable regions. In such embodiments, the two nucleic acids may be separated by an internal ribosome entry site (IRES) and under the control of a single promoter, such that the light and heavy chains are expressed from the same mRNA transcript. Alternatively, the two nucleic acids may be under the control of two separate promoters, such that the light and heavy chains are expressed from two separate mRNA transcripts. In some embodiments, nucleic acids encoding anti-PAC1 antibody light chains or variable regions are cloned into one expression vector, and nucleic acids encoding anti-PAC1 antibody heavy chains or variable regions are cloned into a second expression vector. In such embodiments, host cells may be co-transfected with the two expression vectors to produce the complete antibodies or antigen-binding fragments of the present invention.

[0293] After the vectors have been constructed and one or more nucleic acid molecules encoding the components of the antibodies and antigen-binding fragments described herein have been inserted into one or more appropriate sites in one or more vectors, the completed one or more vectors can be inserted into a suitable host cell for amplification and / or polypeptide expression. Thus, the present invention encompasses isolated host cells or cell lines comprising one or more expression vectors encoding the components of the anti-PAC1 antibodies or antigen-binding fragments described herein. As used herein, the term "host cell" refers to a cell that has been transformed or is capable of being transformed with a nucleic acid so as to express a gene of interest. The term includes progeny of a parent cell, whether or not the progeny is identical in morphology or genetic makeup to the original parent cell, as long as the gene of interest is present. A host cell comprising an isolated nucleic acid of the present invention, preferably operably linked to at least one expression control sequence (e.g., a promoter or enhancer), is a "recombinant host cell."

[0294] Transformation of the expression vector for the anti-PAC1 antibody or antigen-binding fragment into the selected host cell can be accomplished by well-known methods including transfection, infection, calcium phosphate coprecipitation, electroporation, microinjection, lipofection, DEAE-dextran mediated transfection or other known techniques. The method selected will be a function of the type of host cell to be used. These and other suitable methods are well known to those skilled in the art and are listed, for example, in Sambrook et al., 2001.

[0295] When cultured under appropriate conditions, the host cells synthesize antibodies or antigen-binding fragments, which can then be collected from the culture medium (if the host cells secrete it into the culture medium) or directly from the host cells that produced it (if it is not secreted). The selection of an appropriate host cell will depend on various factors, such as the desired expression level, polypeptide modifications (e.g., glycosylation or phosphorylation) that are desired or necessary for activity, and ease of folding into a biologically active molecule.

[0296] Exemplary host cells include prokaryotic cells, yeast, or higher eukaryotic cells. Prokaryotic host cells include eubacteria, e.g., Gram-negative or Gram-positive organisms, such as Enterobacteriaceae, such as Escherichia (e.g., E. coli), Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella (e.g., Salmonella typhimurium), Serratia (e.g., Serratia marcescans), Shigella, and Bacillus (e.g., B. subtilis and B. licheniformis), Pseudomonas, and Streptomyces. Eukaryotic microorganisms such as filamentous fungi or yeast are suitable cloning or expression hosts for recombinant polypeptides. Saccharomyces cerevisiae or common baker's yeast is the most commonly used among the lower eukaryotic host microorganisms. However, many other genera, species and strains are generally available and useful herein, such as Pichia (e.g., P. pastoris) Schizosaccharomyces pombe; Kluyveromyces, Yarrowia; Candida; Trichoderma reesia; Neurospora crassa; Schwanniomyces, such as Schwanniomyces occidentalis; and filamentous fungi, such as, for example, Neurospora, Penicillium, Tolypocladium, and Aspergillus hosts (e.g., A. nidulans and A. niger).

[0297] Host cells for expressing glycosylated antibodies and antigen-binding fragments can be derived from multicellular organisms. Examples of invertebrate cells include plants and insect cells. Many baculovirus strains and variants have been identified, as well as corresponding permissive insect host cells from the following hosts, such as Spodoptera frugiperda (caterpillars), Aedes aegypti (mosquitoes), Aedes albopictus (mosquitoes), Drosophila melanogaster (fruit flies) and Bombyx mori. Multiple virus strains for transfecting such cells are publicly available, for example, the L-1 variant of Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV.

[0298] Vertebrate host cells can also be suitable hosts, and the recombinant production of antibodies and antigen-binding fragments from these cells has become routine procedures. Mammalian cell lines that can be used as hosts for expression are well known in the art, and include, but are not limited to, immortalized cell lines available from the American Germplasm Collection Center (ATCC), including, but not limited to, Chinese hamster ovary (CHO) cells, including CHOK1 cells (ATCC CCL61), DXB-11, DG-44, and Chinese hamster ovary cells / -DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States] 77:4216, 1980); monkey kidney CV1 system (COS-7, ATCC CRL1651) transformed by SV40; human embryonic kidney system (subclone 293 or 293 cells are used to grow in suspension culture (Graham et al., J .GenVirol. [Journal of General Virology] 36:59, 1977); baby hamster kidney cells (BHK, ATCCCL10); mouse Sertoli cells (TM4, Mather, Biol. Reprod. [Biology of Reproduction] 23:243-251, 1980); monkey kidney cells (CV1, ATCCCL70); African green monkey kidney cells (VERO-76, ATCCCRL-1587); human cervical cancer cells (HELA, ATCCCL2); canine kidney cells (MDCK, ATCCCCCL34); Buffalo rat liver cells (BRL3A, ATCCCRL1442); human lung cells (W138, ATCCCCCL75); human hepatoma cells (Hep G2, HB8065); mouse mammary tumor (MMT060562, ATCCCCL51); TRI cells (Mather et al., Annals N.Y Acad. Sci. [Annals of the New York Academy of Sciences] 383:44-68, 1982); MRC5 cells or FS4 cells; mammalian myeloma cells, and many other cell lines. In certain embodiments, cell lines can be selected by determining which cell lines have high expression levels and constitutively produce antibodies and antigen-binding fragments with PAC1 binding properties. In another embodiment, a cell line from the B cell lineage can be selected that does not produce its own antibodies but has the ability to produce and secrete heterologous antibodies. In some embodiments, CHO cells are preferred host cells for expressing these anti-PAC1 antibodies and antigen-binding fragments of the present invention.

[0299] Host cells are transformed or transfected with the nucleic acids or vectors described above to produce anti-PAC1 antibodies or antigen-binding fragments, and cultured in conventional nutrient media modified appropriately for inducing promoters, selecting transformants, or amplifying genes encoding the desired sequences. In addition, novel vectors and transfected cell lines having multiple copies of transcription units separated by selectable markers are particularly useful for expression of antibodies and antigen-binding fragments. Therefore, the present invention also provides a method for producing an anti-PAC1 antibody or antigen-binding fragment thereof described herein, the method comprising culturing a host cell containing one or more expression vectors described herein in a culture medium under conditions that allow expression of the antibody or antigen-binding fragment encoded by the one or more expression vectors; and recovering the antibody or antigen-binding fragment from the culture medium or the host cell.

[0300] Host cells for producing the antibodies or antigen-binding fragments of the present invention can be cultured in various media. The following commercially available media are suitable for culturing host cells: Ham's F10 (Sigma), Minimal Essential Medium (MEM, Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle Medium (DMEM, Sigma). In addition, any medium described in Ham et al., Meth. Enz. [Enzymology Methods] 58: 44, 1979; Barnes et al., Anal. Biochem. [Analytical Biochemistry] 102: 255, 1980; U.S. Patent Nos. 4,767,704; 4,657,866; 4,927,762; 4,560,655; or 5,122,469; WO 90103430; WO 87 / 00195; or U.S. Patent Registration No. 30,985 that can be used as a culture medium for host cells. Any of these media may be supplemented as needed with hormones and / or other growth factors (e.g., insulin, transferrin, or epidermal growth factor); salts (e.g., sodium chloride, calcium, magnesium, and phosphate); buffers (e.g., HEPES); nucleotides (e.g., adenosine and thymidine); and antibiotics (e.g., gentamicin). TM drugs); trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations known to those skilled in the art. The culture conditions (e.g., temperature, pH, etc.) are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

[0301] After culturing host cells, antibodies or antigen binding fragments can be produced in cells, in the periplasmic space, or directly secreted into the medium. If antibodies or antigen binding fragments are produced in cells, as a first step, the granular fragments of the fragments of host cells or cracking are removed, for example, by centrifugation or ultrafiltration. The following is used to purify antibodies or antigen binding fragments: for example, hydroxyapatite chromatography, cation or anion exchange chromatography or preferably affinity chromatography, using one or more target antigens or protein A or protein G as affinity ligands. Protein A can be used to purify proteins containing polypeptides based on human γ1, γ2 or γ4 heavy chains (Lindmark et al., J. Immunol. Meth. [Journal of Immunology Methods] 62: 1-13, 1983). Protein G is recommended for all mouse isotypes and human γ3 (Guss et al., EMBO J. [Journal of the European Molecular Biology Association] 5: 1567-1575, 1986). The matrix to which the affinity ligand is attached is usually agarose, but other matrices can also be used. Mechanically stable matrices, such as controlled pore glass or poly(styrenedivinyl)benzene, allow for faster flow rates and shorter processing times than with agarose. When the protein contains a CH3 domain, BakerbondABX TM Resins (JT Baker, Phillipsburg, NJ) can be used for purification. Other techniques for protein purification such as ethanol precipitation, reverse phase HPLC, chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation are also possible, depending on the specific antibody or antigen-binding fragment to be recovered.

[0302] In certain embodiments, the present invention provides compositions (e.g., pharmaceutical compositions) comprising one or more of the anti-PAC1 antibodies or antigen-binding fragments of the present invention (e.g., anti-PAC1 monoclonal antibodies or binding fragments thereof) and a pharmaceutically acceptable diluent, carrier, excipient, solubilizer, emulsifier, preservative and / or adjuvant. The pharmaceutical composition can be used in any of the methods described herein. The pharmaceutical compositions of the present invention include, but are not limited to, liquid, frozen and lyophilized compositions. "Pharmaceutically acceptable" refers to molecules, compounds and compositions that are non-toxic to human recipients at dosages and concentrations administered to humans and / or do not produce allergic or adverse reactions when administered to humans. In some embodiments, the pharmaceutical composition may contain formulation materials for changing, maintaining or preserving the following properties of the composition: for example, pH, osmotic pressure, viscosity, transparency, color, isotonicity, odor, sterility, stability, dissolution or release rate, adsorption or penetration. In such embodiments, suitable formulation materials include, but are not limited to, amino acids (e.g., glycine, glutamine, asparagine, arginine, or lysine); antimicrobials; antioxidants (e.g., ascorbic acid, sodium sulfite, or sodium bisulfite); buffers (e.g., borate, bicarbonate, Tris-HCl, citrate, phosphate, or other organic acids); bulking agents (e.g., mannitol or glycine); chelating agents (e.g., ethylenediaminetetraacetic acid (EDTA)); complexing agents (e.g., caffeine, polyvinylpyrrolidone, β-cyclodextrin, or hydroxypropyl-β-cyclodextrin); bulking agents; monosaccharides; disaccharides; and other sugars (e.g., glucose, mannose, or dextrin); proteins (e.g., serum albumin, gelatin, or immunoglobulins); colorants and diluents; emulsifiers; hydrophilic polymers (e.g., polyvinylpyrrolidone); low molecular weight the invention relates to a pharmaceutical composition comprising a polypeptide; a salt-forming counterion (such as sodium); a preservative (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenylethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide); a solvent (such as glycerol, propylene glycol or polyethylene glycol); a sugar alcohol (such as mannitol or sorbitol); a suspending agent; a surfactant or wetting agent (such as pluronic, PEG, sorbitan ester, polysorbate (such as polysorbate 20, polysorbate 80), tritium, tromethamine, lecithin, cholesterol, tyloxapol); a stability enhancer (such as sucrose or sorbitol); a tonicity enhancer (such as an alkali metal halide, preferably sodium chloride or potassium chloride, mannitol sorbitol); a delivery vehicle; a diluent; an excipient and / or a pharmaceutical adjuvant. Methods and suitable materials for formulating molecules for therapeutic use are known in the pharmaceutical art and are described, for example, in REMINGTON'S PHARMACEUTICAL SCIENCES, 18th ed., (AR Genrmo, ed.), 1990, Mack Publishing Company.

[0303] In some embodiments, the pharmaceutical compositions of the present invention comprise standard pharmaceutical carriers, such as sterile phosphate buffered saline solution, bacteriostatic water, etc. A variety of aqueous carriers may be used, such as water, buffered water, 0.4% saline, 0.3% glycine, etc., and may include other proteins such as albumin, lipoprotein, globulin, etc., which undergo mild chemical modification, etc., for enhanced stability.

[0304] In the formulation, the exemplary concentration of these antibodies or antigen binding fragments can be from about 0.1mg / ml to about 200mg / ml, or from about 0.1mg / mL to about 50mg / mL, or from about 0.5mg / mL to about 25mg / mL, or alternatively from about 2mg / mL to about 10mg / mL. The aqueous formulation of the antibody or antigen binding fragment can be prepared in a pH-buffered solution, for example, in a pH range of from about 4.5 to about 6.5, or from about 4.8 to about 5.5, or alternatively about 5.0. Examples of buffers suitable for pH within this range include acetates (e.g., sodium acetate), succinates (e.g., sodium succinate), gluconates, histidine, citrates, and other organic acid buffers. The buffer concentration can be from about 1mM to about 200mM, or from about 10mM to about 60mM, depending on, for example, the desired isotonicity of the buffer and formulation.

[0305] Tonicity agents may also be included in the formulation to stabilize the antibody or antigen-binding fragment. Exemplary tonicity agents include polyols, such as mannitol, sucrose, or trehalose. Preferably, the aqueous formulation is isotonic, although hypertonic or hypotonic solutions may be suitable. Exemplary concentrations of the polyol in the formulation may range from about 1% to about 15% w / v.

[0306] Surfactant can also be added to the formulation to reduce the aggregation of the antibody or Fab prepared and / or to minimize the formation of particles in the formulation and / or reduce adsorption. Exemplary surfactants include nonionic surfactants, such as polysorbate (e.g., polysorbate 20 or polysorbate 80) or poloxamer (e.g., poloxamer 188). The exemplary concentration of surfactant can be from about 0.001% to about 0.5%, or from about 0.005% to about 0.2%, or alternatively from about 0.004% to about 0.01% w / v.

[0307] In one embodiment, the formulation contains the above-mentioned reagents (i.e., antibody or antigen binding fragment, buffer, polyol and surfactant), and is substantially free of one or more preservatives (e.g., benzyl alcohol, phenol, metacresol, chlorobutanol and benzethonium chloride). In another embodiment, the preservative may be included in the formulation, for example, at a concentration ranging from about 0.1% to about 2%, or alternatively from about 0.5% to about 1%. One or more other pharmaceutically acceptable carriers, excipients or stabilizers (such as those described in REMINGTON'S PHARMACEUTICAL SCIENCES, 18th Edition (AR Genrmo, ed.), 1990, Mack Publishing Company) may be included in the formulation, provided that they do not adversely affect the desired properties of the formulation.

[0308] Therapeutic formulations of antibodies or antigen-binding fragments are prepared for storage by mixing an antibody or antigen-binding fragment having the desired degree of purity with an optional physiologically acceptable carrier, excipient or stabilizer (REMINGTON'S PHARMACEUTICAL SCIENCES, 18th ed., (AR Genrmo, ed.), 1990, Mack Publishing Company) in the form of a lyophilized formulation or an aqueous solution. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include those described above, such as buffers (e.g., phosphates, citrates, and other organic acids); antioxidants (e.g., ascorbic acid and methionine); preservatives (e.g., octadecyldimethylbenzyl ammonium chloride, hexamethylammonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl or benzyl alcohol, alkyl parabens (e.g., methyl or propyl paraben); catechol; resorcinol, cyclohexanol, 3-pentanol, and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins (e.g., serum albumin, gelatin, or immunoglobulin); globulin); hydrophilic polymers (e.g., polyvinyl pyrrolidone); amino acids (e.g., glycine, glutamine, asparagine, histidine, arginine, or lysine); monosaccharides, disaccharides, and other carbohydrates (including glucose, mannose, maltose, or dextrin); chelating agents such as EDTA; sugars (e.g., sucrose, mannitol, trehalose, or sorbitol); salt-forming counterions (e.g., sodium); metal complexes (e.g., zinc-protein complexes); and / or nonionic surfactants such as polysorbates (e.g., polysorbate 20 or polysorbate 80) or poloxamers (e.g., poloxamer 188); or polyethylene glycol (PEG).

[0309] In one embodiment, a suitable formulation of the present invention contains an isotonic buffer (such as phosphate, acetate or TRIS buffer), combined with a tonicity agent (e.g., a polyol, sorbitol, sucrose or sodium chloride), which has a tonicity and stabilizing effect. An example of such a tonicity agent is 5% sorbitol or sucrose. In addition, the formulation may optionally contain a surfactant, for example, at 0.01% to 0.02% wt / vol, to prevent aggregation or improve stability. The pH of the formulation may be in the range of from 4.5 to 6.5 or 4.5 to 5.5. Other exemplary descriptions of pharmaceutical formulations for antibodies and antigen-binding fragments can be found in U.S. Patent Publication No. 2003 / 0113316 and U.S. Patent No. 6,171,586, each of which is incorporated herein by reference in its entirety.

[0310] The formulation for in vivo administration must be sterile. The compositions of the present invention can be sterilized by conventional, well-known sterilization techniques. For example, sterilization can be easily accomplished by filtration through a sterile filtration membrane. The resulting solution can be packaged for use or filtered and lyophilized under aseptic conditions, and the lyophilized preparation is combined with a sterile solution before administration.

[0311] The freeze-drying process is usually used to stabilize polypeptides for long-term storage, especially when the polypeptides are relatively unstable in liquid compositions. The freeze-drying cycle usually consists of three steps: freezing, primary drying and secondary drying (see Williams and Polli, Journal of Parenteral Science and Technology [Enteral Science and Technology Magazine], Vol. 38, No. 2, pp. 48-59, 1984). In the freezing step, the solution is cooled until it is fully frozen. A large amount of water in the solution forms ice at this stage. Ice sublimates in the primary drying stage, which is carried out by reducing the chamber pressure to a vapor pressure lower than ice using a vacuum. Finally, adsorbed water or bound water is removed in the secondary drying stage at the reduced pressure chamber pressure and the elevated shelf temperature. The process produces a material known as a freeze-dried cake. Thereafter, the freeze-dried cake can be reconstituted before use. The standard reconstitution procedure for lyophilized material is to add back a volume of purified water (usually equal to the volume removed during the lyophilization process), although dilute solutions of antimicrobial agents are sometimes used to prepare drugs for parenteral administration (see Chen, Drug Development and Industrial Pharmacy, Vol. 18: 1311-1354, 1992).

[0312] In some cases, it has been noted that excipients can act as stabilizers for freeze-dried products (see Carpenter et al., Vol. 74: 225-239, 1991). For example, known excipients include polyols (including mannitol, sorbitol and glycerol); sugars (including glucose and sucrose) and amino acids (including alanine, glycine and glutamic acid). In addition, polyols and sugars are also often used to protect polypeptides from damage induced by freezing and drying and to enhance stability during storage in a dry state. In general, sugars (particularly disaccharides) are effective during the freeze-drying process and storage. Classes of other molecules, including monosaccharides and disaccharides and polymers (such as PVP), have also been reported as stabilizers for freeze-dried products.

[0313] For injection, the pharmaceutical formulation and / or drug may be a powder suitable for reconstitution with an appropriate solution as described above. Examples of these include, but are not limited to, freeze-dried, rotary-dried or spray-dried powders; amorphous powders; granules; precipitates or particles. For injection, the formulation may optionally contain stabilizers, pH adjusters, surfactants, bioavailability modifiers, and combinations of these.

[0314] Sustained release preparations can be prepared. Suitable examples of sustained release preparations include semipermeable matrices of solid hydrophobic polymers containing antibodies or antigen binding fragments, which are in the form of molded articles (e.g., films or microcapsules). Examples of sustained release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) or poly(vinyl alcohol)), polylactic acid (U.S. Patent No. 3,773,919), copolymers of L-glutamic acid and ethyl-L-glutamic acid, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers (e.g., Lupron Depot TM (Injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate)) and poly-D-(-)-3-hydroxybutyric acid. Although polymers (such as ethylene-vinyl acetate and lactic acid-glycolic acid) are able to release molecules for more than 100 days, some hydrogels release proteins for shorter periods of time. When encapsulated polypeptides are retained in the body for a long time, they may denature or aggregate due to exposure to moisture at 37°C, resulting in loss of biological activity and possible changes in immunogenicity. Rational strategies can be designed to achieve stabilization based on the mechanism involved. For example, if the aggregation mechanism is found to be intermolecular SS bond formation through sulfo-disulfide exchange, stabilization can be achieved by changing the sulfhydryl residues, lyophilizing from acidic solutions, controlling the moisture content, using appropriate additives, and developing specific polymer matrix compositions.

[0315] As described herein, the formulations of the present invention can be designed for short-acting, fast-release, long-acting or sustained release. Thus, the pharmaceutical formulations can also be formulated for controlled or sustained release.

[0316] The specific dosage may be adjusted depending on the disease, disorder or condition to be treated (e.g., episodic migraine, chronic migraine or cluster headache); the age, weight, general health, sex and diet of the subject; dosage interval; route of administration; excretion rate and drug combination.

[0317] These anti-PAC1 antibodies or antigen-binding fragments of the present invention can be administered by any suitable means, including parenteral, subcutaneous, intravenous, intraperitoneal, intrapulmonary and intranasal, and if necessary for local treatment, intralesional administration. Parenteral administration includes intravenous, intraarterial, intraperitoneal, intramuscular, intradermal or subcutaneous administration. In addition, the antibody or antigen-binding fragment is suitable for administration by pulse infusion, especially with decreasing doses of the antibody or antigen-binding fragment. Preferably, the administration is given by injection, most preferably intravenous or subcutaneous injection, depending in part on whether the administration is short-term or chronic. Other methods of administration are contemplated, including topical administration, particularly transdermal administration, transmucosal administration, rectal administration, oral administration or local administration (e.g., by a catheter placed near the desired site). The antibodies or antigen-binding fragments of the present invention can be administered in a physiological solution at a dosage range of between 0.01 mg / kg and 100 mg / kg, with a frequency range from daily to weekly to monthly.

[0318] These anti-PAC1 antibodies and antigen-binding fragments described herein are useful for treating or ameliorating a condition associated with the biological activity of the PAC1 receptor in a patient in need thereof. Thus, disclosed herein are anti-PAC1 antibodies and antigen-binding fragments of the invention for use in a method of treatment. The term "patient" includes human patients and is used interchangeably with the term "subject." As used herein, the term "treating" or "treatment" is an intervention performed to prevent the development of a disease or to alter the pathology of a disease. Thus, "treatment" refers to both therapeutic treatment and preventive or defensive measures. Patients in need of treatment include patients who have been diagnosed with or are suffering from a disorder or condition and patients in need of prevention of a disorder or condition. "Treatment" includes any sign of success in ameliorating an injury, pathology, or condition, including any objective or subjective parameter, such as reducing, alleviating, alleviating symptoms, or making an injury, pathology, or condition more tolerable to a patient, slowing the rate of degeneration or decline, making the endpoint of degeneration weaker, or improving the patient's physical and mental health. Treatment or amelioration of symptoms can be based on objective or subjective parameters, including the results of a physical examination, self-report by the patient, neuropsychiatric examination, and / or psychiatric assessment.

[0319] Thus, in some embodiments, the present invention provides a method for treating or preventing a condition associated with the biological activity of a PAC1 receptor (e.g., a condition associated with PACAP-induced activation of a PAC1 receptor) in a patient in need thereof, the method comprising administering to the patient an effective amount of an anti-PAC1 antibody or antigen-binding fragment thereof as described herein. The PACAP / PAC1 signaling pathway has been implicated in a variety of physiological processes, including cardiovascular function, metabolic and endocrine function, inflammation, stress response, regulation of vasomotor tone, and regulation of the autonomic nervous system, particularly the balance between the sympathetic and parasympathetic nervous systems. See, e.g., Tanida et al., Regulatory Peptides, Vol. 161: 73-80, 2010; Moody et al., Curr. Opin. Endocrinol. Diabetes Obes., Vol. 18: 61-67, 2011; and Hashimoto et al., Current Pharmaceutical Design, Vol. 17: 985-989, 2011. Conditions associated with abnormal or excessive activation of the PACAP / PAC1 signaling pathway include, but are not limited to, headache conditions such as migraine, cluster headache, tension-type headache, hemiplegic migraine, and retinal migraine; inflammatory skin disorders; chronic pain such as neuropathic pain; anxiety disorders irritable bowel syndrome; and vasodilatory symptoms such as hot flashes, facial flushing, sweating, and night sweats. Therefore, the anti-PAC1 antibodies and antigen-binding fragments thereof of the present invention can be administered to patients to prevent, ameliorate, or treat any of these conditions or disorders or other conditions associated with abnormal or excessive PAC1 receptor biological activity. In certain embodiments, the present invention provides methods for treating or preventing headache conditions (e.g., episodic migraine, chronic migraine, cluster headache, tension-type headache, hemiplegic migraine, and retinal migraine) in patients in need thereof, the method comprising administering to the patient an effective amount of an anti-PAC1 antibody or antigen-binding fragment thereof as described herein. In some embodiments, the present invention provides methods for inhibiting activation of human PAC1 receptors in patients suffering from headache conditions, the method comprising administering to the patient an effective amount of an anti-PAC1 antibody or antigen-binding fragment thereof as described herein. In one embodiment, the patient suffers from a migraine headache condition (such as episodic migraine or chronic migraine). In another embodiment, the patient suffers from a cluster headache condition.

[0320] "Effective amount" is usually produced by a specific condition or is related to a specific condition, which is enough to reduce the severity and / or frequency of symptoms, eliminate symptoms and / or potential causes, prevent the occurrence of symptoms and / or their potential causes, and / or improve or remedy the amount of damage. In certain embodiments, the effective amount is a therapeutically effective amount or a preventive effective amount. "Therapeutically effective amount" is an amount sufficient to treat a disease state or one or more symptoms, particularly a state or one or more symptoms related to a disease state, or otherwise prevent, hinder, delay or reverse the progress of a disease state or any other adverse symptoms related to the disease in any way (i.e., provide "therapeutic efficacy"). "Preventive effective amount" is the amount of an antibody or antigen binding fragment that will have an expected preventive effect when administered to a subject, for example, preventing or delaying the onset (or recurrence) of a disease, or reducing the possibility of an onset (or recurrence) of a disease. A complete therapeutic or preventive effect does not necessarily occur through the administration of a dose, but may only occur after a series of doses. Therefore, an effective amount for treatment or prevention may be administered in the form of one or more doses.

[0321] In certain embodiments, the present invention provides a method for inhibiting vasodilation in a patient in need thereof, the method comprising administering to the patient an effective amount of an anti-PAC1 antibody or antigen-binding fragment thereof as described herein. Ligands of the PAC1 receptor, such as PACAP38 and VIP, are potent vasodilators, and blocking the binding of these ligands to the PAC1 receptor can inhibit vasodilation and improve conditions associated with abnormal or excessive vasodilation (such as headache conditions, hot flashes, and flushing). In one embodiment, the patient suffers from a headache condition (such as migraine or cluster headache). In another embodiment, the patient suffers from vasodilation symptoms (e.g., hot flashes, facial flushing, sweating, or night sweats). In a related embodiment, the patient suffers from vasodilation symptoms associated with menopause.

[0322] In some embodiments of the methods of the present invention, the headache condition to be treated, prevented or improved is migraine. Therefore, the present invention includes a method for treating, preventing or alleviating migraine in a patient in need thereof, the method comprising administering to the patient an effective amount of an anti-PAC1 antibody or antigen-binding fragment thereof described herein. Migraine is a recurrent headache lasting from about 4 to about 72 hours, characterized by unilateral, throbbing, and / or moderate to severe pain, and / or pain aggravated by physical activity. Migraine is often accompanied by nausea, vomiting, and / or sensitivity to light (photophobia), sound (phonophobia) or smell. In some patients, an aura precedes the onset of a migraine. An aura is usually a visual, sensory, language or motor disturbance that indicates that a headache is about to occur. The methods described herein prevent, treat or improve one or more symptoms of migraine in the presence and absence of an aura in a human patient.

[0323] PACAP38, through activation of its receptor, induces vasodilation, especially of the dural vasculature (Schytz et al., Neurotherapeutics, Vol. 7(2):191-196, 2010). In particular, the PACAP38 / PAC1 receptor signaling cascade has been implicated in migraine pathophysiology (Amin et al., Brain, Vol. 137:779-794, 2014). Infusion of PACAP38 (which has a higher affinity for PAC1 receptors than VPAC1 and VPAC2 receptors) induces migraine-like headaches in migraine patients (Schytz et al., Brain, 132:16-25, 2009; Amin et al., Brain, Vol. 137:779-794, 2014; Guo et al., Cephalalgia, Vol. 37:125-135, 2017). In addition, PACAP38 levels are elevated in the intracranial circulation of patients with migraine attacks, and PACAP38 levels are reduced after the use of triptans to treat migraine symptoms (Tuka et al., Cephalalgia [Headache Journal], Vol. 33, 1085-1095, 2013; Zagami et al., Ann. Clin. Transl. Neurol. [Clinical and Translational Neurology Annals], Vol. 1: 1036-1040, 2014). These reports suggest that endogenous release of PACAP38 is an important trigger of migraine and that its effects are primarily mediated through activation of the PAC1 receptor.

[0324] In some embodiments, patients treated according to the methods of the invention have, suffer from, or are diagnosed with episodic migraine. Episodic migraine is diagnosed when a patient with a history of migraine (e.g., at least five lifetime attacks of migraine) has 14 or fewer migraine days per month. "Migraine days" include any calendar days on which a patient experiences an onset, duration, or recurrence of a "migraine" with or without an aura lasting more than 30 minutes. "Migraine" is a headache associated with nausea or vomiting or light or sound, and / or a headache characterized by at least two of the following pain characteristics: unilateral pain, throbbing pain, moderate to severe pain intensity, or pain aggravated by physical activity. In certain embodiments, patients with, suffering from, or diagnosed with episodic migraine have at least 4, but less than 15 migraine days per month. In a related embodiment, patients with, suffering from, or diagnosed with episodic migraine have an average of less than 15 headache days per month. As used herein, a "headache day" is any calendar day on which a patient experiences a migraine as defined herein or any headache that lasts more than 30 minutes or requires acute headache treatment.

[0325] In certain embodiments, patients treated according to the methods of the invention have, suffer from, or are diagnosed with chronic migraine. Chronic migraine is diagnosed when a migraine patient (i.e., a patient with at least five lifetime episodes of migraine) has 15 or more headache days per month and at least 8 of the headache days are migraine days. In some embodiments, patients having, suffering from, or diagnosed with chronic migraine have an average of 15 or more migraine days per month. In certain embodiments of the methods described herein, administration of an anti-PAC1 antibody or antigen-binding fragment of the invention prevents, reduces, or delays the progression of episodic migraine to chronic migraine in a patient.

[0326] In some embodiments, the present invention provides a method for treating, preventing or alleviating cluster headache in a patient in need thereof, the method comprising administering to the patient an effective amount of an anti-PAC1 antibody or antigen-binding fragment thereof described herein. Cluster headache is a condition whose most important feature is recurrent severe headaches on one side of the head, usually around the eyes (see Nesbitt et al., BMJ [British Medical Journal], Vol. 344: e2407, 2012). Cluster headaches often occur periodically: spontaneous relief of pain interrupts the active period. Cluster headaches are often accompanied by intracranial autonomic symptoms, such as tearing, nasal congestion, ptosis, pupil constriction, facial blanching, sweating and periocular swelling, usually confined to the side of the head with pain. The average age of onset of cluster headache is about 30-50 years old. Cluster headaches are more common in men, with a male to female ratio of about 2.5:1 to about 3.5:1. Sphenopalatine ganglion (SPG) stimulation has been used to treat cluster headaches. Neurostimulation systems that deliver low-level (but high-frequency, physiologically blocked) electrical stimulation to the SPG have been shown to be effective in relieving the acute, debilitating pain of cluster headache in a recent clinical trial (see Schoenen J, et al., Cephalalgia, Vol. 33(10):816-30, 2013). Given this evidence and because PACAP is one of the major neurotransmitters in the SPG, it is expected that inhibition of PACAP / PAC1 signaling with the anti-PAC1 antibodies or antigen-binding fragments thereof described herein will have efficacy in treating human cluster headache.

[0327] Other conditions associated with the PACAP / PAC1 signaling pathway that can be treated according to the methods of the present invention include, but are not limited to, inflammatory skin conditions such as rosacea (see U.S. Patent Publication No. 20110229423), chronic pain syndromes such as neuropathic pain (see Jongsma et al., Neuroreport, Vol. 12: 2215-2219, 2001; Hashimoto et al., Annals of the New York Academy of Sciences, Vol. 1070: 75-89, 2006), tension-type headaches, hemiplegic migraines, retinal migraines, anxiety disorders such as post-traumatic stress disorder (see Hammack and May, Biol. Psychiatry, Vol. 78(3): 167-177, 2015), irritable bowel syndrome, and vasodilatory symptoms (e.g., hot flashes, facial flushing, sweating, and night sweats), such as those associated with menopause. In one embodiment, the condition treated by administering an anti-PAC1 antibody or antigen-binding fragment thereof of the invention is chronic pain. In another embodiment, the condition treated by administering an anti-PAC1 antibody or antigen-binding fragment thereof of the invention is neuropathic pain.

[0328] In any of the methods described herein, treatment can include prophylactic treatment. Prophylactic treatment refers to treatment performed before or at the onset of a condition (e.g., before an attack of a migraine or an episodic cluster headache) to reduce the frequency, severity, and / or length of symptoms (e.g., migraine or cluster headache) in a patient.

[0329] In some embodiments, the methods of the present invention for treating or preventing a headache condition in a patient comprise administering to the patient an anti-PAC1 antibody or antigen-binding fragment thereof described herein in combination with one or more agents suitable for the acute or prophylactic treatment of migraine or other headache disorders described herein. As used herein, the term "combination therapy" encompasses administration of two compounds (e.g., an anti-PAC1 antibody and an additional agent) in a sequential manner (i.e., each compound is administered at different times in any order) as well as administration of the two compounds in a substantially simultaneous manner. Substantially simultaneous administration includes simultaneous administration and can be achieved by administering a single formulation comprising the two compounds (e.g., a single formulation comprising a fixed ratio of the two compounds or a prefilled syringe having a fixed ratio of each compound) or by administering separate formulations comprising each compound simultaneously. Thus, in certain embodiments, the methods of the present invention comprise administering an anti-PAC1 antibody or antigen-binding fragment thereof described herein together with a second headache therapeutic agent.

[0330] In certain embodiments, the second headache therapeutic agent may be an acute headache therapeutic agent for the acute treatment of headache or migraine. In some embodiments, the acute headache therapeutic agent is a serotonin (5-hydroxytryptamine; 5-HT) receptor agonist, such as a 5HT1 receptor agonist. The acute headache therapeutic agent may be a 5HT 1B , 5HT 1D and / or 5HT 1F Serotonin receptor agonists. Such serotonin receptor agonists include, but are not limited to, triptans (e.g., almotriptan frovatriptan, rizatriptan, sumatriptan, naratriptan, eletriptan, and zolmitriptan); ergotamines (e.g., dihydroergotamine and ergotamine tartrate), and 5HT 1F -Selective serotonin receptor agonists (such as lasmiditan). Other suitable acute headache therapeutics include nonsteroidal anti-inflammatory drugs (e.g., acetylsalicylic acid, ibuprofen, naproxen, indomethacin, and diclofenac) and opioids (e.g., codeine, morphine, hydrocodone, fentanyl, meperidine, and oxycodone). In one embodiment, the acute headache therapeutic administered in combination with the anti-PAC1 antibody or antigen-binding fragment of the present invention is a triptan. In another embodiment, the acute headache therapeutic administered in combination with the anti-PAC1 antibody or antigen-binding fragment of the present invention is ergotamine. In yet another embodiment, the acute headache therapeutic administered in combination with the anti-PAC1 antibody or antigen-binding fragment of the present invention is a nonsteroidal anti-inflammatory drug. In yet another embodiment, the acute headache therapeutic administered in combination with the anti-PAC1 antibody or antigen-binding fragment of the present invention is an opioid.

[0331] In some embodiments, the second headache therapeutic agent is a prophylactic headache therapeutic agent for the prophylactic treatment of headache or migraine. In one embodiment, the prophylactic headache therapeutic agent is a triple antiepileptic drug, such as divalproex sodium, sodium valproate, valproic acid, topiramate or gabapentin. In another embodiment, the prophylactic headache therapeutic agent is a beta-blocker, such as propranolol, timolol, atenolol, metoprolol or nadolol. In yet another embodiment, the prophylactic headache therapeutic agent is an antidepressant, such as a tricyclic antidepressant (e.g., amitriptyline, nortriptyline, doxepin and fluoxetine). In yet another embodiment, the prophylactic headache therapeutic agent is botulinum toxin A.

[0332] In certain embodiments, the methods of the present invention include administering an anti-PAC1 antibody or antigen-binding fragment thereof described herein in combination with an antagonist of the calcitonin gene-related peptide (CGRP) signaling pathway (i.e., inhibition of activation or signaling of the CGRP receptor by a CGRP ligand). For example, an anti-PAC1 antibody or antigen-binding fragment of the present invention can be administered in combination with a CGRP pathway antagonist to treat or prevent headache conditions (e.g., migraine or cluster headache) in a patient in need thereof. In some embodiments, the CGRP pathway antagonist is an antagonist of the human CGRP receptor. CGRP receptor antagonists include small molecule inhibitors of CGRP receptors, such as those described in U.S. Patent Application No. 20060142273 and U.S. Patent Nos. 7,842,808; 7,772,244; 7,754,732; 7,569,578; 8,685,965; 8,569,291; 8,377,955; 8,372,859; 8,143,266; 7,947,677; and 7,625,901, all of which are incorporated herein by reference in their entirety. CGRP receptor antagonists may also include peptide antagonists of the receptor, such as those described in U.S. Patent No. 8,168,592, which is incorporated herein by reference in its entirety. In certain embodiments, the CGRP receptor antagonist administered with the anti-PAC1 antibodies and antigen-binding fragments of the present invention is a monoclonal antibody that specifically binds to the human CGRP receptor, such as the antibodies described in U.S. Pat. No. 9,102,731 and U.S. Patent Publication No. 20160311913, both of which are incorporated herein by reference in their entirety. In a specific embodiment of the methods of the present invention, the anti-PAC1 antibodies or antigen-binding fragments thereof described herein are administered in combination with an anti-CGRP receptor monoclonal antibody to treat or prevent a headache condition (e.g., migraine or cluster headache) in a patient, the anti-PAC1 antibody or antigen-binding fragment thereof comprising: a light chain variable region comprising the sequence of SEQ ID NO: 502 (sequence provided below) and a heavy chain variable region comprising the sequence of SEQ ID NO: 503 (sequence provided below). In another specific embodiment of the methods of the present invention, the anti-CGRP receptor monoclonal antibody administered in combination with the anti-PAC1 antibodies or antigen-binding fragments of the present invention to treat or prevent a headache condition (e.g., migraine or cluster headache) is errekinumab.

[0333] Light chain variable region sequences of exemplary anti-CGRP receptor monoclonal antibodies:

[0334]

[0335] Heavy chain variable region sequences of exemplary anti-CGRP receptor monoclonal antibodies:

[0336]

[0337] In some embodiments, the CGRP pathway antagonist administered with the anti-PAC1 antibodies or antigen-binding fragments of the present invention to treat or prevent a patient's headache condition (e.g., migraine or cluster headache) is an antagonist of a CGRP ligand. The CGRP ligand antagonist may be a decoy or soluble CGRP receptor or other protein that binds to a CGRP ligand (e.g., an anti-CGRP ligand antibody). Anti-CGRP ligand antibodies are known in the art and are described, for example, in WO 2007 / 054809; WO 2007 / 076336; WO 2011 / 156324; and WO 2012 / 162243, all of which are incorporated herein by reference in their entirety. In certain embodiments, the CGRP ligand antagonist administered with these anti-PAC1 antibodies and antigen-binding fragments of the present invention is a monoclonal antibody that specifically binds to human α-CGRP and / or human β-CGRP. In one embodiment, the anti-CGRP ligand antibody is remanezumab. In another embodiment, the anti-CGRP ligand antibody is ganezumab. In yet another embodiment, the anti-CGRP ligand antibody is eprenetuzumab.

[0338] The present invention also includes the use of anti-PAC1 antibodies and antigen-binding fragments in any of the methods disclosed herein. For example, in certain embodiments, the present invention provides an anti-PAC1 antibody or antigen-binding fragment described herein for use in a method of treating or preventing a headache condition in a patient in need thereof. In some such embodiments, the headache condition is a migraine. The migraine can be an episodic migraine or a chronic migraine. In other embodiments, the headache condition is a cluster headache. In some embodiments, the method for treating or preventing a headache condition comprises administering a second headache therapeutic agent in combination with the anti-PAC1 antibody or antigen-binding fragment thereof. In one embodiment, the second headache therapeutic agent is an acute headache therapeutic agent, such as 5HT 1B , 5HT 1D and / or 5HT 1FSerotonin receptor antagonists (e.g., triptans or ergotamines), nonsteroidal anti-inflammatory drugs, or opioids. In another embodiment, the second headache therapeutic agent is a preventive headache therapeutic agent, such as an antiepileptic, a beta-blocker, an antidepressant, botulinum toxin A, or a CGRP pathway antagonist. In some embodiments, the CGRP pathway antagonist is a human CGRP receptor antagonist. In a specific embodiment, the human CGRP receptor antagonist is a monoclonal antibody that specifically binds to the human CGRP receptor, such as erinuzumab. In other embodiments, the CGRP pathway antagonist is an antagonist of a CGRP ligand, such as a monoclonal antibody that specifically binds to human α-CGRP and / or human β-CGRP. In certain embodiments, the anti-CGRP ligand antibody is remanezumab, ganezumab, or eprezumab.

[0339] In some embodiments, the present invention provides an anti-PAC1 antibody or antigen-binding fragment described herein for use in a method of inhibiting vasodilation in a patient in need thereof. In such embodiments, the patient may be diagnosed as having or suffering from a headache condition, such as migraine (e.g., episodic or chronic migraine) or cluster headache. In other embodiments, the present invention provides an anti-PAC1 antibody or antigen-binding fragment described herein for use in a method of inhibiting activation of a human PAC1 receptor in a patient suffering from a headache condition. The headache condition may be migraine (e.g., episodic or chronic migraine) or cluster headache.

[0340] Specifically contemplated are the use of an anti-PAC1 antibody or antigen-binding fragment thereof for the preparation of a medicament for administration according to any of the methods disclosed herein. For example, in some embodiments, the present invention encompasses the use of an anti-PAC1 antibody or antigen-binding fragment described herein in the preparation of a medicament for treating or preventing a headache condition in a patient in need thereof. In some such embodiments, the headache condition is migraine. The migraine can be episodic migraine or chronic migraine. In other embodiments, the headache condition is cluster headache. In certain embodiments, the anti-PAC1 antibody or antigen-binding fragment thereof is formulated for administration with a second headache therapeutic agent. In one embodiment, the second headache therapeutic agent is an acute headache therapeutic agent, such as 5HT. 1B , 5HT 1D and / or 5HT 1FSerotonin receptor antagonists (e.g., triptans or ergotamines), nonsteroidal anti-inflammatory drugs, or opioids. In another embodiment, the second headache therapeutic agent is a preventive headache therapeutic agent, such as an antiepileptic, a beta-blocker, an antidepressant, botulinum toxin A, or a CGRP pathway antagonist. In some embodiments, the CGRP pathway antagonist is a human CGRP receptor antagonist. In a specific embodiment, the human CGRP receptor antagonist is a monoclonal antibody that specifically binds to the human CGRP receptor, such as erinuzumab. In other embodiments, the CGRP pathway antagonist is an antagonist of a CGRP ligand, such as a monoclonal antibody that specifically binds to human α-CGRP and / or human β-CGRP. In certain embodiments, the anti-CGRP ligand antibody is remanezumab, ganezumab, or eprezumab.

[0341] In some embodiments, the present invention includes the use of an anti-PAC1 antibody or antigen-binding fragment described herein in the preparation of a medicament for inhibiting vasodilation in a patient in need thereof. In such embodiments, the patient may be diagnosed as having or suffering from a headache condition, such as migraine (e.g., episodic or chronic migraine) or cluster headache. In other embodiments, the present invention includes the use of an anti-PAC1 antibody or antigen-binding fragment described herein in the preparation of a medicament for inhibiting human PAC1 receptor activation in a patient suffering from a headache condition. The headache condition may be migraine (e.g., episodic or chronic migraine) or cluster headache.

[0342] The anti-PAC1 antibodies and antigen-binding fragments of the present invention can also be used to detect human PAC1 in biological samples and identify cells or tissues expressing human PAC1. For example, the anti-PAC1 antibodies and antigen-binding fragments can be used in diagnostic assays, such as immunoassays for detecting and / or quantifying PAC1 expressed in tissues or cells. In addition, the anti-PAC1 antibodies and antigen-binding fragments described herein can be used to inhibit the formation of a complex between PAC1 and PACAP, thereby modulating the biological activity of PAC1 in cells or tissues. Such biological activities include the increase of intracellular cAMP and vasodilation.

[0343] The anti-PAC1 antibodies and antigen-binding fragments described herein can be used for diagnostic purposes to detect, diagnose or monitor diseases and / or conditions associated with PAC1, including migraine, cluster headache, and anxiety disorders (eg, post-traumatic stress disorder). Also provided are methods for detecting the presence of PAC1 in a sample using classical immunohistological methods known to those of skill in the art (e.g., Tijssen, 1993, Practice and Theory of Enzyme Immunoassays, Vol. 15 (RH Burdon and PH van Knippenberg, eds., Elsevier, Amsterdam); Zola, 1987, Monoclonal Antibodies: A Manual of Techniques, pp. 147-158 (CRC Press, Inc.); Jalkanen et al., 1985, J. Cell. Biol. 101:976-985; Jalkanen et al., 1987, J. Cell Biol. 105:3087-3096). Examples of methods that can be used to detect the presence of PAC1 include immunoassays such as enzyme-linked immunosorbent assays (ELISA) and radioimmunoassays (RIA) using the anti-PAC1 antibodies and antigen-binding fragments described herein. Detection of PAC1 can be performed in vivo or in vitro.

[0344] For diagnostic applications, the anti-PAC1 antibody or antigen-binding fragment may be labeled with a detectable labeling group. Suitable labeling groups include, but are not limited to, the following: a radioisotope or radionuclide (e.g., 3 H. 14 C. 15 N. 35 S. 90 Y. 99 Tc, 111 In, 125 I. 131 I); fluorescent groups (e.g., FITC, rhodamine, lanthanide phosphors); enzyme groups (e.g., horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase); chemiluminescent groups; biotinyl groups; or predetermined polypeptide epitopes recognized by secondary reporter genes (e.g., leucine zipper pair sequences, binding sites of secondary antibodies, metal binding domains, epitope tags). In some embodiments, the labeling group is coupled to the antibody or antigen-binding fragment by spacer arms of various lengths to reduce potential steric hindrance. Various methods for labeling proteins are known in the art and can be used.

[0345] In another embodiment, the anti-PAC1 antibodies and antigen-binding fragments described herein can be used to identify one or more cells expressing PAC1. In a specific embodiment, the antibody or antigen-binding fragment is labeled with a labeling group, and the binding of the labeled antibody or antigen-binding fragment to PAC1 is detected. These antibodies or antigen-binding fragments can also be used in immunoprecipitation assays in biological samples. In another specific embodiment, the binding of the antibody or antigen-binding fragment to PAC1 is detected in vivo. In another specific embodiment, the antibody or antigen-binding fragment is isolated and assayed using techniques known in the art. See, for example, Harlow and Lane, 1988, Antibodies: A Laboratory Manual, New York: Cold Spring Harbor (1991 ed. and regular supplements); John E. Coligan, ed., 1993, Current Protocols In Immunology, New York: John Wiley & Sons.

[0346] The following examples, including experiments performed and results achieved, are for illustrative purposes only and should not be construed as limiting the scope of the appended claims.

[0347] Examples

[0348] Example 1. Crystal structure of human PAC1 antibody - guiding design

[0349] The crystal structure of the complex between the extracellular domain (ECD) of human PAC1 and the Fab fragment of human anti-PAC1 neutralizing antibody (29G4v9) was determined. Human PAC1 ECD and anti-PAC1 Fab were purified separately and then complexed together in a 1:1 molar ratio. The sample was then run through a gel filtration column, equilibrated in 20mM TRIS (pH7.5), 50mM NaCl, 5mM EDTA, and concentrated to 35mg / ml and filtered.

[0350] The sequences of the heavy chain (comprising the variable region (VH), CH1 constant region, upper hinge and caspase III cleavage site) and light chain (comprising the variable region (VL) and CL constant region) of the Fab fragment are listed below. The sequence of the human PAC1 ECD construct is provided below and comprises amino acids 26 to 143 of human PAC1 (SEQ ID NO: 1) minus the region between amino acids 89-109.

[0351] The amino acid sequence of the heavy chain of 29G4v9 Fab (composed of: VH region (amino acids: 1-120); CH1 region (amino acids: 121-218); upper hinge region (amino acids 219-221), and caspase III cleavage site (222-226):

[0352]

[0353] The amino acid sequence of the light chain of 29G4v9 Fab (composed of: VL region (amino acids: 1-108) and CL region (amino acids: 109-214):

[0354]

[0355] Amino acid sequence of human PAC1 ECD construct:

[0356]

[0357] Purified human PAC1 ECD and anti-PAC1 Fab were initially co-crystallized with commercially available screens using the sitting drop vapor diffusion method. Crystallization conditions were further expanded using the hanging drop vapor diffusion method (Qiagen MPD Suite Screen #61 (134561)). Protein and crystallization buffer (0.1 M citric acid, pH 4.0, 40% MPD) were dropped in 1 μl of a reservoir solution of crystallization buffer at 4°C in a 1:1 ratio. Rod-shaped crystals formed within a few weeks.

[0358] Crystals were equilibrated in crystallization buffer as a cryoprotectant and frozen in liquid nitrogen and shipped to Lawrence Berkeley National Laboratories for data collection. The data set was collected at the Advanced Light Source Synchrotron Beamline 5.0.2. The data were integrated and scaled using HKL2000 (Otwinowski and Minor, Methods Enzymology, Vol. 276, 307-326, 1997) and were 99.8% complete to Where R 合并 0.081 (98.0% completed the final shell The crystal belongs to the orthorhombic space group P21212, where the unit cell size is α = 90°, β = 90°, γ = 90°. The crystal structure can be solved by molecular replacement using PhaserMR (Winn et al., Acta Crystallogr., Sect. D: Biol. Crystallogr. [Journal of Crystallography, Vol. 67: 235-242, 2011]. A proprietary Fab structure was used as the first research model to solve the anti-PAC1 Fab component. Subsequent molecular replacement used PDBID: 2JOD (Sun et al., Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States of America], Vol. 104: 7875, 2007), human PAC1 ECD NMR structure as the initial model to solve the human PAC1 ECD component. There is one ECD molecule and one Fab molecule in the asymmetric unit. The structure was refined using Refmac5 (Winn et al., Acta Crystallogr., Sect. D: Biol. Crystallogr., vol. 67: 235-242, 2011; Murshudov et al., Acta Crystallogr., Sect. D: Biol. Crystallogr., vol. 67: 355-367, 2011) and Phenix.refine (Adams et al., Acta Crystallogr., Sect. D: Biol. Crystallogr., vol. 66: 213-221, 2010) and modeled using the graphics program Coot (Emsley and Cowtan, Acta Crystallogr., vol. 67: 355-367, 2011). Crystallogr., Sect. D: Biol. Crystallogr. [Acta Crystallogr. D: Biological Crystallography], 2004, Vol. 60: 2126-2132, 2004).

[0359] The structure of the human PAC1 ECD:anti-PAC1 Fab complex was refined to The R-factor is 20% and R 自由 The front view and side view of the structure of the composite are shown in Figure 1A and 1B The interaction between 29G4v9 Fab and PAC1 ECD consists of hydrophobic, electrostatic and hydrogen bonding interactions. The interaction between 29G4v9 Fab and PAC1 ECD has a hidden surface area typical for antibody-antigen interactions. and shape complementarity value (0.695). All amino acids in the PAC1 ECD that contain at least one non-hydrogen atom at a distance of 100 to 1000 nm or less are determined to be core interface amino acids in the PAC1 ECD. Atomic distances were calculated using the PyMOL program (DeLano, WL The PyMOL Molecular Graphics System. [PyMOL Molecular Graphics System] (Palo Alto, 2002)). The core interface amino acids in the PAC1 ECD include: Asp59, Asn60, Ile61, Arg116, Asn117, Thr119, Asp121, Gly122, Trp123, Ser124, Glu125, Pro126, Phe127, Pro128, His129, Tyr130, Phe131, Asp132, and Gly135 with amino acid position numbers relative to SEQ ID NO: 1.

[0360] The interface between 29G4v9 Fab and PAC1 ECD in the crystal structure was analyzed to identify regions where the interaction between the two molecules was suboptimal. Based on the structural analysis, amino acid mutations in the light chain and heavy chain variable regions were designed to enhance the interaction in these regions between the Fab and PAC1 ECD to improve the binding affinity and / or inhibitory potency of the antibody. In particular, analysis of the interaction between the Fab light chain and PAC1 ECD revealed four regions where mutations in the Fab light chain may improve interaction with PAC1. In region 1 (the region containing PAC1 ECD amino acids Glu120 and Asp121), mutations of Gln27 in the light chain CDR1 (SEQ ID NO: 3) to lysine, tyrosine, or arginine were proposed to provide better charge complementarity or hydrogen bonding potential with the Glu120 and Asp121 PAC1 amino acids ( Figure 2A Region 2 is a region with positive electrostatic potential, and it is proposed that Ser28 in the light chain CDR1 (SEQ ID NO: 3) is mutated to glutamic acid to provide better charge complementarity ( Figure 2A Region 3 is a hydrophobic region containing PAC1ECDPhe127 residue and has hydrogen bonding potential. Gly30, Arg31 and Ser32 in the light chain CDR1 are located away from region 3 ( Figure 2A ). Therefore, as summarized in Table 6 below, multiple mutations were proposed at these three sites to improve the hydrophobic or hydrogen bonding interactions between these three residues and this region of the PAC1 ECD. Arg93 in the light chain CDR3 sits in a pocket of PAC1 residues with negative electrostatic potential (region 4; Figure 2BHowever, due to geometry, Arg93 does not form any direct hydrogen bonds with PAC1 residues. Mutation of Arg93 in the light chain CDR3 to glutamine, lysine, histidine, or asparagine has been proposed to provide alternative charge complementarity or hydrogen bonding potential with residues in the PAC1 ECD ( Figure 2B ).

[0361] Analysis of the interaction between the 29G4v9 Fab heavy chain and PAC1 ECD revealed three major regions where mutations in the Fab heavy chain could improve the interaction with PAC1 ECD. Figure 3A As shown in , region 5 encompasses PAC1 amino acid Phe131 and can be divided into two subregions located on either side of Phe131. Arg31 and Phe32 in the heavy chain CDR1 are located in these subregions, and mutations at these sites are proposed to improve hydrophobic interactions with the PAC1 Phe131 residue or provide alternative charge complementarity interactions. See Table 6 for a list of mutations. In region 6, which includes PAC1 ECD residues Asn60 and Ile61 (relative to SEQ ID NO: 1), mutations of heavy chain CDR2 residues Tyr53, Asp54, and Gly56 are proposed to improve hydrophobic interactions or provide alternative hydrogen bonding with Asn60 and Ile61 PAC1 residues ( Figure 3B In region 7 (a region with hydrophobic residues and some negative electrostatic potential), mutations of heavy chain CDR3 residues Val102, Leu103, and Thr104 as listed in Table 6 were proposed to improve hydrophobic interactions or provide alternative hydrogen bonding interactions ( Figure 3C ).

[0362] Based on analysis of the crystal structure of the Fab / PAC1 ECD complex, a summary of specific mutations proposed to improve the interaction between anti-PAC1 antibodies and the human PAC1 receptor is provided in Table 6 below.

[0363] Table 6. Summary of structure-based mutations in the variable region of the PAC1 antibody

[0364]

[0365]

[0366] 1 The amino acid positions are relative to the light chain of SEQ ID NO:3 and relative to the heavy chain of SEQ ID NO:2.

[0367] In addition to the mutations designed by analysis of amino acids interacting between the anti-PAC1 Fab and the human PAC1 ECD as described above, an in silico affinity maturation analysis was performed using the crystal structure to identify additional mutations to improve the binding affinity and / or inhibitory potency of the anti-PAC1 antibody. Amino acid residues in the 29G4v9 Fab involved in binding to the human PAC1 ECD were identified by visual inspection of the crystal structure of the complex described above. These interface residues of the antibody were selected for substantial mutation of all other amino acids except cysteine. The binding free energy (ΔΔG) following mutation of specific residues was calculated using Discovery Studio molecular modeling software from Biovia. 结合 ) were used to assess the effect of mutations on the antibody / PAC1 ECD binding interaction. Negative values ​​for ΔΔG binding compared to the parental molecule indicated that the mutation resulted in a stronger binding to the PAC1 ECD. These calculations identified approximately 65 mutations that resulted in negative ΔΔG binding values. Based on visual inspection and analysis of the "modeled" structures of these variants with the PAC1 ECD, these 65 mutations were further narrowed down to 50 (18 light chains and 32 heavy chains). Based on binding free energy calculations, these 50 mutations that were predicted to increase the binding affinity of the antibody to PAC1 are summarized in Table 7 below.

[0368] Table 7. Summary of mutations in the variable region of PAC1 antibody predicted by computer simulation analysis

[0369]

[0370]

[0371] 1 The amino acid positions are relative to the light chain of SEQ ID NO:3 and relative to the heavy chain of SEQ ID NO:2.

[0372] In silico approaches led to the identification of additional mutations at different amino acids and positions within the light and / or heavy chains compared to structure-based analysis.

[0373] The mutations described in this example were incorporated into anti-PAC1 antibodies by recombinant production and tested for the ability to inhibit PACAP-induced activation of human PAC1 in an in vitro cell-based assay as described in Example 3 herein.

[0374] Example 2. Yeast Display Affinity Maturation of 29G4v10 Human PAC1 Antibody

[0375] An efficient method for affinity maturation involves constructing a library of yeast-displayed antibody Fab mutants and selecting improved binders by fluorescence-assisted cell sorting (FACS) ( Figure 4). To generate anti-PAC1 antibodies with improved inhibitory potency, the 29G4v10 antibody (VH region of SEQ ID NO: 191; VL region of SEQ ID NO: 52) was affinity matured by FACS of a yeast display Fab library. The library design was guided by the solved co-crystal structure described in Example 1 of a complex between human PAC1 ECD and 29G4v9 Fab, the CDRs of which were almost identical to those of 29G4v10. Structural analysis initially identified six and seven CDR positions within the light chain (LC) and heavy chain (HC), respectively, for mutagenesis, and proposed strategies for affinity enhancement. Mutants were designed to improve hydrophobic interactions and charge complementarity, and to provide alternating hydrogen bonding interactions at the interface. See Example 1. These point mutants initiated an engineering approach that involved iterative rounds of production, characterization, and rational combination of beneficial mutations. The yeast library design attempted to complement the linear approach described in Example 1 by more comprehensively exploring mutation combinations in the 13 positions and adding diversification strategies at each selected position.

[0376] By making separate LC and HC libraries, the theoretical diversity was kept manageable at <10 7 The size of LC library was designed to utilize MIX19 saturation mutagenesis at five of the six selected positions (Gln27, Gly30, Arg31, Ser32 and Arg93 of SEQ ID NO:52). MIX19 represents a trimer phosphoramidite (codon) mixture encoding all amino acids except cysteine. At the remaining light chain position (Ser28 of SEQ ID NO:52), mutations for serine, glutamic acid, alanine or stop codons were used. To explore all seven HC positions in one library (Arg31, Phe32, Tyr53, Gly56, Val102, Leu103 and Thr104 of SEQ ID NO:191), we designed a conventional mixture of nine codons (MIX9) for diversification at five positions of seven heavy chain CDRs (Arg31, Phe32, Tyr53, Val102 and Leu103 of SEQ ID NO:191). Conventional MIX9 contains hydrophobic amino acids, basic amino acids, and hydrogen bond donors and acceptors (e.g., F, L, Y, M, Q, H, K, R, and S). Importantly, conventional MIX9 excludes cysteine, asparagine, and tryptophan to reduce the introduction of sequence biases that may pose downstream manufacturability risks. Mutations of glycine, alanine, serine, and threonine were performed on the remaining two heavy chain positions (Gly56 and Thr104 of SEQ ID NO: 191). In summary, for the first campaign, a theoretical diversity of 8.5x10 6The mutHC library and theoretical diversity are 9.9x10 6 The constructed mutLC library oversampled the theoretical diversity by >9-fold.

[0377] Two constructed mutHC and mutLCFab libraries were enriched using FACS for binding to human PAC1 ECD, increasing the stringency of each successive round by reducing the concentration of ECD used for binding (Round 1: 30nM PAC1 ECD; Round 2: 0.67nM PAC1 ECD; and Round 3: 0.2nM PAC1 ECD). The same treated 29G4v10Fab-yeast samples were routinely used to specifically gate yeast clones that exhibited improved binding relative to the parental Fab. The standardized binding / display ratio for each clone was calculated by dividing the median fluorescent binding signal of each clone by the median fluorescent display signal of each clone. By round 3, improved binders were enriched from the mutHC library instead of the mutLC library. Simple screening of approximately 200 yeast clones from the mutHC round 3 library produced 11 appropriately improved binders (Table 8). As described in Example 3, improved affinity variants were recombinantly produced and functional activity in vitro was evaluated. Fortunately, the aspartate isomerization site in the 29G4v10 parental Fab, a potential liability for manufacturability, was restored in all 11 unique mutants.

[0378] Table 8. Best improved binders from MutHC library screening

[0379]

[0380]

[0381] 1 There were no changes in the light chain sequence relative to the 29G4v10 antibody for any of these variants.

[0382] To generate further affinity improvements, chain shuffled libraries were also constructed that combined enriched mutations from mutHC and mutLC sorted libraries. To improve the discrimination between the best binding clones, a binding off-rate driven selection and screening strategy was implemented ( Figure 5). Yeast cells displaying mutant Fabs were first permeabilized with biotinylated human PAC1 ECD, washed extensively, and then incubated for a long time (up to 24 hours) in a buffer containing excess unlabeled human PAC1 ECD. Incubation with unlabeled human PAC1 ECD, which occurred at a temperature range of 25°C to 37°C, made the dissociation event of the cells irreversible. After staining with a fluorescent streptavidin conjugate, cells that retained the most binding to biotinylated PAC1, thus exhibiting the slowest dissociation rate, were isolated by FACS. Figure 5 ). The yeast clone of the Fab showing the slowest off-rate was highly fluorescent.

[0383] In the dissociation rate driven chain shuffling library sorting, after overnight competition with unlabeled PAC1, the 29G4v10 Fab-yeast samples treated identically were used to specifically isolate cells with higher biotinylated PAC1 binding. From two pools collected under different gating stringency conditions, about 600 individual yeast clones were screened using the binding dissociation rate assay, and 190 clones with higher residual PAC1 binding compared to the parental 29G4v10 Fab were identified. The binding specificity of these promising clones was evaluated by confirming that the clones did not bind to the ECD of irrelevant receptors (programmed cell death protein 1 (PD1) and gastric inhibitory polypeptide receptor (GIPR)). Mutants containing additional cysteine ​​abnormalities, N-linked glycosylation, aspartate isomerization, asparagine deamidation, and tryptophan oxidation sites were also removed during the screening process relative to the starting 29G4v10 sequence. The best 30 binding mutants with sequence changes in the CDRs from the parental 29G4v10 antibody and the percentage of human PAC1 ECD binding after off-rate assay are shown in Table 9. A higher percentage binding of PAC1 ECD binding indicates that the mutant Fab has a slower off-rate.

[0384] Table 9. Best improved binders from off-rate driven screening of chain shuffling libraries

[0385]

[0386]

[0387]

[0388]

[0389] 1 The histidine residue at position 34 relative to the 29G4v10 light chain variable region sequence (SEQ ID NO: 52) is deleted in these mutants.

[0390] A set of second generation libraries was designed to generate further affinity improvements. The first generation libraries described above focused on the PAC1 ECD in the crystal structure. The diversification of the subset of 29G4v10 parent antibody CDR positions within the second generation library (Example 1). For the second generation library, the mutagenesis in the region that was not substantially touched in the first generation library was explored, such as CDR2 and CDR3 of the light chain. For several positions that have been explored in the first generation library, the sequencing trend is used to diversify to the limited neutral / beneficial mutation groups that appear after three rounds of sorting. Finally, some hidden framework residues that may affect CDR conformation are targeted for limited diversification, and the mutation strategy is conducive to the amino acid often found at the same position in other people's VH3 and VK3 germlines.

[0391] A total of four second generation Fab libraries were designed to target 24 heavy chain CDR residues (amino acids 27, 29, 31-34, 49, 52-57, 70, 72, 77, 79, 98, 100-104, and 106 of SEQ ID NO: 191) and 17 light chain CDR residues (amino acids 27, 28, 30-32, 34, 46, 49-54, 92-94, and 96 of SEQ ID NO: 52) for diversification. The restricted diversity at many targeted positions enables interrogation of more CDR positions within one library, as well as co-optimization of HCDR1 and HCDR3 and LCDR1 and LCDR3. The four constructed libraries provide from 7x10 6 Up to 1x10 7 The range of theoretical diversity is 8-24x coverage.

[0392] As described above, four constructed Fab libraries were enriched using FACS to bind to human PAC1 ECD. By the third round, only mutHCDR2 and mutLCDR1-LCDR3 libraries produced libraries with the same or higher binding to the parental 29G4v10 antibody. Therefore, these two libraries were used to prepare the library of mutH2 / mutL1L3 chain shuffling for further improvement of affinity. In order to enrich the mutants with the highest affinity, the best performing yeast clone 2B10 from the first generation library (Table 9) was used to set a more stringent sorting gate. After overnight dissociation rate competition with unlabeled PAC1 at 30°C or 37°C, yeast clones with significantly reduced dissociation rates compared to 2B10 clones can be sorted. Restricted screening of about 200 clones revealed that about 100 clones had a slower dissociation rate than 2B10, but most of the promising binders contained potential asparagine deamidation tendencies in HCDR2. For all clones screened, non-specific binding to the ECD of PD1 or GIPR was minimal. Applying stringent binding and sequence filters produced 10 best mutants that had significantly improved PAC1 binding (>2x high percentage binding after overnight competition at 37°C) compared to the 2B10 clone and without any potential sequence bias (Table 10). After dissociation rate determination at 30°C and 37°C, the sequence changes from the parental 29G4v10 antibody and the percentage binding of human PAC1 ECD for these ten best mutants are shown in Table 10. Percentage binding is calculated as the standardized binding after the dissociation rate determination divided by the standardized binding without dissociation rate determination. The higher percentage binding of PAC1 ECD binding indicates that the mutant Fab has a slower dissociation rate.

[0393] Table 10. Best improved binders from off-rate screening of the second generation chain shuffling library

[0394]

[0395]

[0396] As shown in Table 10, all of these top ten binding mutants contained a Q27K mutation in CDRL1, and all but one contained an R31W mutation in CDRL1. All mutants had mutations at amino acid positions D54 and N57 in CDRH2, and most also had mutations at amino acid position G56 in CDRH2. Conservative mutations at amino acid positions 49 and 70 in the heavy chain framework 2 (FR2) and framework 3 (FR3) regions, respectively, were also observed in many of the ten mutants.

[0397] In summary, guided by the structure of the PAC1 ECD in complex with 29G4v9 Fab (a closely related variant of 29G4v22 and 29G4v10 anti-PAC1 neutralizing antibodies), a combinatorial library of 29G4v10 mutants was designed and sorted for improved binding to the PAC1 ECD. To isolate the most improved binders, enriched mutations were combined by constructing CDR-shuffled and / or chain-shuffled libraries for selection under more stringent conditions. Screening of single yeast Fab clones after sorting produced improved human PAC1 ECD binders with significantly slower binding-off rates and minimal nonspecific binding compared to the 29G4v10 parent antibody. A subset of improved affinity variants was recombinantly produced and evaluated for in vitro functional activity as described in Example 3.

[0398] Example 3. In vitro functional activity of human PAC1 antibody variants

[0399] To evaluate the effects of mutations in the heavy and light chain variable regions identified by analysis of co-crystal structures (Example 1) or yeast display libraries (Example 2) on the inhibitory potency of anti-PAC1 antibodies, variants were produced by recombinant expression methods as complete bivalent monoclonal antibodies and / or as monovalent Fab-Fc fusions (e.g., Fab regions fused to dimeric IgG Fc regions) and evaluated in a cell-based cAMP assay as described in more detail below. The light chains of the monoclonal antibodies and Fab fragments comprised the light chain variable region from the specified antibody variants fused to a human kappa light chain constant region having the sequence of SEQ ID NO: 318 or SEQ ID NO: 319. The heavy chains of the monoclonal antibodies and Fab-Fc fusions comprised the heavy chain variable region from the specified antibody variants fused to a non-glycosylated, disulfide-stabilized human IgG1z constant region having the sequence of SEQ ID NO: 325.

[0400] In the case of unsuccessful SDM, PAC1 antibody variant sequences are produced by site-directed mutagenesis (SDM) or by Golden Gate Assembly (GGA). Site-directed mutagenesis utilizes paired mutagenic primers of flanking mutation sites. Full vector PCR reaction is carried out using double-stranded plasmid DNA template. Primers for all desired mutations in a specific clone are combined into a master primer mixture, wherein one to several mutations are incorporated into a separate reaction. After amplification, template plasmid DNA is removed by digestion with DpnI, which is a nuclease that preferentially cuts methylated DNA. The SDM product is then transformed into competent cells for growth and screening by sequencing. Following the manufacturer's instructions, SDM reaction is carried out using QuikChange Lightning Multi Site-Directed Mutagenesis Kit (QuikChange Lightning multi-site mutagenesis kit) (Agilent (Agilent)).

[0401] Where SDM was unsuccessful, an alternative cloning strategy was used. In brief, GGA relies on type II restriction enzymes and T4 DNA ligase to cut and seamlessly join multiple DNA fragments together. (Engler et al., PLOS One [Public Library of Science Comprehensive], Volume 3 (11): e3647, 2008). In this example, multiple DNA fragments consist of: (i) a synthetic nucleic acid sequence encoding a Kozak consensus sequence, a signal peptide sequence, and an antibody variable region sequence (gBlock, Integrated DNA Technologies, Coralville, Iowa); (ii) an antibody constant domain fragment released from a parts vector; and (iii) an expression vector backbone. The GGA reaction consisted of 10 ng of gBlock, 10 ng of Part vector, 10 ng of expression vector, 1 μl 10xFast Digest Reaction Buffer + 0.5 mM ATP (Thermo Fisher Scientific, Waltham, MA), 0.5 μl FastDigest Esp3I (Thermo Fisher Scientific, Waltham, MA), 1 μl T4 DNA ligase (5 U / μl, Thermo Fisher Scientific, Waltham, MA) and water to 10 μl. The reaction was performed for 15 cycles, including a 2-minute digestion step at 37°C and a 3-minute ligation step at 16°C. After 15 cycles, a final 5-minute digestion step at 37°C and a 5-minute enzyme inactivation step at 80°C were performed.

[0402] After cloning, PAC1 antibody polypeptides whose first 22 amino acids are the VK1 signal peptide (MDMRVPAQLLGLLLLWLRGARC; SEQ ID NO: 486) were produced by transiently transfecting 293 HEK cells with the corresponding cDNA. 0.5 mg / L DNA (0.5 mg / L PAC1 in pTT5 vector) or (0.1 mg / L PAC1 in pTT5 vector with 0.4 mg / L blank pTT5 vector) (Durocher et al., NRCC, Nucleic Acids. Res. [Nucleic Acids Research], Vol. 30: e9, 2002) and 4 ml PEI / mg DNA were transfected in F17 medium (Thermo Fisher Scientific) at 1.5×10 6 One hour after transfection, yeast extract (Yeastolate) and glucose were added to the culture, and the cells were then grown in suspension for 6 days using F17 expression medium supplemented with 0.1% Kolliphor, 6mM L-glutamine and 50μg / ml Geneticin, after which the conditioned medium was harvested for purification.

[0403] PAC1 antibody variants were purified from conditioned media using protein A affinity chromatography (MabSelect SuRe, GE Healthcare Life Sciences, Little Chalfont, Buckinghamshire, UK) followed by cation exchange chromatography (SP cross-linked agarose high performance column (SPHP) (GE Healthcare Life Sciences). The protein concentration in each purified pool was determined by UV absorbance at 280 nm (A280) using a NanoDrop 2000 (Thermo Fisher Scientific, Rockford, IL, USA). The purified pool was dialyzed against 2 L of 10 mM sodium acetate, 9% sucrose, pH 5.2 (A52Su) using a 20 kDa MWCO Slide-A-Lyzer dialysis flask (Thermo Fisher Scientific) at 4°C for 2 hours with gentle stirring on a stir plate. The spent dialysate was decanted, fresh 2 L of A52Su was added and dialyzed overnight. After dialysis, the purified pool was dialyzed against 30 kDa Samples were concentrated by centrifugation at 2,000 x g in a floating bucket rotor using a MWCO ultrafiltration concentrator (Thermo Fisher Scientific) until each sample was approximately 40 mg / mL based on A280. Caliper LabChip GXII microtube electrophoresis (PerkinElmer, Waltham, MA, USA) and size exclusion chromatography with an ACQUITY UPLC Protein BEH SEC column were used. The final product was analyzed for main peak purity using a 4.6x300 mm (Waters Corporation, Milford, MA, USA). Endotoxin content was measured using Endosafe-MCS (Charles River, Wilmington, MA, USA) and a 0.05 EU / mL PTS column (Charles River Laboratories).

[0404] The functional activity of purified monoclonal antibodies or Fab-Fc fusion proteins was assessed using a cell-based PAC1 receptor cAMP activity assay. Both PACAP38 and PACAP27 are agonists of the PAC1 receptor, and their activation leads to an increase in intracellular cAMP. The assay uses a human neuroblastoma-derived cell line (SH-SY5Y; Biedler JL et al., Cancer Res. [Cancer Research], Vol. 38: 3751-3757, 1978) obtained from ATCC (ATCC No. CRL-2266; "CRL-2266 cells"). CRL-2266 cells endogenously express human PAC1 receptors (Monaghan et al., J Neurochem. [Journal of Neurochemistry], Vol. 104 (1): 74-88, 2008). In addition, CHO cell lines stably expressing rat PAC1 receptor (GenBank Accession No. NM_133511.2) or cynomolgus PAC1 receptor (NCBI Reference Sequence XP_015303041.1) were used in the assay instead of CRL2266 cells to evaluate the species cross-reactivity of anti-PAC1 antibodies or Fab-Fc fusions on rat and cynomolgus PAC1 receptors. The LANCE Ultra cAMP Assay Kit (PerkinElmer, Boston, MA) was used to measure cAMP concentrations.

[0405] On the day of the assay, frozen CRL-2266 cells were thawed at 37°C and washed once with assay buffer. 10 μL of a cell suspension containing 2,000 cells was added to a 96-well half-area white plate. After adding 5 μL of anti-PAC1 variant monoclonal antibody or Fab-Fc fusion protein (10-point dose-response curve: concentration range from 1 μM to 0.5 fM), the mixture was incubated at room temperature for 30 minutes. Then, 5 μL of human PACAP38 (10 pM final concentration) was added as an agonist, and the mixture was further incubated at room temperature for 15 minutes. After human PACAP38 stimulation, 20 μL of the detection mixture was added and incubated at room temperature for 45 minutes. At an emission wavelength of 665 nm, the plates were read on an EnVision instrument (PerkinElmer, Boston, Massachusetts). The data were processed and analyzed by Prizm (GraphPad Software Inc.) to display POC (percent of control, where control is defined as the activity of the agonist used in the assay) as a function of the concentration of the antagonist (e.g., anti-PAC1 variant antibody or Fab-Fc fusion protein) tested and fit with a standard nonlinear regression curve to generate IC50 values. POC was calculated as follows:

[0406]

[0407] Monovalent Fab-Fc fusion proteins with the mutations summarized in Tables 6 and 7 were generated and tested for functional activity in the above cell-based cAMP assay. The mutant Fab-Fc fusion proteins were divided into two independent groups: mutations that improved the inhibitory potency of the human PAC1 receptor compared to the parent molecule and mutations characterized as neutral (Table 11). Mutations were characterized as neutral if they had an average potency that was less than 1.5x weaker than the parent molecule, and at least one potency measurement was tighter than the parent molecule in the same run.

[0408] Table 11. In vitro inhibitory potency of single mutant Fab-Fc fusion proteins

[0409]

[0410] 1 Amino acid positions relative to the light chain (LC) of SEQ ID NO:52 and amino acid positions relative to the heavy chain (HC) of SEQ ID NO:191.

[0411] The mutation that provides the inhibitory effect increase for people PAC1 receptor is located in three different regions of three-dimensional space on the antibody surface. The variant antibody and Fab-Fc fusion protein of the second round are produced by combining the mutations in these three regions to potentially provide an additional increase in effectiveness. In addition, some neutral mutations are incorporated because they may not have a significant effect on binding, but may provide a mechanism for modifying the biophysical characteristics of the antibody. The variable region containing the required mutation is incorporated into the bivalent monoclonal antibody with people's unglycosylated IgG1Fc region and / or monovalent Fab-Fc fusion protein. Unglycosylated human IgG1 antibody Fc region includes the sequence (SEQ ID NO:325) of the human IgG1zFc region with N297G, R292C and V302C mutations according to EU numbering. The functional activity of these variant antibodies and Fab-Fc fusion proteins with mutation combinations is evaluated in the cell-based cAMP assay. These results are shown in the following table 12.

[0412] Table 12. In vitro inhibitory potency of variant antibodies and Fab-Fc fusion proteins

[0413]

[0414]

[0415]

[0416]

[0417]

[0418]

[0419]

[0420] 1 This value represents the fold increase in IC50 as compared to the IC50 value of the 29G4v10 parent molecule formatted as mAb or Fab-Fc fusion protein, which was run in parallel with each variant molecule.

[0421] 2 This value represents the fold increase in IC50 compared to the mean IC50 value of the 29G4v10 parent molecule formatted as mAb or Fab-Fc fusion protein.

[0422] ND = Not Determined

[0423] The greatest improvement in potency was observed when the antibody had a mutation at position Q27 (Q27K) in the light chain variable region and a mutation at position D54 (D54I, D54Q, or D54N) and / or position G56 (G56R or G56N) in the heavy chain variable region. Q27 in the light chain variable region of SEQ ID NO:52 corresponds to amino acid position 29 in AHo numbering. D54 and G56 in the heavy chain variable region of SEQ ID NO:191 correspond to amino acid positions 61 and 66, respectively, in AHo numbering. It is hypothesized that the basic amino acid (e.g., lysine or arginine) at position Q27 in the light chain variable region provides improved charge complementarity with the acidic amino acids Glu120 and Asp121 in the PAC1 ECD (see Figure 2A A hydrophobic residue (e.g., isoleucine) or a neutral hydrophilic residue (e.g., glutamine or asparagine) at position D54 in the heavy chain variable region and a basic residue (e.g., arginine) or a neutral hydrophilic residue (e.g., asparagine) at position G56 in the heavy chain variable region appear to improve hydrophobic interactions or hydrogen bonds with amino acid residues Asn60 and Ile61 in the PAC1 ECD (see Figure 3B in zone 6).

[0424] The best eleven mutants from the MutHC library screen (Table 8) were formatted as unglycosylated IgG1 monoclonal antibodies and monovalent Fab-Fc molecules as described above for production and functional testing in cAMP assays (Table 13). For this set of variants, moderately improved yeast binding translated into improved PAC1 receptor blocking function for 4 of 11 mAbs and 7 of 11 Fab-Fcs. However, as an antibody, the iPS:421873 mutant showed an approximately 4-fold improvement in PAC1 blocking function compared to the parental 29G4v10 antibody. The activity rankings of these mutants were roughly consistent in both formats, with Fab-Fcs consistently showing weaker function (higher IC50 values) than mAbs, likely due to loss of avidity.

[0425] Table 13. In vitro inhibitory potency of variants from MutHC library screening

[0426]

[0427] 1 This value represents the fold increase in IC50 as compared to the IC50 value of the 29G4v10 parent molecule formatted as mAb or Fab-Fc fusion protein, which was run in parallel with each variant molecule.

[0428] 2This value represents the fold increase in IC50 compared to the mean IC50 value of the 29G4v10 parent molecule formatted as mAb or Fab-Fc fusion protein.

[0429] A subset of 29G4v10 mutants from the chain shuffled libraries (Tables 9 and 10) were converted to aglycosylated IgG1 monoclonal antibodies and tested for functional activity in a cell-based cAMP assay. These results are shown in Table 14 below.

[0430] Table 14. In vitro inhibition potency of variants from chain shuffling yeast display library

[0431]

[0432] 1 29G4v22 is another anti-PAC1 neutralizing antibody that shares significant structural similarity with 29G4v10. The VL and VH sequences of 29G4v22 are provided in SEQ ID NOs: 53 and 192, respectively.

[0433] 2 Historical values ​​were obtained from previous determinations and are included for comparison purposes.

[0434] When formatted as monoclonal antibodies (mAbs), 29G4v10 mutants from the second generation chain shuffling library (Table 10) were more effective antagonists of PAC1 than mutants from the first generation chain shuffling library (Table 9), indicating that enhanced PAC1 blocking function correlates with improved binding, and particularly slowed binding dissociation rates. However, surprisingly, most mutants were less active as mAbs than antibody iPS:421873 (the most potent mutant from the mutHC library screen) (Table 13), despite the assumption that they had enhanced binding to human PAC1 ECD. However, the 30_D05 mutants exhibited approximately 10-fold and 67-fold improvements in function as compared to the 29G4v10 parent antibody and the 29G4v22 control antibody, respectively. A common feature shared by the high potency S8_30_D05 and iPS:421873 mAbs is the D54R mutation in HCDR2, which is absent in all other less potent mAb mutants. Interestingly, all affinity matured variants showed cross-reactivity with the rat PAC1 receptor compared to the 29G4v10 parent antibody and the 29G4v22 control antibody (Table 14).

[0435] Example 4. In vivo functional activity of human PAC1 antibody variants

[0436] Maxadilan is a vasodilator peptide and agonist of the PAC1 receptor. When administered intradermally, maxadilan causes an increase in local skin blood flow that can be measured by laser Doppler imaging. Inhibition of this effect by PAC1 antagonists (e.g., anti-PAC1 antibodies) can serve as a translational pharmacodynamic model of antagonism of PAC1 bioactivity. When formatted as the monoclonal antibody from Example 3, the efficacy of a subset of PAC1 variants that inhibit PAC1 receptor activation in vivo was tested using a rat skin blood flow model, and the PAC1 variants exhibited improved in vitro inhibitory efficacy.

[0437] In vivo pharmacodynamic models

[0438] In the young male Sprague Dawley rats of 8-12 weeks of age, they were purchased from Charles River Laboratories. All procedures in this example were carried out in accordance with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the Office of Laboratory Animal Welfare. In the facilities approved by the Laboratory Animal Assessment and Accreditation Committee (AAALAC) of Amgen, animals were grouped and raised in non-sterile, ventilated micro-isolation housing. Animals were given free access to pellet feed (Harlan Teklad 2020X, Indianapolis, Indiana, IN) and water (on-site reverse osmosis production) by automatic water supply system.

[0439] A subset of anti-PAC1 antibodies was tested in the rat maxadilan-induced increase in skin blood flow (MIIBF) pharmacodynamic (PD) model using laser Doppler imaging. Dosing solutions of maxadilan (Bachem, H6734.0500) were prepared fresh daily by diluting a maxadilan stock solution (0.5 mg / mL) in 1X phosphate-buffered saline (PBS) to a final concentration of 0.5 μg / mL. All anti-PAC1 antibodies (Abs) were prepared at different concentrations in 10 mM sodium acetate, 9% sucrose, pH 5.2 (A52Su) depending on the dose required for the experiment and administered by a single intravenous bolus injection one day before skin blood flow (DBF) was measured by laser Doppler imaging.

[0440] DBF was measured on shaved patches of the rat abdomen using a laser Doppler imager (LDI-2, Moor Instruments, Ltd, Wilmington, Delaware) using a low-power laser beam generated by a 633 nm helium-neon bulb. The measurement resolution was 0.2 mm to 2 mm, with a scanning distance of 30 cm between the instrument aperture and the tissue surface. DBF was measured and expressed as % change from baseline [100x (maxadilan post-flux alone - baseline flux alone) / baseline flux alone] or % DBF inhibition [mean of vehicle % change from baseline - mean of antibody-treated rats % change from baseline) / mean of vehicle % change from baseline] to quantify the magnitude of the antibody effect.

[0441] On the day of the test, after anesthesia with propofol, the abdominal area of ​​the rats was shaved and each animal was placed in a supine position on a temperature-controlled circulating warm water pad to maintain a stable body temperature during the study. After a stabilization period of 10 to 15 minutes, a rubber O-ring (0.925 cm inner diameter, O-RingsWest, Atto, Washington) was placed on the rat abdomen (not directly positioned on a visible blood vessel). After placing the O-ring on the selected area, a baseline (BL) DBF measurement was performed. After the BL scan, the PAC1 agonist maxadilan was administered in the center of the O-ring by intradermal injection (20 μL of 0.5 μg / mL). DBF was measured 30 minutes after maxadilan injection or 24 ± 1.5 hours after antibody treatment. The O-ring defines the target area for DBF analysis.

[0442] All DBF results are expressed as mean ± SEM. One-way ANOVA followed by Dunnett's multiple comparison test (MCT) was used to assess the statistical significance of PAC1Ab relative to vehicle treatment. p value < 0.05 was used to determine significance between two groups.

[0443] Single-dose intravenous (iv) screening evaluation

[0444] Pretreatment of rats with one of seven different anti-PAC1 antibodies (420653, 420845, 420943, 421873, 420889 (PL-50347), 421091 (PL-50350), and 421051 (PL-50351)) for 24 hours followed by maxadilan challenge at either 0.1 mg / kg or 0.3 mg / kg (20 μl of 0.5 μg / mL) resulted in a decrease in MIIBF compared to the vehicle (A52Su) treated group. At 30 minutes after maxadilan treatment, there was a statistically significant inhibitory effect on MIIBF at 0.3 mg / kg compared to the vehicle group for five of the seven antibodies tested ( Figure 6 The final serum concentrations at 24 ± 1.5 hours for six of the seven antibodies are listed in Table 15 below.

[0445] Table 15. Terminal serum concentrations for single injection (screening) studies

[0446]

[0447] Dose-response assessment

[0448] Rats were pretreated with 4 different anti-PAC1 antibodies (420653, 420845, 420943, and 421873) for 24 hours and then challenged with maxadilan (20 μl of 0.5 μg / mL) at doses ranging from 0.01 mg / kg to 30 mg / kg. For each of the four antibodies, a dose-dependent reduction in MIIBF was observed compared to the vehicle-treated group ( Figures 7A-7D At doses as low as 0.06 mg / kg, Ab420653 produced significant effects, with inhibition of 44%, 68%, 86%, 95% and 101% at 0.06 mg / kg, 0.1 mg / kg, 0.3 mg / kg, 1 mg / kg and 3 mg / kg, respectively ( Fig. 7A At doses of 0.3 mg / kg, 1 mg / kg and 3 mg / kg, Ab420845 produced significant effects, with inhibition of 79%, 102% and 107% ( Figure 7B ). Ab420943 and 421873 were slightly less effective than Ab420845 and Ab420653, but still produced significant inhibition at 1 mg / kg. The % inhibition of Ab420943 in DBF was 56%, 46%, 52% and 81% at 1 mg / kg, 3 mg / kg, 10 mg / kg, and 30 mg / kg, respectively ( Figure 7C ). The % inhibition of Ab421873 in DBF was 34%, 55%, 72% and 100% at 1 mg / kg, 3 mg / kg, 10 mg / kg and 30 mg / kg, respectively ( Fig.7D ).

[0449] The experimental results described in this example show that antibodies that effectively inhibit ligand-induced activation of the PAC1 receptor in vitro also inhibit activation of the PAC1 receptor in vivo as assessed by the skin blood flow assay (a model of PAC1-mediated vasodilation).

[0450] Example 5. Pharmacokinetic characteristics of human PAC1 antibody variants

[0451] Preliminary pharmacokinetic (PK) studies of four anti-PAC1 antibodies (420653, 420845, 420943, and 421873) were performed with juvenile male Sprague-Dawley rats and juvenile male cynomolgus monkeys. The 29G4v10 parent antibody or the structurally related 29G4v22 antibody (comprising a VL of SEQ ID NO: 53 and a VH of SEQ ID NO: 192) was evaluated as a control. The test antibodies were administered to the study animals by intravenous bolus administration. Blood samples were collected at designated time points after dosing and processed into serum. All serum samples were stored at approximately -70°C (±10°C) until transferred for subsequent analysis.

[0452] For measuring the amount of test antibody in serum samples from rats and cynomolgus monkeys after administration, a colorimetric enzyme-linked immunosorbent assay (ELISA) was developed using mouse monoclonal antibodies (mAb) for human IgG Fc (Amgen, Inc., California, the United States). Microtiter plates were coated with 2 μg / mL of mouse anti-human Fc mAb. The coated microtiter plates were sealed with I-block (Applied Biosystems, California, the United States). Standards for determination (STD) and quality control (QC) were prepared by incorporating test antibodies into 100% serum from the research species. STD, QC, blanks and research samples were diluted by 1:30 in assay buffer (1XPBS, 1% BSA and 0.5% Tween20 with 1M NaCl). Diluted STD, QC, blanks and research samples were incubated on coated microtiter plates at 25°C for 1 hour without stirring. After the washing step, the mouse anti-human FcmAb of the horseradish peroxidase (HRP) coupling of 30ng / mL in the assay buffer is added to the microtiter plate, and incubated at 25°C for 1 hour without stirring. After the last washing step, tetramethylbenzidine (TMB) peroxide substrate solution (KPL company, Maryland (MD), the U.S.) is added to the microtiter plate. In the presence of HRP, TMB produces a colorimetric signal, which is proportional to the amount of binding human Fc present in STD, QC and research samples. The color development time depends on analyte and is terminated by adding 2N sulfuric acid. Using SpectraMax 340PC microtiter plate reader (Molecular Devices, California, the U.S.) and SoftMax Pro software, optical density (OD) is measured at 450nm with reference to 650nm. Using a logical (automatic estimation) regression model (wherein the weighting factor is 1 / y), the assay data are regressed. The dynamic range of the assay was from 20 ng / mL to 2000 ng / mL.

[0453] For PK studies in rats and cynomolgus monkeys, (Version 6.4; Cherthala, NJ, USA) Non-compartmental analysis was performed on individual serum concentration-nominal time data. Individual concentration values ​​less than the lower limit of quantitation (LLOQ, 20 ng / mL) were reported as below the limit of quantitation (BQL) and set to zero for calculation of summary statistics. Mean concentration values ​​below the LLOQ were not reported or plotted. All concentration values ​​below the LLOQ were excluded from the non-compartmental analysis. The nominal dose and nominal sampling time were used for PK analysis. The following PK parameters were estimated:

[0454] • Initial concentration (C0) values ​​following intravenous administration were estimated by back extrapolation to time zero using the first 2 observed declining concentration values.

[0455] • The area under the concentration-time curve from time zero to infinity (AUCinf) was calculated by the linear trapezoidal method.

[0456] Terminal phase half-life (t 1 / 2,z ) is calculated as ln2 / λ z ,λ z is the first-order rate constant for the drug associated with the terminal portion of the curve.

[0457] Systemic clearance (CL) was calculated as follows: CL = dose after intravenous administration / AUCinf

[0458] The steady-state volume of distribution (Vss) was estimated as follows: Vss = CL x MRTinf (mean residence time from time zero to infinity)

[0459] A summary of the in vitro inhibitory potency of the four antibodies, as well as the 29G4v10 parent antibody and the 29G4v22 control antibody against human, rat and canine PAC1 is provided below in Table 16. Using the cAMP assay described in Example 3, the antibodies were assessed for their ability to inhibit ligand-induced (PACAP38 or maxadilan) activation of PAC1 receptors from different species.

[0460] Table 16. Summary of in vitro inhibitory potency of PAC1 variant antibodies

[0461]

[0462]

[0463] Rats were intravenously dosed with one of the four antibodies at 1 mg / kg, 5 mg / kg, and 25 mg / kg. Blood samples were collected at various time points after dosing, and the antibody concentration in serum samples was measured at each time point using the ELISA assay described above. The PK parameters for the rat study are summarized in Table 17 below, and the serum concentration-time curves for each dose are shown in Table 17. Figures 8A-8C middle.

[0464] Table 17. Summary of PK parameters of PAC1 variant antibodies in rats

[0465]

[0466] Cynomolgus monkeys were given one of the four antibodies at a dose of 10 mg / kg intravenously. Blood samples were collected at different time points after dosing, and the antibody concentration in the serum samples was measured at each time point using the ELISA assay described above. The PK parameters for the cynomolgus monkey study are summarized in Table 18 below, and the serum concentration-time curves are shown in Fig. 9 The PK curve of 29G4v22 antibody is shown for comparison.

[0467] Table 18. Summary of PK parameters of PAC1 variant antibodies in cynomolgus monkeys

[0468]

[0469] At this dose, all four PAC1 variant antibodies had longer serum half-lives than the 29G4v22 control antibody. Interestingly, although all four PAC1 variant antibodies exhibited higher in vitro inhibitory potency against the PAC1 receptor than the 29G4v22 control antibody (Table 16), the PK profiles of some variants were less favorable in cynomolgus monkeys. For example, Ab420845 had a faster clearance rate and lower total exposure than the 29G4v22 control antibody. However, Ab420653 had a PK profile comparable to the 29G4v22 control antibody (Table 16). Fig. 9 ), indicating that Ab420653 can be administered at a lower dose at the same dosing frequency to achieve similar pharmacological effects.

[0470] Example 6. Yeast Display Affinity Maturation of 19H8 Human PAC1 Antibody

[0471] To generate anti-PAC1 antibodies with improved inhibitory potency, the 19H8 antibody (VH region of SEQ ID NO: 296; VL region of SEQ ID NO: 67) was affinity matured by FACS of a yeast-displayed Fab library using the method described in Example 2. The 19H8 antibody is structurally different from the 29G4v9, 29G4v10, and 29G4v22 antibodies, but also exhibits very potent neutralizing activity against the human PAC1 receptor.

[0472] Because no crystal structure information was initially available for the PAC1 ECD-19H8 Fab complex, homology models were generated to identify surface-exposed residues within each CDR loop. Because PAC1 ECD is expected to make direct contacts with surface-exposed CDR residues, it was hypothesized that altering the nature of these contacts or creating new contacts by global mutagenesis could result in improved binding of antibodies to PAC1 ECD. To limit the theoretical diversity of each library to a manageable 10 6 -10 7 , up to five positions per CDR were identified for MIX19 saturation mutagenesis, and a separate library was constructed for each CDR. Given the accuracy of the modeled CDRH3 loop conformation, the most solvent-exposed residues within the loop could not be reliably identified. Therefore, diversification at 8 of the 11 CDR residues within CDRH3 was considered, excluding residues at the beginning and end of th...

Claims

1. An isolated antibody or antigen-binding fragment thereof, which specifically binds to human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1), wherein the antibody or antigen-binding fragment thereof comprises: a light chain variable region comprising complementary determining regions CDRL1, CDRL2 and CDRL3 and a heavy chain variable region comprising complementary determining regions CDRH1, CDRH2 and CDRH3, wherein: (a) CDRL1, CDRL2 and CDRL3 consist of the sequences of SEQ ID NOs: 7, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 consist of the sequences of SEQ ID NOs: 88, 108 and 171, respectively; (b) CDRL1, CDRL2 and CDRL3 consist of the sequences of SEQ ID NOs: 7, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 consist of the sequences of SEQ ID NOs: 88, 116 and 171, respectively; (c) CDRL1, CDRL2 and CDRL3 consist of the sequences of SEQ ID NOs: 5, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 consist of the sequences of SEQ ID NOs: 88, 134 and 171, respectively; (d) CDRL1, CDRL2 and CDRL3 consist of the sequences of SEQ ID NOs: 5, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 consist of the sequences of SEQ ID NOs: 92, 145 and 174, respectively; (e) CDRL1, CDRL2 and CDRL3 consist of the sequences of SEQ ID NOs: 7, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 consist of the sequences of SEQ ID NOs: 88, 108 and 172, respectively; (f) CDRL1, CDRL2 and CDRL3 consist of the sequences of SEQ ID NOs: 5, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 consist of the sequences of SEQ ID NOs: 88, 128 and 172, respectively; (g) CDRL1, CDRL2 and CDRL3 consist of the sequences of SEQ ID NOs: 7, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 consist of the sequences of SEQ ID NOs: 88, 134 and 171, respectively; or (h) CDRL1, CDRL2 and CDRL3 consist of the sequences of SEQ ID NOs: 12, 26 and 36, respectively, and CDRH1, CDRH2 and CDRH3 consist of the sequences of SEQ ID NOs: 88, 153 and 171, respectively.

2. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the light chain variable region comprises a sequence selected from the group consisting of SEQ ID NOs: 54, 55 and 62.

3. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable region comprises a sequence selected from SEQ ID NOs: 194, 203, 214, 228, 240, 274 and 282.

4. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein: (a) the light chain variable region comprises the sequence of SEQ ID NO: 54, and the heavy chain variable region comprises the sequence of SEQ ID NO: 194; (b) the light chain variable region comprises the sequence of SEQ ID NO: 54, and the heavy chain variable region comprises the sequence of SEQ ID NO: 203; (c) the light chain variable region comprises the sequence of SEQ ID NO: 55, and the heavy chain variable region comprises the sequence of SEQ ID NO: 228; (d) the light chain variable region comprises the sequence of SEQ ID NO: 55, and the heavy chain variable region comprises the sequence of SEQ ID NO: 274; (e) the light chain variable region comprises the sequence of SEQ ID NO: 54, and the heavy chain variable region comprises the sequence of SEQ ID NO: 214; (f) the light chain variable region comprises the sequence of SEQ ID NO: 55, and the heavy chain variable region comprises the sequence of SEQ ID NO: 240; (g) the light chain variable region comprises the sequence of SEQ ID NO: 54, and the heavy chain variable region comprises the sequence of SEQ ID NO: 228; or (h) the light chain variable region comprises the sequence of SEQ ID NO: 62, and the heavy chain variable region comprises the sequence of SEQ ID NO:

282.

5. The isolated antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, wherein the antibody or antigen-binding fragment thereof is a monoclonal antibody or antigen-binding fragment thereof.

6. The isolated antibody or antigen-binding fragment thereof of claim 5, wherein the monoclonal antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof, or a fully human antibody or antigen-binding fragment thereof.

7. The isolated antibody or antigen-binding fragment thereof of claim 5, wherein the monoclonal antibody comprises a light chain comprising a human kappa constant region.

8. The isolated antibody or antigen-binding fragment thereof of claim 7, wherein the human kappa constant region comprises the sequence of SEQ ID NO: 318 or SEQ ID NO:

319.

9. The isolated antibody or antigen-binding fragment thereof of claim 5, wherein the monoclonal antibody comprises a light chain comprising a human lambda constant region.

10. The isolated antibody or antigen-binding fragment thereof of claim 9, wherein the human lambda constant region comprises the sequence of SEQ ID NO:

315.

11. The isolated antibody or antigen-binding fragment thereof of claim 5, wherein the monoclonal antibody is a human IgG1, IgG2, IgG3 or IgG4 antibody.

12. The isolated antibody or antigen-binding fragment thereof of claim 11, wherein the monoclonal antibody is a human IgG1 antibody.

13. The isolated antibody or antigen-binding fragment thereof of claim 12, wherein the monoclonal antibody is an aglycosylated human IgG1 antibody.

14. The isolated antibody or antigen-binding fragment thereof of claim 13, wherein the monoclonal antibody comprises a mutation in its heavy chain at amino acid position N297 according to EU numbering.

15. The isolated antibody or antigen-binding fragment thereof of claim 14, wherein the mutation is N297G.

16. The isolated antibody or antigen-binding fragment thereof of claim 15, wherein the monoclonal antibody further comprises R292C and V302C mutations according to EU numbering in its heavy chain.

17. The isolated antibody or antigen-binding fragment thereof of claim 13, wherein the monoclonal antibody comprises a heavy chain constant region comprising the sequence of SEQ ID NO: 324 or SEQ ID NO:

325.

18. The isolated antibody or antigen-binding fragment thereof of any one of claims 1-4, wherein the antibody or antigen-binding fragment thereof inhibits PACAP-induced activation of rat PAC1 with an IC50 of less than 10 nM as measured by a cell-based cAMP assay.

19. An isolated antibody that specifically binds to human PAC1, wherein the antibody comprises a light chain and a heavy chain, wherein: (a) the light chain comprises the sequence of SEQ ID NO: 506, and the heavy chain comprises the sequence of SEQ ID NO: 521; (b) the light chain comprises the sequence of SEQ ID NO: 506, and the heavy chain comprises the sequence of SEQ ID NO: 522; (c) the light chain comprises the sequence of SEQ ID NO: 504, and the heavy chain comprises the sequence of SEQ ID NO: 523; (d) the light chain comprises the sequence of SEQ ID NO: 504, and the heavy chain comprises the sequence of SEQ ID NO: 524; (e) the light chain comprises the sequence of SEQ ID NO: 506, and the heavy chain comprises the sequence of SEQ ID NO: 525; (f) the light chain comprises the sequence of SEQ ID NO: 504, and the heavy chain comprises the sequence of SEQ ID NO: 526; (g) the light chain comprises the sequence of SEQ ID NO: 506, and the heavy chain comprises the sequence of SEQ ID NO: 523; or (h) the light chain comprises the sequence of SEQ ID NO: 507, and the heavy chain comprises the sequence of SEQ ID NO:

527.

20. A pharmaceutical composition comprising the isolated antibody or antigen-binding fragment thereof according to any one of claims 1 to 4 and 19, and a pharmaceutically acceptable excipient.

21. An isolated polynucleotide encoding the isolated antibody or antigen-binding fragment thereof as described in any one of claims 1-4 and 19.

22. An expression vector comprising the polynucleotide of claim 21.

23. A host cell comprising the expression vector of claim 22.

24. A method for producing an antibody or an antigen-binding fragment thereof that specifically binds to human PAC1, the method comprising culturing the host cell of claim 23 under conditions that allow expression of the antibody or the antigen-binding fragment thereof; and recovering the antibody or the antigen-binding fragment thereof from the culture medium or the host cell.

25. Use of the antibody or antigen-binding fragment thereof of any one of claims 1-4 and 19 in the preparation of a medicament for treating or preventing a headache condition in a patient in need thereof.

26. The use of claim 25, wherein the headache condition is migraine.

27. The use of claim 26, wherein the migraine is episodic migraine.

28. The use of claim 26, wherein the migraine is chronic migraine.

29. The use of claim 25, wherein the headache condition is cluster headache.

30. The use of claim 25, wherein the treatment is a prophylactic treatment.

31. The use of claim 25, wherein the medicament is administered in combination with a second headache therapeutic agent.

32. The use of claim 31, wherein the second headache therapeutic agent is an acute headache therapeutic agent.

33. The use of claim 32, wherein the acute headache therapeutic agent is 5HT 1B , 5HT 1D and / or 5HT 1F Serotonin receptor agonists.

34. The use of claim 33, wherein the serotonin receptor agonist is a triptan or ergotamine.

35. The use of claim 32, wherein the acute headache therapeutic agent is a nonsteroidal anti-inflammatory drug or an opioid.

36. The use of claim 31, wherein the second headache therapeutic agent is a prophylactic headache therapeutic agent.

37. The use of claim 36, wherein the prophylactic headache therapeutic agent is an anti-epileptic drug, a beta-blocker, an antidepressant, botulinum toxin A, or a CGRP pathway antagonist.

38. The use of claim 37, wherein the CGRP pathway antagonist is a human CGRP receptor antagonist.

39. The use of claim 38, wherein the human CGRP receptor antagonist is a monoclonal antibody that specifically binds to the human CGRP receptor.

40. The use of claim 39, wherein the anti-CGRP receptor monoclonal antibody is erenuzumab.